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There are extensive alterations to cervical structure and function throughout
pregnancy and labour. The cervical deep stromal layer is the target for many of these
structural alterations. The underlying mechanisms of cervical change in pregnancy
are unresolved, yet clinical interventions are in common usage. There are limitations
with vaginal administration of current cervical ripening agents with varied absorption
rates and unpredictable effects. A small study of potential direct clinical benefit is
performed to assess the capability of a needle-free injection device to administer a
solution to the human uterine cervix. The principle of cervical needleless injection is
proven with a mean depth of penetration to 5.6mm. There could be major benefits in
dose accuracy and speed of effect due to the direct nature of administration, but
whether this is sufficient to be clinically advantageous is questionable.
Key component of the cervical stroma, the fibroblast, possesses many of the
properties required to facilitate the cervical changes seen throughout pregnancy.
Little is known about the phenotypic alteration and functions of the commonest
resident cervical cell, the fibroblast, during pregnancy and labour. Decidualisation of
endometrial stromal cells has been extensively investigated occurs under the
influence of progesterone, with the added requirement of cAMP levels in-vitro. The
cervix, like the endometrium is exposed to this progesterone-rich environs during
pregnancy, and like the endometrium undergoes significant structural re-arrangement
during this period. The hypothesis that a decidual-like phenotypic variation in
cervical stromal cells exists is tested. Cervical ripening in the last few weeks of
pregnancy has also been likened to an inflammatory reaction with invasion of
leukocytes, activation of proinflammatory cytokines and of connective tissue
degrading matrix metalloproteinases. Prior studies have observed upregulation of
collagen and proteoglycan degrading MMPs in the labouring cervix. However if
leukocyte extravasation is a key component to cervical remodelling at term, then
MMP-2, whose main substrate is collagen type IV i.e. basement membrane, would
provide a mechanism to facilitate this. ProMMP-2 requires activation by MMP-14,
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known to be regulated by prostaglandin in the human monocyte, but previously
unrecognised in the human cervix.
Human cervical biopsies were divided as untreated samples and homogenised for
RNA extraction, or prepared as cultured human cervical stromal cells (CSC) and
treated with medroxyprogesterone acetate and cAMP elevating agents for 6 and 10
days. Messenger RNA expression by quantitative RT-PCR and/ or protein release by
ELISA was performed for decidualisation markers PRL, IGFBP-1, TF, VEGF,
desmin, laminin and fibronectin, and receptor expression PR, EP2 and EP4. IL-8
gene expression and protein release was compared under decidual stimulus. MMP-
14 mRNA expression in cervical explants, cultured stromal cells, and a monocyte
population was compared under prostaglandin E2 and MCP-1 stimulus. Cervical
explants from the first trimester demonstrate the major decidualisation markers with
xl4-fold prolactin and x58-fold IGFBP-1 mRNA expression, relative to non¬
pregnant explants. CSCs under the influence of progesterone and cyclic-AMP, from
both pregnant and non-pregnant women, display a "decidual-like" morphological
alteration, and markedly increased mRNA expression (pregnant: PRL 26 ± 5 s.e.m,
IGFBP-1 559 ± 282 s.e.m, p< 0.01) and protein release (PRL x 6-fold, IGFBP-1 x
25-fold, p< 0.01) relative to control. CSCs exposed to decidual stimuli show reduced
IL-8 mRNA expression (0.39 ± 0.04, p< 0.01) and protein release (p< 0.01). MMP-
14 is expressed by the human cervix and CSC but is not upregulated by
prostaglandin E2 as demonstrated in a monocyte population (x 5-fold ± 0.6).
This altered cervical fibroblast phenotype has extensive implications in the study of
the mechanism of pregnancy associated cervical remodelling, possibly serving as
protective mechanism of cervical integrity until functional progesterone withdrawal.
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EP2 prostaglandin E2 type 2 receptor
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LMP last menstrual period
LPS lipopolysaccharide
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MCP-1 monocyte chemotactic protein-1
MLCK myosin light chain kinase
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1.1.1 The Physiology of Parturition
The physiological process of parturition is complex and, although most cases
proceed without complication, we do not yet fully understand the underlying
biological mechanisms. Our ability to intervene effectively where necessary is thus
limited. The process of human labour has been well characterised in terms of regular
uterine contractions resulting in effacement and dilatation of the cervix allowing
passage of the mature fetus to the outside world. Prior to this the myometrium
gradually becomes more responsive to stimuli over months, the cervix "ripens" over
several weeks and eventually, effectors initiate the process of labour (see Fig 1.1). It
is this synchronous preparatory process and its regulators that must be unravelled.
The complexities of this process are numerous. The fetal organs must mature
appropriately for independent existence, the uterus and cervix must have undergone
the preparatory phases pre-labour for optimal response to uterine contractility
stimuli, and the maternal lactation requirements must have been triggered to sustain
the newborn. All these integrated systems must be orchestrated with precision for a
successful outcome. This review will focus on the human cervix and the changes
seen in pregnancy and labour.
The preparatory process named cervical ripening has been described in humans as
taking place over several weeks in late gestation. In reality it is perhaps a continuum
of changes that are seen in early and throughout pregnancy. During this time the
cervix undergoes tissue remodelling resulting a softer, more compliant organ that
will efface and dilate in response to myometrial contractions and mechanical stretch
by the presenting part of the fetus. The structure of the non-pregnant cervix will be
discussed in detail together with the changes then seen before and during labour.
Mediators influencing this process are varied but prostaglandins are currently the
favoured therapeutic agent exploited in clinical practice. Nitric oxide donors,
relaxin, antiprogestogens, oestrogen, and cytokines (IL-8 & IL-1) have been
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successful cervical ripening agents in human, rabbit, rat and guinea-pig studies and
the search for the ideal therapeutic tool continues (Radestad et al 1990; Calder et al
1993; Chwalisz et al 1994; El Maradny et al 1994; Chwalisz et al 1997; Thomson et
al 1997b; Elliott et al 1998; Luque et al 1998; Shi et al 2000).
The endocrine system in pregnancy has been investigated for decades but systemic
and local changes have now been distinguished. In general it appeared that increased
systemic prostaglandins, progesterone (P4) withdrawal, and the increased oestrogen:
progesterone ratio (E2:P4 ratio) are responsible for maintenance or progression of
labour rather than the initiation. These factors are known to enhance myometrial
activity by promoting gap junction formation, oxytocin receptors and increasing the
agonist response.
Undoubtedly prostaglandins are important in parturition, and increased peripartum
production in fetal membranes, with locally attenuated catabolism, have supported
this across several species (Keirse 1979; Mitchell 1987b; Geirsson et al 1990;
Lundin-Schiller et al 1990; Kelly et al 1992; Van Meir et al 1997). Prostaglandins
are produced in many tissues including fetal membranes, myometrium, cervix and
macrophages. Cytokines, particularly interleukin-8 (IL-8) are also produced in
abundance by these cells. Prostaglandins are certainly involved in myometrial
responsiveness and cervical ripening but appear to represent a final common
pathway in parturition rather than an early event in initiation. Control of
prostaglandin levels in parturition may be controlled in part by the catabolic enzyme
prostaglandin 15-dehydrogenase (PGDH) since levels of this enzyme are lower in the
membranes overlying the cervix (Van Meir et al 1997). These variations seen in
PGDH activity/ expression are particular to the chorion but are not reflected in
placentae. Moreover, infection of the membranes leads to a decrease in the levels of
PGDH and thus will be permissive of prostaglandin actions (van Meir et al 1997).
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Immune cells, macrophages and neutrophils in particular, are prevalent in the uterus
throughout the menstrual cycle, implantation, pregnancy and more so at parturition
(De et al 1991; Hunt 1994; Hunt et al 2000). The possible roles for these cells will
be explored.
Recent studies have explored a neuro-immune hypothesis based on the increased
innervation seen in the cervix at term concurrent with macrophage migration. It is
possible that local neuropeptide release has a chemoattractant role but has not yet
been investigated. Rat studies have shown than cervical denervation by transection
disrupts parturition (Renegar et al 1992). Without doubt cervical remodelling takes
place well in advance of any changes in uterine contractility and cervical changes in
labour are associated with immune cell recruitment, activation and enzymatic
degradation. The interaction between immune mediators (PGs, iNOS and cytokines)
is complex and must integrate endocrine, paracrine and possibly neural pathways.
The average human pregnancy lasts 40 weeks from the first day of the last menstrual
period, yet due to advances in perinatal care infants can survive from 24 weeks
gestation whether delivered spontaneously or by intervention. Despite this, preterm
delivery accounts for at least 75% of perinatal mortality (Slattery et al 2002).
Pregnancy can also be prolonged for several weeks although recommendations
suggest delivery by 42 weeks (RCOG Clinical effectiveness support group 2001).
There is therefore a wide variation in gestation at delivery in humans. This we
combat largely by relying on advancing neonatal care, but have little means of
intervention to predict or prevent preterm delivery or to initiate labour artificially.
Many avenues explored attempt to intervene at the end of a gradual and prolonged
cascade initiated several days or weeks beforehand. For example, tocolytics of all
kinds may be successful in delaying delivery for a matter of hours or days but none
have improved perinatal outcomes (Gyetvai et al 1999; Worldwide Atosiban versus
Beta-agonists Study Group 2001). Is this "last gasp rescue" just too late to reverse
all the interactive mechanisms that have gone before, and perhaps by this stage it is
not in the interests of that fetus to remain in an environment that could be
increasingly dangerous. Similarly, is it any surprise that when pregnancy is
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prolonged and our efforts focus on emulating the final events when the preparatory
phases are not complete, that we sometimes fail and produce dysfunctional labour?
1.1.2 Evidence from Animal Models
Several species-specific theories exist regarding the initiation of labour including
mechanical distension of the uterus, progesterone withdrawal in sheep and rodents,
oxytocin stimulation, maturation of the fetal HPA axis and decidual activation. In
fact it is probably a result of all of these elements combined. There does however
appear to be distinct mechanisms in term and preterm labour where, in the latter, the
fetoplacental unit fires the trigger early to escape an increasingly hostile
environment. In cases such as infection or placental insufficiency or abruption, the
immense stimulation of cytokines and prostaglandins (PG) supercedes the
physiological control mechanisms of pregnancy maintenance. In idiopathic preterm
labour, there is no such sign of fetal compromise and other explanation must be
sought.
Primates do share a similar reproductive tract and a similar placental structure but
some species, such as the baboon, differ in corticotrophin releasing hormone (CRH)
and oestrogen secretion throughout pregnancy (Smith et al 2002). Studies in
baboons have suggested a marked regional up-regulation in COX-2 mRNA
expression in lower uterine, cervical and decidual tissues compared to the fundus,
placenta and amnion (Wu et al 2000). This suggests a site-specific activation of
prostaglandin synthesis with a temporal relationship to increased myometrial
contractility. Gorillas and chimpanzees most closely mirror human events but studies
with these animals are difficult for ethical reasons and in no species does
implantation occur to the depth seen in humans.
In sheep, interruption of the HPA-axis results in the failure of labour. Labour is
driven by fetal HPA-axis maturation, hypothalamic corticotrophin releasing hormone
(CRH) and ACTH release causing raised fetal adrenal Cortisol levels which in turn
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cause an increased oestrogen synthesis by the placenta, via increased 17a-
hydroxylase-17,20-lyase activity, with a concurrent reduction in progesterone
production. This results in both prostaglandin synthesis and induction of
contraction-associated proteins (CAPs), and so labour ensues (Lundin-Schiller et al
1990). More recently the control of peripartum prostaglandin production has been
brought into question as this seems to occur before the rise in fetal and maternal
oestrogen, but concurrent with the fetal plasma Cortisol levels, and placental
prostaglandin synthase/ cyclooxygenase-2 (COX-2) expression. The hypothesis that
there are two separate pathways of intrauterine PG production is supported by the
work of Whittle et al (Whittle et al 2000). This proposes a cortisol-dependent fetal
placental trophoblast pathway directly increasing fetal plasma PGE2, and an E2-
dependent pathway in maternal intrauterine non-trophoblast tissues directly up-
regulating PGF2a production and stimulating uterine activity. Progesterone
withdrawal may be a prerequisite but although in humans this is not a systemic
effect, there may be local variation in progesterone activity in intrauterine and
cervical tissues. Ovine PGDH activity increases in labour (Riley et al 2000) but the
reverse has been shown in humans and the control of PGDH itself is multifactorial
(Challis et al 1999).
Luteolysis induced progesterone withdrawal occurs in other animals (e.g. mouse, rat)
but again this event is absent in humans where progesterone production shifts from
the corpus luteum to placenta. Indeed prostaglandin F receptor (FP) or COX-2
deficient mice have shown reproductive failure in both early pregnancy and
parturition (Lim et al 1997; Sugimoto et al 1997) and this could be as a result of the
lack of prostaglandin induced P4 withdrawal. Interestingly, 5a-reductase is an
enzyme that inactivates progesterone and Mahendroo et al reported the important
discovery that the 5a-reductase knockout mouse will labour but does not undergo
cervical ripening (Mahendroo et al 1999). Delivery can then expedited by
ovariectomy which imitates a luteolytic progesterone fall, or by administration of
relaxin. This shows that there are differing mechanisms controlling the various
components of parturition. Rat studies have confirmed the interaction of
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progesterone withdrawal, cytokines, leukocyte recruitment, NO and prostaglandins
in cervical ripening (Shi et al 2000).
Guinea pigs have similarities to the endocrinology of humans as progesterone
secretion shifts from corpus luteum to placenta and remains high throughout
gestation (Elger et al 1987). Chwalisz et al have demonstrated the key role of
antiprogestins in cervical softening in guinea pigs and have had reasonable success
initiating cervical ripening with cytokines and NO (Chwalisz et al 1994; Chwalisz et
al 1997).
1.1.3 Human Initiation of Labour
The necessity for an intact HPA axis appears not to be essential for humans as
anencephalic fetuses can be spontaneously delivered around term, as can fetuses with
adrenal hypoplasia. Endogenous placental Cortisol production is impossible as the
necessary hydroxylases are absent in humans. Nor in humans is there the prelabour
circulatory progesterone withdrawal, although there may be subtle local intrauterine
changes in progesterone receptor status.
In human labour, progesterone receptors (PR-A/ PR-B ratio) and oestrogen receptor
isoform (ERa) increase in myometrium and lower uterine segment reducing
functional progesterone responsiveness (Smith et al 2002; Winkler et al 2002). PR-
A in human myometrial cells is a repressor of PR-B acitivity (Pieber et al 2001).
This also increases oestrogen activation and correspondingly COX-2 and oxytocin
receptor (OTr) mRNA encouraging a contractile state. See Figure 1.2.
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Figure 1.2 Myometrialprogesterone/ oestrogen receptor interaction
OESTROGEN PROGESTERONE
Adapted from (Smith et al 2002)
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Maternal plasma Cortisol rises in late pregnancy, CRH increases exponentially
throughout gestation and is related to timing of delivery with a high second trimester
value strongly associated with preterm labour (McLean et al 1999). Prelabour,
CRH-binding protein falls thereby increasing free CRH concentration. CRH
receptors are present in maternal pituitary and myometrium, and fetal pituitary and
adrenal, thereby providing a mechanism to influence fetal adrenal androgen synthesis
and oestrogen concentrations. The myometrial CRH receptor expressed throughout
pregnancy is different to that seen at term and this may reflect a change in function
from relaxation to contraction (Lopez Bernal et al 1995). The differing roles of
hypothalamic and placental CRH in parturition are still under investigation.
In the human fetus the effect of the Cortisol surge may have a different emphasis, to
promote key enzymes responsible for fetal lung maturation and preparing other
organs to meet the demands of extra-uterine function (see Fig 1.3). Recent
publications would support the postulation of fetal HPA maturation being the
primary trigger. Whittle et al in their review of the glucocorticoid regulation of
parturition discuss the central role of Cortisol, both its direct prostaglandin effects
and its indirect intrauterine CRH mediated effects, stimulating COX-2 expression
and initiating human labour (Whittle et al 2001). Cortisol from fetal membranes
may also serve to alter PGDH activity by competitively displacing progesterone from
GR with down-regulated PGDH transcription (Challis et al 1999). The human
mechanism is different to that of sheep in that it is adrenal androgen production that
drives the HPA axis as opposed to a placental source. Dehydroepiandrosterone
sulphate (DHEAS) is then converted by placental sulphatase and aromatase to
oestradiol. So, a similar mechanism may operate in sheep and humans after all, with
the exception of the androgen precursor source, where humans rely on fetal and
maternal adrenal supplies to provide the term rise in intrauterine oestrogen, without a
drop in progesterone.
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1.2 CLINICAL ASPECTS OF ABNORMAL PARTURITION
Failure of the timely process of parturition results in prolonged pregnancy with its
increased risk of perinatal mortality. Premature initiation results in preterm labour.
Greater understanding of parturition would lead to safe, effective interventions for
both prolonged pregnancy and preterm labour.
1.2.1 Preterm Delivery
Preterm delivery is defined as delivery between 20 and 37 completed weeks
gestation. Prematurity is associated with 60-80% of all perinatal deaths excluding
congenital anomalies, the disproportionate majority occurring in the small group
delivered before 32 weeks gestation (Goldenberg 2002; Slattery et al 2002). This
reflects the increased severity of complications of prematurity at earlier gestations.
Between 24 and 28 weeks gestation, perinatal survival increases from 40 to 80% in
developed countries with neonatal facilities, whereas survival approaches 100% at 32
weeks gestation (Slattery et al 2002). Perinatal morbidity has long term sequelae for
those affected and is positively associated with both preterm delivery and low birth
weight. At extreme prematurity (24 weeks), only 12 % of those babies born alive
will survive without disability by the age of 30 months, corrected to expected date of
delivery (Wood et al 2000). And 23-24% of those delivered before 25 weeks
gestation that survive to discharge, will have severe disability (Tin et al 1997; Wood
et al 2000). Cerebral palsy, neurological and developmental disability and chronic
lung disease are a few of the many health problems affecting these individuals and
their families. Not only are families affected by physical disability and dependence,
but these children often display behavioural dysfunction and poor school
performance, which may limit their options in adult life. Accompanying these direct
effects, there are also wider economic considerations for health services (Kilpatrick
et al 1997) and society as a whole.
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Although, with good neonatal facilities, survival is much improved, the prevalence of
preterm delivery is increasing with variable reported rates from 6-15% (Slattery et al
2002) depending on the population studied. The current UK rate of preterm labour is
7-9% (Gardosi et al 2000; Aveyard et al 2002). The higher risk group, delivered
before 32 weeks gestation, accounts for 1-2 % of all deliveries. Approximately half
of these are due to preterm labour, another 25% result from preterm premature
rupture of the membranes (PROM) and the rest are attributable to obstetric
intervention (Tucker et al 1991). The observed rise is difficult to explain and varies
in different ethnic groups, but the increasing use of assisted conception and resultant
multiple pregnancies cannot be ignored. Multiple pregnancies have a substantial risk
(40-50%) of preterm delivery, but a proportion of this is due to increased
intervention beyond 34 weeks in an attempt to reduce late losses. The higher the
order of pregnancy, the shorter the average gestation at delivery; 36 weeks gestation
is average for twins compared with 33 weeks gestation for triplets.
Idiopathic preterm labour is multifactorial with risk factors such as social
disadvantage, multiple pregnancy, ethnic origin, substance misuse, age, parity and
previous reproductive history interacting. The pathogenesis of preterm labour is not
well understood, and it is often not clear whether preterm labour represents early
idiopathic activation of the normal labour process or results from a pathologic
mechanism.
The pathway to the initiation of preterm labour probably involves premature decidual
activation. Although decidual activation may be mediated in part by the fetal-
decidual paracrine system, in many cases of preterm labour, it appears that this
activation occurs in association with occult upper genital tract infection. Infection
has been widely investigated as a cause of preterm labour, and while it is known that
any maternal systemic infection may initiate labour, it is less clear whether intra¬
uterine or genital tract infection has a significant role. There is a current hypothesis
that sub-clinical choriodecidual inflammation may be responsible (Sebire 2001).
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1.2.2 Induction of Labour
Delivery beyond 42 weeks gestation occurs in 3.5-12% of pregnancies (Lagrew et al
1986; Sue-A-Quan et al 1999; Rand et al 2000). Prolonged gestation, defined as >
294 days from last menstrual period, is associated with increased perinatal mortality,
where late intra-uterine death is a particularly tragic outcome for an otherwise
uncomplicated pregnancy. Although the gestation specific risk of perinatal death
with prematurity is high, when considered relative to total ongoing pregnancies, the
risk is highest at term and post-dates. The rate of stillbirth or perinatal death rises
seven-fold, from 0.7 per 1000 ongoing pregnancies at 37 weeks gestation to 4.8 per
1000 at 42 weeks gestation (Hilder et al 1998).
Perinatal mortality statistics show that the risk of unexplained intra-uterine death
increases significantly beyond 41 weeks (Yudkin et al 1987; Hilder et al 1998;
Cotzias et al 1999). The identification of the fetuses at risk has eluded us, despite
various methods of antenatal monitoring, and so routine induction of labour serves as
intervention in an attempt to reduce these late deaths. There has been hesitation to
introduce routine elective induction prior to 42 weeks due to the reported increased
rates of intervention and caesarean delivery without improvement in perinatal
outcome (Prysak et al 1998; Seyb et al 1999; Alexander et al 2000; Maslow et al
2000). This has now been questioned as evidence grows that elective induction after
41weeks does not increase caesarean section rates (Hannah et al 1992; Parry et al
1998; Sue-A-Quan et al 1999; Rand et al 2000; RCOG Clinical effectiveness support
group 2001). Several studies have also shown that accurate dating by ultrasound
(Gardosi et al 1997), and clear departmental guidelines (Harris et al 2000) can
reduce the number of pregnancies requiring induction for postmaturity.
Induction of labour is a common intervention in post-dates and complicated
pregnancies. It occurs in approximately 20% of all pregnancies in the UK and in
excess of this in some regions (Gardosi et al 1997; Robson et al 1997; Nuutila et al
1999; MacDorman et al 2002). The commonest indication for induction of labour is
post-dates pregnancy, in 60-70% of cases. However routine induction in nulliparous
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women at term has been associated with increased caesarean section rates (Prysak et
al 1998; Seyb et al 1999; Maslow et al 2000). It must therefore be recognised that
there is still a balance of risks to achieve, so each case should be judged individually
and induction should not be considered entirely risk free.
Although much progress has been made in the last 40 years and current methods are
reasonably successful, difficulties are still encountered. These range from lack of
efficacy, in a small sub-group of women, to unpleasant side effects and dangerous
complications such as uterine rupture. Uterine rupture can have catastrophic results
and is a particular risk for those women who have previously had a caesarean section
where the risk of perinatal death is estimated 0.02-0.05% (Plaut et al 1999; Zelop et
al 1999; Lydon-Rochelle et al 2001; Smith et al 2004).
Induction of labour is defined as any intervention designed to artificially initiate
cervical ripening and/or uterine contractions leading to progressive dilatation and
effacement of the cervix with the purpose of vaginal delivery. Favoured methods of
induction of labour at present are artificial rupture of membranes, vaginal
prostaglandins and intravenous syntocinon infusion. Each of these methods has its
limitations and complications so the search is still on to find the ideal agent.
It is now a well-established fact that unripe cervices lead to prolonged labour with
associated complications of maternal pyrexia, sepsis and postpartum haemorrhage,
failed induction, an increased risk of caesarean delivery and fetal effects such as poor
Apgar scores, birth asphyxia and neonatal sepsis (Calder 1979; Edwards et al 2000).
PGE2 produces cervical ripening as well as relaxing the cervical smooth muscle and
contracting the myometrium. Dinoprostone (PGE2) is currently the agent of choice,
either as a vaginal/intracervical gel or a slow release polymer insert, but a
requirement for special storage and the relatively high cost of these preparations can
be prohibitive for some countries.
Misoprostol, a PGE, analogue is an inexpensive alternative and simplifies storage
requirements, but there are licensing and dosage issues, despite many studies
27
supporting its efficacy and safety. Developed for the prevention of NSAID induced
peptic ulcers, misoprostol was designed to resist catabolism by 15-OH PGDH and
was always known to have abortifacient properties. After development for use in
termination, the first assessment of misoprostol as a labour induction agent were in
1992. Misoprostol has been repeatedly shown to effectively induce labour, resulting
in improved cervical score, shortened delivery interval and reduced requirement for
other oxytocics (Danielian et al 1999; Hofmeyr et al 1999; Wing 1999; Sanchez-
Ramos et al 2000). Yet the ideal regime has not been established due to concerns
about its uterotonic effect and association with hyperstimulation and higher rates of
meconium stained liquor (Goldberg et al 2001). Vaginally administered misoprostol
has different pharmacokinetics to oral, with a slower and lower peak plasma
concentration which may be sustained for up to four hours (Sanchez-Ramos et al
2000; Hofmeyr et al 2001). This results in a greater exposure overall while avoiding
the surge seen with oral administration. The result is greater efficacy when
considering delivery outcomes against time, (How et al 2001; Kwon et al 2001) but
concern remains with fetal safety. Currently lower dose regimes are being assessed.
Misoprostol has repeatedly been shown to be as efficacious if not more, than
dinoprostone but sufficient safety data has yet to be established, particularly in those
women with a uterine scar (Kolderup et al 1999; Rowlands et al 2001; Rozenberg et
al 2001). Clearly, until the safety issues are clarified this therapy will not be
universally welcomed.
The antigestagen mifepristone (see p32) at a dose of 200mg given 24, 48 or 72 hours
before induction of labour results in a slightly shorter delivery interval and a reduced
requirement for either prostaglandins or oxytocin, but not the more dramatic effect
we see in early pregnancy (Elliott et al 1998; Wing et al 2000).
Uterine rupture is a rare but catastrophic complication of labour following a previous
caesarean delivery, and can result in fetal death with serious maternal morbidity.
Induction of labour is always performed with caution in these cases, but restricted
prostaglandin use has been successful. The incidence of uterine rupture is 0.2-1.5%
depending on the definition used (Sanchez- Ramos et al 2000). There is an
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associated uterine dehiscence where scar separation is noted incidentally at caesarean
section or post delivery where there have been no clinical signs or complications.
An American retrospective cohort analysis reports the overall uterine rupture rate at
0.45% in women with one previous caesarean delivery and found an increased rate
with labour, labour induction and labour induction with PGE2. The risk with repeat
caesarean prelabour was 0.16% increasing to 0.52%, 0.77% and 2.45% respectively
(Lydon-Rochelle et al 2001). This reflects findings in other studies and reinforces
the concern that any agent that also stimulates myometrial activity is not ideal for
cervical ripening (Zelop et al 1999; Smith et al 2004). Smith's population based
study confirms the increased risk of uterine rupture with perinatal death where the
woman has had no previous vaginal birth and is induced with prostaglandins (Smith
et al 2004).
Uterine disruption has been reported in 5.6% women with previous caesarean
deliveries, treated with misoprostol compared to only 0.2% in those not exposed
(Plaut et al 1999). However uterine rupture has also been reported in parous women
without prior uterine surgery (Bennett 1997). Currently there is not enough data to
support safety of misoprostol use in those women with a scarred uterus until enough
properly conducted controlled studies have been completed.
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1.2.3 Clinical Markers of Cervical Ripening
Many authors have commented on the importance of cervical assessment before
induction of labour and several methods, from examination to biochemical markers
or ultrasound assessment, have been explored. The most cost effective and widely
used system is that of the Bishop score (Edwards et al 2000), or a modified version
(Calder et al 1974), where five cervical parameters are scored and the total reflects
ripeness. A low score is unfavourable and equips the clinician with pertinent
information allowing decisions regarding suitability and method of induction.
Fetal fibronectin is an extracellular matrix protein produced by choriodecidual cells
and can be found in cervical secretions in advance of labour. Indeed fetal fibronectin
correlates well to cervical ripening at term (Ekman et al 1995) and is detectable in
cervical secretions of those at risk of preterm labour. It is thought to reflect
choriodecidual separation at internal os, but does not add to the clinical findings at
term. A randomized controlled clinical trial did not show any reduction in preterm
labour for asymptomatic fibronectin positive women treated with antibiotics
(Andrews et al 2003). Although fibronectin has not proved to be of any benefit in
predicting or preventing preterm labour, it can provide reassurance for some due to
its high negative predictive value (Hellemans et al 1995).
Transvaginal sonography (TVS) can detect several signs of potential cervical
incompetence or preterm labour: Firstly, dilatation of the internal os - this can be
seen prior to dilatation of the external os detectable on digitial vaginal examination.
Secondly, funnelling - prolapse of membranes into the cervical canal with shortened
closed cervical length. Again this is visible prior to external os dilatation, either
spontaneously or with fundal pressure. Thirdly, shortening of the cervix - the length
of the endocervical canal seen in apposition.
TVS of cervical length has low positive predictive value for low risk women (lams et
al 1996), but may be a useful adjunct in managing high risk cases to select those
requiring cervical cerclage. Retrospective studies have confirmed an association
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with reduced endocervical canal length and prior preterm labour (Guzman et al
1998a), and a longitudinal study showed that this can be detected between 16 and 24
weeks' gestation (Guzman et al 1998b). Cervical length has been shown to be the
best indicator of subsequent preterm delivery (Rozenberg et al 2002) with 48% of
women with a cervical length <15mm at 22 weeks gestation delivering before 32
weeks (Hassan et al 2000). The negative predictive value of 96.7% is also reassuring
in this group, but limitations for use as a screening tool in low risk women arise with
a low sensitivity of 8.2%. Even though high risk cases can be identified, selection
for cervical cerclage based on shortened cervical length < 15mm has not been shown
to reduce subsequent preterm delivery in a randomized controlled trial (To et al
2004). Outwith screening where there is symptomatic evidence of threatened
preterm labour, cervical length < 15mm is the best predictor of subsequent preterm
delivery within 7 days ; 37% vs 0.7% with Cx length > 15mm (Tsoi et al 2003).
Outwith clinical practice, other methods have been used to assess cervical state.
Fluorescence spectroscopy can inform molecular and physical structure and has been
used to examine collagen content in various tissues. Garfield et al have used this
technology in the form of a collascope to assess cervical tissue changes in pregnancy
in both rats and humans, the advantage being the ability to perform longitudinal
studies in the same subjects. Light-induced autofluorescence (LIF) in the cervix is
thought to originate from pyridinoline, a major crosslink in collagen fibril structure,
and was seen in rats to reduce in late gestation and after treatment with
antiprogesterone (Garfield et al 2001). These findings were corroborated by parallel
cervical resistance studies and electron microscopy and the changes spontaneously
reversed. Human studies have shown a similar decline in the last 15 weeks of
pregnancy with slow postpartum recovery, and may prove clinically useful in
prediction of preterm labour (Maul et al 2003). The non-invasive nature of LIF may
aid future investigations in cervical function in addition to potential benefits in
labour management.
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1.2.4 Termination of Pregnancy
Around 192,000 terminations of pregnancy procedures are performed in the UK each
year at present (RCOG Guideline Development Group 2001). There are two main
methods of termination of pregnancy, surgical and medical. Surgical, largely
vacuum aspiration and medical, induced abortion techniques have both benefited
from the use of prostaglandins. Indeed prostaglandin use has so dramatically
changed medical methods to the extent that where it was once a rare alternative to
vacuum aspiration, it is now commonplace and in many cases preferred.
It is known that myometrial stimulation occurs in all trimesters with exogenous
prostaglandin administration (Mitchell 1987b). It has also been shown that
prostaglandins are synthesized in the cervix itself and prostaglandin receptor (mostly
EP2) presence in the cervix has been demonstrated (Uldbjerg et al 1987; Smith et al
1998). Therefore, termination of pregnancy either medically or surgically in the first
trimester, and medically at any gestation can be facilitated by prostaglandin use.
Those analogues in use initially had success rates of 94-100% (Norman 1992). The
1980's saw virtual universal use of vaginal prostaglandin analogues, mostly
gemeprost, both for medical abortion and cervical ripening pre-surgical vacuum
aspiration. More recently, the discovery of mifepristone and misoprostol has further
improved the efficacy of medically induced abortion.
Mifepristone is an antiprogestin that competes with progesterone at the receptor level
thus producing a reduced progesterone effect, and sensitising the uterus to
prostaglandins (Kelly et al 1990). Csapo's theory that progesterone withdrawal
results in uterine activity is borne out here, despite many studies being unable to
show a physiological reduction in progesterone in normal term pregnancy (Csapo
1956; Csapo et al 1965). Not only is uterine activity stimulated after approximately
36hours, but increased myometrial sensitivity to prostaglandins also results. The
exact mechanism of action is not known but increased leukocyte and monocytes
numbers, with elastase and MMP stimulation is seen (Denison et al 2000).
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Mifepristone alone is not a particularly effective abortifacient (success rates of 60-
70%) (Cameron et al 1986; Bygdeman 1993), but in combination with prostaglandin
analogues results in successful termination of pregnancy in 92-99% of cases
(Silvestre et al 1990; Norman et al 1991; McKinley et al 1993; Peyron 1993; Baird
et al 1995; Ashok et al 1998b; Spitz et al 1998; Schaff et al 1999; Schaff et al 2000).
Mifepristone is also helpful in reducing side effects as the prostaglandin dose
required can be significantly reduced.
Misoprostol has been exploited for the precise purposes of therapeutic termination of
pregnancy with great success (Norman et al 1991; Peyron 1993; Jain et al 1994; el-
Refaey et al 1995). Although there has been recent controversy surrounding its use in
pregnancy in terms of licensing (Friedman 2001; Gebhardt 2001; Hale et al 2001;
Mackenzie 2001; Wagner 2001), misoprostol has been extensively evaluated
(Goldberg et al 2001) and introduced into routine clinical practice for termination of
pregnancy.
Mifepristone alone is relatively free of side effects, but did not approach the efficacy
of prostaglandins (Cameron et al 1986). A combined approach allowed a reduction
in prostaglandin dosage and attendant side effects, with equivalent efficacy of 94-
100% (Cameron et al 1986; Rodger et al 1989; Silvestre et al 1990; UK Multicentre
Trial 1990).
Misoprostol has been explored as a prostaglandin alternative since 1991 and has been
shown to be extremely effective (McKinley et al 1993; Peyron 1993; Spitz et al
1998) with the advantage or oral administration. Paradoxically many investigators
are now using misoprostol vaginally as efficacy improves in the 7-9 week group
(Ashok et al 1998b; Schaff et al 1999; Schaff et al 2000). Complete abortion rates of
97.5% have been achieved in women up to 63 days pregnant, and 95% at 9-13 weeks
have been achieved using a combination of mifepristone and vaginal misoprostol,
with 93% of women treated as day cases (Ashok et al 1998a; Ashok et al 1998b).
Similarly, mifepristone and misoprostol use has now extended to managing silent or
incomplete miscarriage, giving women an option to avoid surgical intervention or
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prolonged conservative management. Equally in second trimester terminations,
abortion within 24hrs can be achieved in 90-97% of cases depending on the
misoprostol regime (Goldberg et al 2001).
Surgical vacuum aspirations are performed throughout the first trimester. Cervical
priming before surgical termination of pregnancy reduces the operative morbidity
associated with aspiration procedures, by reducing the force required to achieve
adequate cervical dilatation and thereby minimising the incidence of uterine
perforation, cervical damage, false passages and incomplete evacuation. The same
problem lies with the usual side effects seen with prostaglandin administration, those
of abdominal pain, nausea, vomiting and diarrhoea (Ledingham et al 2001a).
Vaginal misoprostol has been proven at least as effective with the added benefits of a
reduced side effect profile and much reduced expense (el-Refaey et al 1994).
Clinical trials have found 400pg misoprostol vaginally three hours prior to surgery to
be the optimal regime (Fong et al 1998; Henry et al 1999).
Following success in guinea-pigs (Chwalisz et al 1997), the nitric oxide donors have
been evaluated as a cervical ripening agent in first trimester termination of pregnancy
in humans (Thomson et al 1997b; Thomson et al 1998; Facchinetti et al 2000). The
advantage of nitric oxide would be that it is known to be a smooth muscle relaxant
and so should not cause the same the side effects as prostaglandins and may therefore
be safer. Results showed less effective ripening with increased intra-operative blood
loss, but a much improved side effect profile than PGE2 (Thomson et al 1998).
However the blood loss was no greater than a control group of parous women. Use
of sodium nitroprusside may be more effective than isosorbide mononitrate and
appears to reduce the rate of headache (Facchinetti et al 2000). This may with
further assessment be a useful adjunct to current methods, but the myometrial effect
requires more attention, particularly if this is be extrapolated to term pregnancy and
the frequency and acceptability of headache must be established.
An ideal induction agent would cause cervical ripening without uterine activity,
allowing this process to complete uninterrupted prior to the initiation of active
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labour, and without any unwanted side effects. As there are so many mechanisms
involved and their mediators often have wide-ranging effects, the difficulty is with
the specificity of effect. Many of the previously mentioned mediators such as
cytokines and nitric oxide are under investigation as the search continues. It may
well be that a combined approach may be the way forward in optimising our clinical
procedure. Clearly prostaglandins are a major factor in parturition and they have
already contributed greatly to our understanding of this process and provided useful
clinical tools. The challenge is to further define the role of specific prostaglandins
and their receptors, in combination with the many inflammatory mediators known to
be involved.
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1.3 THE HUMAN UTERINE CERVIX
1.3.1 Cervical Changes in Pregnancy
Before labour begins, the human uterine cervix undergoes some structural changes.
Both physiologically and therapeutically, this is referred to as cervical ripening and
applies to the process whereby the cervix undergoes significant connective tissue
remodelling resulting in a compliant and distensible organ. Cervical remodelling
takes place gradually throughout pregnancy with "cervical ripening" occurring in the
latter stage, before the dramatic cervical changes seen during labour. Ledger et al
confirmed that this cervical change was an active process when softening was shown
in cervices, surgically separated from the uterus, where the effects could not be a
passive result of uterine contractions (Ledger et al 1985).
Although comparisons have been made between many aspects of parturition and the
inflammatory process, it is perhaps cervical ripening that provides the most
compelling evidence. PGE and NO are both vasoactive and may also have effects in
allowing leukocyte ingress. Activated macrophages and circulating leukocytes
release pro-inflammatory chemotactic cytokines, up-regulating adhesion molecules
and leukocyte recruitment. Leukocyte degranulation releases MMPs, degrades
collagen, activates fibroblasts to release MMPs specific to basement membrane,
further enhancing leukocyte migration, degranulation and enzymatic degradation of
collagen. The result is remodelled tissue that is more compliant and which readily
dilates in response to mechanical stretch and uterine activity. The evidence for this
hypothesis will be examined.
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1.3.2 The Non-pregnant Cervical Structure
To understand the changes occurring in pregnancy and labour one must first
appreciate the cervical structure in the non-pregnant state. The nature of cervical
tissue was well described by Danforth in 1947 (Danforth 1947). The cervix is
bounded proximally by the uterine body, at the internal os, and distally, by the
external os and vagina. Distinct from the muscular uterine corpus, the cervix is a
fibrous organ with less than 15% of its content contributed by smooth muscle, mostly
found peripherally and increasingly abundant nearer to the corpus (Danforth 1954).
The remaining extracellular matrix consists of dense collagen (66% type I, 33% type
III) fibril bundles and small numbers of elastin fibres, with intervening ground
substance (Kleissl et al 1978). Type IV collagen was only found in the basement
membrane region in non-pregnant cervices (Minamoto et al 1987). The endocervical
canal is lined by tall columnar epithelium, with highly branched glands, down to the
external os where the squamo-columnar junction marks the transition to stratified
squamous epithelium, which is continuous with that of the vagina.
Danforth reported that in the non-pregnant state, elastin constitutes less than 1
percent of cervical tissue, largely located perivascularly and sparsely scattered.
Subsequent technologies have allowed for this to be further refined and suggest that
these elastin fibres run between the epithelium and smooth muscle cells in a
longitudinal direction, from external to internal os. At this proximal point there is a
slightly higher ratio of elastin to collagen, relative to the more distal portion (Leppert
1995). In the uterine body, elastin remains a small component, sparsely distributed,
although largely in the outer third.
Smooth muscle cells account for 10-15% of cervical tissue, largely placed
peripherally and maximally near the internal os. Near the histological internal os is
the fibromuscular junction, above which smooth muscle becomes the dominant
component of the uterine body, and this transition is variable from gradual to abrupt
(Danforth 1947).
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The fibroblast or stromal cell is the main cellular constituent in the human cervix as
described by Junqueira (Junqueira et al 1980) and supported by evidence in other
species (Hegele-Hartung et al 1989). Fibroblasts are connective tissue cells which
secrete extracellular matrix rich in collagen, glycoaminoglycogens, glycoproteins
and elastic fibres and so are involved in growth, healing and repair processes. They
are small spindle shaped cells when inactive but when active they have branched
cytoplasm with abundant rough endoplasmic reticulum around an elliptical enlarged
nucleus and prominent nucleoli. The fibroblast can give rise to smooth muscle cells
or bone or fat cells all of which are of mesodermal origin, and has the capbility to
regress or re-differentiate.
1.3.3 The Cervix in Pregnancy
In early pregnancy, uterine muscle and fibrous elements hypertrophy and undergo
hyperplasia. Cervical oedema and increased vascularity is evident. The length of the
cervix remains unchanged in the first trimester, as does the smooth muscle content.
Nor is there any consistent evidence of change in total elastin content, but it has been
noted that elastin fibres are more numerous at the internal os (Leppert et al 1986).
The existence of a distinct uterine "isthmus" was questioned after Danforth's work
showed no anatomical or functional distinction between this and the uterine body
(Danforth 1947). However the concept of the lower uterine segment (LUS), which
establishes during the third trimester, has persisted and behaviour of this segment is
clearly different to that of the uterine fundus. Is the isthmus or LUS merely a
continuum between the uterus and cervix? As a transitional zone, this may possess
similar properties to both regions above and below at different points in reproductive
life.
Later studies revealed the cervical musculature to be slightly concentrated
peripherally and more specifically, laterally in the supravaginal portion (Danforth
1954). The cervix is capable of contractile activity, though this is mild when
compared to the abilities of the uterus. The purpose of the cervical smooth muscle
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and elastin distribution may be to protect the uterine vessels and to aid restoration to
normal postpartum function. Does this relative concentration of elastin and smooth
muscle near the internal os suggest a sphincteric function, either in retaining the
uterine contents antepartum, or restoring the cervix postpartum? (Leppert et al 1987)
In late pregnancy, cervical smooth muscle cells appear hypertrophied and aligned in
the vicinity of leukocytes, surrounded by collagen bundles in the presence of
fibroblasts (Minamoto et al 1987). Apoptosis of smooth muscle cells has been
observed in rat models (Leppert et al 1994) and may be involved in the initiation of
extracellular matrix reorganisation. Fibroblasts do appear to undergo some changes
in gestation at least in animal models. Bassett studied uterine, cervical and
ligamental fibroblasts in the pregnant ewe and found a progressive enlargement of
both fibroblast nuclei and cytoplasm with the nuclei being distinctly rounder as
gestation advanced (Bassett 1959). These changes were accompanied by more
sparse and loosely arranged collagen fibres, were not seen in other parts of the body
and were also seen in other species (pig, cow, rabbit, guinea-pig). In the guinea -pig
advanced gestation is associated with an increased number of activated cervical
fibroblasts and a relative increase in mast cells and macrophages (Hegele-Hartung et
al 1989).
In humans, there is no particular arrangement of type I and III collagens at any stage,
but advancing gestation results in dissociation and branching of collagen fibrils into
components with oedematous expansion of intervening spaces. The combination of
collagen bundle reorganistion and apoptosis may, in concert, effect cervical ripening.
A loosening of the collagen network is evident as early as the first trimester. In
pregnancy and labour there is a large increase in the solubility of collagen and
collagen breakdown products (the hydroxyproline containing peptides), relative to
non-pregnant cervices (Kleissl et al 1978). Petersen et al demonstrated a lower
cervical collagen concentration in women with cervical incompetence (as measured
by hydroxyproline concentration and extractability), stressing the importance of the
cervix in maintaining pregnancy in addition to its vital role in parturition (Petersen et
al 1996). This study also demonstrated that pregnancy-related cervical changes do
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not fully reverse with a gradual reduction in hydroxyproline concentrations following
recurrent pregnancies. For collagen to retain tensile strength the fibres must exceed a
critical length (20pm) and there must be strong chemical bonds between the collagen
fibres and other matrix proteins. Throughout pregnancy there is a net loss of
collagen fibre length, cross-linking and alignment and therefore loss of strength.
Studies on cervical collagen have used various methods from hydroxyproline content
(both polymerised and depolymerised collagen) to picrosirius red staining
(polymerised), with denominators of dry, wet or dry defatted tissue. Also different
sites and types of biopsy obtained at different stages of pregnancy or labour have
been compared. However, the following represents a summary of findings.
Extracellular matrix is composed of large molecules such as fibronectin, laminin and
proteoglycan complexes. Proteoglycan complexes consist of various







These complexes bind tightly, investing the collagen fibrils and providing rigidity. In
general the longer the GAG chain the greater the binding affinity to collagen. The
dominant GAGs in the cervix are chondroitin sulphate and dermatan sulphate. They
contain iduronic acid, which binds very strongly helping to confer strength. Certain
other glucuronic acid containing GAGs, such as heparan sulphate, bind less strongly
leading to destabilisation of the organised fibril bundles, loss of mechanical strength
and thus, enhanced compliance (Uldbjerg et al 1983b). This is represented by smaller
widely scattered dissociated fibrils seen at term, compared to the non-pregnant state.
1.3.4 The Cervix in Labour
During active labour, the cervix is mechanically expanded by the downward force of
uterine contractions on the fetal presenting part. Both the cervix and LUS become
thinned and are passively dilated as the fetal head descends. For this to occur the
cervix must have previously transformed to a softened, non-resistant state.
Effacement is where the cervix shortens or thins and this may occur in either the
latent or active phase of labour.
Biomechanically, the cervix is subject to cyclic stretch and relaxation, where greater
cervical dilatation is achieved during contraction than by the end of contraction. The
visco-elastic nature of the cervix (i.e. the mixed collagen and elastin components)
contributes to this recoil effect, while allowing overall progressive dilatation.
There are many biochemical changes in the cervix peri-partum, the end result being a
reduction in overall collagen content by 50-70% (Junqueira et al 1980; Uldbjerg et al
1983b), an increase in water content (from 80 to 86%), and a change in the
proportions of different GAGs (Osmers et al 1993) with a relative increase in
heparan sulphate (Danforth et al 1974; Uldbjerg et al 1983a; Ekman et al 1986).
Recently it has been suggested that a large keratan sulphate proteoglycan may be
involved in the matrix reorganisation at term, but this has not yet been fully
characterised (Fischer et al 2001).
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Hyaluronic acid (HA) content in the cervix also increases in labour, and as a
hydrophilic compound may be partially responsible for the higher water content
(Osmers et al 1993; El Maradny et al 1997). HA also induces neutrophil migration,
collagenase synthesis, cytokine release (IL-1) and is secreted by fibroblasts, where
there is some evidence of regulation by cytokines (IL-1, IL-8), hormones
(progesterone), prostaglandins and lipopolysaccharide (see(El Maradny et al 1997)
for review). HA is capable of producing cervical ripening in rabbit cervices, and is
distributed throughout human cervical connective tissue. There appears to be a
mutual interaction between IL-8 and HA in connective tissue remodelling. Rapid
postpartum reduction of HA to normal levels has been shown previously and is
thought to be as a result of progesterone induced depolymerisation regulated by the
progesterone receptor (Tanaka et al 1994).
Human cervical connective tissue expresses both oestrogen and progesterone
receptors, both of which are down-regulated as pregnancy advances (Stjernholm et al
1997). Progesterone inhibits IL-8 production and stimulates HA degradation, so
with reduced PR effect at term the reverse may apply, encouraging ECM
degradation. Human cervical studies have confirmed an increase in cervical IL-8 in
and after labour but not with pre-labour cervical ripening (Sakamoto et al 2004;
Tornblom et al 2005) so the role of IL-8 in cervical ECM reorganisation pre-labour
remains uncertain, as does the distinction between labour or post-partum contribution
to these changes. Additionally as no ripe cervices (Bishop score >8) were studied,
then it could be argued that this data set is incomplete as IL-8 could be altered in this
late stage of cervical ripening.
There is no doubt that these dramatic events in the extracellular matrix are an
essential part of cervical ripening, and that significant activity in the connective
tissue cells must be responsible to some degree. Studies in both guinea-pigs and
humans concur on the cervical stromal appearances in labour. Both note a
significant increase in mast cells, macrophages and in particular polymorphonuclear
leukocytes, highly active fibroblasts and pericellular halos suggestive of
collagenolysis (Junqueira et al 1980; Hegele-Hartung et al 1989; Montes et al 2002).
42
Outwith pregnancy fibroblast cells in the mucous layer of the human cervix stain for
vimentin, but not oc-smooth muscle actin or desmin. Those examined from
intrapartum specimens display desmin positivity in association with myofibroblasts
morphology as seen on electron microscopy, a finding peculiar to labour suggesting
a specific phenotypic alteration for a particular function at that time (Montes et al
2002).
The fibroblast is undoubtedly central to this process as a source of collagen, GAGs
and lytic enzymes in addition to the capability for phenotypic alteration, but there is
more to consider. There are other contributory factors such as vascular permeability
and its regulation (Cabrol et al 1990). What of migratory cells which do not
constitutively form part of the connective tissue? There are many similarities to
inflammatory events which will now be discussed.
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1.4 INFLAMMATORY EVENTS IN THE CERVIX IN PREGNANCY
Infection has a long been identified as having a definite causative role in some cases
of preterm labour, where there is an exaggerated inflammatory response leading to
excess stimulation of cyclooxygenase pathways and cytokines. It is more recently
that this theory has expanded to include parturition at all gestations, but the trigger
without bacterial invasion will be different and the events appear attenuated. Pro¬
inflammatory cytokines now have a secure place in the pathophysiology of
parturition in both term and preterm pregnancy. The extensive interaction between
cytokines and prostaglandins in uterine, intrauterine and cervical tissues has been
reviewed by Keelan et al (Keelan et al 2001).
Cervical ripening has been likened to an active inflammatory event culminating in
extensive alteration within connective tissue (Junqueira et al 1980; Liggins 1981;
Uldbjerg et al 1983a; Leppert 1995). There are several components; biochemical
rearrangement of extracellular matrix, inflammatory reaction with enzymatic
degradation, cervical smooth muscle relaxation and even apoptosis has been
described (Leppert et al 1994).
The onset of cervical ripening occurs weeks before that of labour and cervical
changes pre-exist even that. Vaginal washings display a significant increase in
number of viable leukocytes and concentration of IL-8 towards term (Yamada et al
2002). Pro-inflammatory cytokines (IL-1, IL-8) increase in cervical stroma
concurrent with cervical dilatation (Barclay et al 1993; Winkler et al 1998; Winkler
et al 2003). In addition cervical ripening can be induced by PGE2, NO and IL-8 in
humans, and guinea-pigs (Uldbjerg et al 1983b; Rajabi et al 1988; Uldbjerg et al
1990; Calder et al 1993; Chwalisz et al 1994; Chwalisz et al 1997; Winkler et al
1999b; Winkler et al 1999a). There appears to be a temporal relationship between
cytokine release, macrophage migration within uterine and cervical tissues and
prostaglandin synthesis via COX-2 activity (Romero et al 1991; Bennett et al 1992;
Allport et al 2001). Changes in macrophage numbers, activation and location have
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been shown in mice and human uteri and may represent a shift from non¬
inflammatory to inflammatory response as gestation progresses (Thomson et al 1999;
Ledingham et al 2001b; Yellon et al 2003).
There has been much work into the final "cervical ripening" seen in pregnancy but
limited study into the cervix throughout pregnancy. For obvious reasons this is a
difficult area to study but the preparatory phase of cervical remodelling that is likely
to occur throughout gestation is an essential component to the events that follow.
Late stage cervical ripening, cervical effacement, dilatation and the remarkable post
partum recovery to a pre-pregnant state will all rely on gestation-dependent
regulatory mediators.
1.4.1 Chemotaxis
Leukocyte recruitment occurs as a result of chemotactic stimuli, vasodilation and
extravasation of immune cells, immune cell activation and MMP release.
Chemokines are particular cytokines that induce chemotaxis (migration) and
activation of leukocytes (Baggiolini 1998). As such, chemokines have an important
role in inflammatory responses and pathological inflammatory disorders (arthritis,
pulmonary fibrosis, hepatic fibrogenesis, multiple sclerosis). Fibroblasts have the
ability to synthesize chemokines and therefore initiate leukocyte recruitment and
inflammatory responses in both physiological and pathological situations. Thus the
fibroblast is likely to play a key role in cervical remodelling. Chemokine synthesis is
stimulated by bacterial products, pro-inflammatory cytokines, growth factors and
hypoxia (Galindo et al 2001). With neutrophil chemotaxis there is an early
requirement for cell adhesion, as has been demonstrated by Winkler and others,
where an increased expression of adhesion molecules in the LUS/ cervix was shown
in association with term and preterm labour (Ledingham et al 2001b; Winkler et al
2003). Expression was largely on vascular endothelial cells, but also on leukocytes,
and in vitro studies revealed potential modulation by pro-inflammatory cytokines,
PGE2 and sex hormones.
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Leukocyte chemotaxis occurs in several phases. Firstly, vascular endothelial cell
adhesion molecules (VCAMs) are activated, weakly binding leukocyte cell adhesion
molecules (CAMs) and causing these bound leukocytes to roll along the vessel wall.
The high local concentration of cytokines causes the leukocyte to both shed its
surface CAM, and upregulate integrin expression. Integrins bind much more
strongly to the endothelial VCAM-1 or ICAM-1 and result in leukocyte arrest,
adherence and flattening against the vessel wall. The chemokines present in the
surrounding tissue stroma adhere to GAGs and attract the extravasating leukocytes
along a chemokine gradient into the target tissue.
Chemokine receptors are seven-transmembrane-bound-G-coupled receptors (7-
TMB). The antigen specific extracellular N-terminal domain is linked to the
intracellular C-terminal domain by 7 hydrophobic a-helical transmembrane spanning
regions. Activation is by binding to the extracellular domain, resulting in a
conformational change coupled to intracellular signalling systems and 2nd messenger
pathways. Inactive GDP is converted to active GTP via adenyl cyclase,
phospholipase or tyrosine kinase pathways.
Liggins initiated the theory of the inflammatory reaction mechanism for cervical
ripening (Liggins 1981). This proposes that vasodilatation, exudation, fibroblast
proliferation and collagen remodelling; all typical of the inflammatory reaction occur
in the cervix. Following leukocyte invasion, these cells degranulate, releasing matrix
metalloproteinases which degrade the structural proteins of the extracellular matrix.
Studies have observed a lack of collagen around neutrophils in the cervix peripartum,
but whether this is due to collagen degradation or simply rearrangement is unclear
(Junqueira et al 1980). Infiltration of the cervix by inflammatory cells may occur
with an initial trigger of macrophage activation, release of cytokines (IL-1,11-6, IL-8,
PAF) and then enhancement of leukocyte recruitment. IL-8 is a known neutrophil
chemoattractant and may have a synergistic effect with PGE2 or NO, which are both
vasodilators (Thomson et al 1997b; Kelly 2002). This would aid extravasation of
these recruited cells from vessels into cervical stroma.
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1.4.2 Migratory Cells
As early as 1980, there has been good evidence of cervical leukocyte infiltration in
labour (Junqueira et al 1980). Surprisingly few studies since have adequately
supported or refuted these findings. The original study compared non-pregnant
cervical biopsies with those taken intrapartum and whilst reporting increased
neutrophil numbers in labour compared to non-pregnant samples, also combined this
with evidence of increased collagen depolymerisation. The biopsy method is not
detailed but a thorough account of microscopy and electron microscopic findings are
given. This does not allow assessment of gestation dependent changes outwith
labour.
Bokstrom took cervical needle biopsies in early pregnancy, term pregnancy before
labour and also in labour to study leukocytes subpopulations by
immunohistochemistry, and showed T-lymphocyte predominance in the first
trimester, compared to significantly increased densities of neutrophils and
macrophages at term with no further significant increase in labour (Bokstrom et al
1997). The perivascular distribution of leukocytes was noted in both early and late
gestation, but this added a gestation dependent alteration of leukocyte sub-types with
no significant change seen in labour. Denison's study group was first trimester
pregnancy and Shumaker punch biopsies of the cervix were compared after
mifepristone administration. Immunolocalisation of leukocyte markers in untreated
samples showed CD45 and neutrophil elastase to be mainly stromal whilst CD68 was
negative. Mifepristone markedly increased all leukocyte markers in the stromal
compartment, and epithelium in the case of CD68 (Denison et al 2000). T-cells were
not distinguished in this study, but it confirms the presence of leukocytes early in
gestation, and the phenomenon of leukocyte invasion after antiprogestin
administration.
Stygar again confirmed an increased density of CD45 and CD68 immunopositive
cells at term and post-partum, agreeing with Bokstrom (Stygar et al 2001). These
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leukocytes and monocytes were largely seen perivascularly and in the subepithelial
areas. Another comparison of non-pregnant, term and labouring cervices found
increased intercellular cell adhesion molecule mRNA expression in labour in
association with leukocytes, whereas VCAM mRNA only upregulated in pregnancy
with no further increase with labour (Ledingham et al 2001b).
The table below summarises the differing timing of cervical samples taken in
relevant studies.
Table 1.1








Sakamoto 04 cytokines vag del
Stygar 02 MMPs vag del
Sennstrom 00 cytokines vag del
NP= late pregnancy, EP = early pregnancy, TP = term pregnancy, IP = intrapartum, PP =
post partum.
Two studies compared term cervical biopsies taken at CS before or during labour
(Young et al 2002; Osman et al 2003). Young immunolocalised proinflammatory
cytokines, IL1-J3 and IL-6 to invading leukocyte populations, whereas IL-8 was
distributed throughout the cervical stroma and epithelium in addition. In all cases the
leukocyte density was increased in labour. Osman then further refined this by
specifying the leukocyte subpopulations involved as neutrophils and monocyte types,
identified by CD45, CD68 and neutrophil elastase immunohistochemistry. The
distribution of these cells was largely stromal. These studies can then only relate
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their findings to labour and no comparisons were made with early or non-pregnant
cervical leukocyte populations. So Bokstrom and Stygar agree that this appears to be
a gestational leukocyte invasion prelabour, whereas most of the other studies
conclude that this leukocyte recruitment occurs only in labour.
In assessing the cervix throughout pregnancy and labour, one ideally needs to study
cervical tissue from all stages; non-pregnant, first trimester, mid-trimester, term
pregnancy before labour (ripe and unripe cervices), in labour and post-partum.
Clearly there are ethical issues that have made this area of study difficult, but one
must carefully compare the evidence available with these distinctions in mind.
Even these groups cannot be equally compared as TP groups are not always
described as ripe and unripe cervices. This is an important differentiation and
intrapartum groups are not always comparable dependent on the stage of labour and
reason for caesarean section. Some groups have endeavoured to take samples
specifically after vaginal delivery as this is the physiological outcome (Stygar et al
2001; Stygar et al 2002; Sennstrom et al 2003; Sakamoto et al 2005), but many
groups only take samples in those women delivered electively by CS, which may be
relatively distant from cervical ripening, or those delivered in labour by CS (Young
et al 2002; Osman et al 2003). Some effort has been made to exclude dysfunctional
labour and infection but this is by no means consistent across study populations.
Most of this work has only informed on leukocyte population changes in or after
labour, omitting cervical ripening pre-labour.
Recent localisation studies demonstrate cervical CD45+ leukocyte numbers to be
greater in the subepithelium than deep stromal layer outwith pregnancy, in early and
late pregnancy and after labour (Sakamoto et al 2005). Vaginal delivery is associated
with increased macrophage and leukocyte populations in both the subepithelium and
deep stromal layer in association with high IL-8 levels (Sakamoto et al 2004). As
these specimens were obtained postpartum, a distinction between labour related or
post-partum changes cannot be made. Prior studies had not determined pre-labour
leukocyte population alterations in the ripe and unripe cervix as these groups had not
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been specified. Sakamoto's work attempts this by dividing the term pre-labour
group into unripe, ripening and ripe cervices based on a Bishop score (BS) of < 4, >4
or >8 (Sakamoto et al 2005). It appears that macrophage but not granulocyte
presence is associated with pre-labour cervical ripening. Crucially with a BS > 4, a
rise in macrophage presence was shown in both the subepithelium and deep stroma
but as there were no samples in the ripe cervix group (BS>8), further conclusions
cannot be drawn.
Early pregnancy appears to be associated with a specific picture of leukocyte
distribution as described by Junqueira but no quality assessment of this has been
performed since. The dramatic leukocyte infiltration seen is certainly a late event
and appears to be associated with labour, but whether this is part of labour initiation,
established labour, or a post-partum phenomenon has yet to be established.
Animal studies have been of little help with this issue as most animal models do not
appear to follow the same pattern of immune cell recruitment. Rat models certainly
show cervical eosinophil invasion at term and this appears to be under hormone
control (Luque et al 1998), but then there are many differences between the rat and
human model, not least the luteolytic progesterone withdrawal with initiation of
labour, and so this is not informative.
Mouse models appeared to confirm macrophage migration to the cervix prior to
labour as has been seen in humans (Yellon et al 2003). In a recent paper (published
after submission) Mahendroo's 5alpha-reductase null mouse model concludes
neutrophils are not involved in cervical ripening but in post partum remodelling
(Timmons et al 2006). Cervical samples of wild-type mice show no increase in
leukocyte numbers or activity, or cytokine expression or release until after delivery,
when the predominant cell migration appears to be the macrophage and the
eosinophil. Regulated by a progesterone fall there is a stromal recruitment of
neutrophils from the subepithelium pre-labour and this is not seen in 5alpha-
reductase null mice (Timmons et al 2006). However there is no increased neutrophil
activity until after delivery, suggesting no role in pre-delivery ECM degradation, but
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rather preparation for postnatal remodelling and repair. Although this parallels
Sakamoto's findings (Sakamoto et al 2005), there are fundamental differences from
the human model such as the longstanding acknowledgement of differing systemic
and local tissue progesterone control between rodents and humans. Also whilst this
refutes a role for these cells in pre-labour cervical ripening, neither of these groups
have assessed intrapartum events. The responsibility of ECM degradation pre¬
delivery then falls again to the resident stromal cell if there is little leukocyte
activation.
Monocyte type cells are a known source of proinflammatory cytokines, which have
increase in labour. Guinea pig, rabbit and sheep models all appear to show some
cervical immune cell trafficking. For example an electron microscopy description of
guinea-pig cervices throughout gestation reported fibroblasts as the main stromal
cellular component, with few leukocytes and densely packed collagen fibres with
little amorphous ground substance between (Flegele-FIartung et al 1989). In late
pregnancy an increase in leukocyte numbers, hypertrophied smooth muscle cells and
increased amorphous ground substance with dissociated collagen fibrils in
association with active fibroblasts, mast cells and macrophages was evident. Term
cervices displayed more marked connective tissue disassociation, oedema, fibroblast
activity and a predominance of neutrophils. Of note these findings were then
replicated after administration of a progesterone antagonist in late gestation.
Significantly, the highly active fibroblast appeared with a halo of reduced collagen
surrounding it, as had been previously noted with leukocytes (Junqueira et al 1980).
This halo reflects the absence of collagen fibrils and is presumed to be a result of
collagenolytic enzymes. It can be postulated that the association between
macrophage presence and timely increase in human cervical stromal cytokine release
would place the macrophage in a central role in the final pre-labour cervical
remodelling phase (Winkler et al 1998; Sennstrom et al 2000; Young et al 2002;
Sakamoto et al 2004).
The association of cervical leukocyte migration with labour is clear yet the evidence
for pre-labour recruitment is less so. This raises the question of whether these cells
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are required for late stage cervical ripening, the ongoing cervical changes throughout
pregnancy or whether their presence is solely required for, or even a result of, active
labour. It appears that the appropriate studies have not yet been performed to clarify
this issue as rather than comparing pre and post labour, one would need to compare
ripe and unripe cervices outwith labour. Recruitment in this particular group can be
extremely difficult for ethical reasons.
Less invasive methods of assessing cervical ripening may be the way forward in this
area, but this will not provide all the information available from tissue samples.
Outwith clinical practice, other methods have been used to assess cervical state.
Fluorescence spectroscopy can inform molecular and physical structure and has been
used to examine collagen content in various tissues. Garfield et al have used this
technology in the form of a collascope to assess cervical tissue changes in pregnancy
in both rats and humans, the advantage being the ability to perform longitudinal
studies in the same subjects. Light-induced auto fluorescence (LIF) in the cervix is
thought to originate from pyridinoline, a major crosslink in collagen fibril structure,
and was seen in rats to reduce in late gestation and after treatment with
antiprogesterone (Garfield et al 2001). These findings were corroborated by parallel
cervical resistance studies and electron microscopy and the changes spontaneously
reversed. Human studies have shown a similar decline in the last 15 weeks of
pregnancy with slow postpartum recovery, and may prove clinically useful in
prediction of preterm labour (Maul et al 2003). The non-invasive nature of LIF may
aid future investigations in cervical function in addition to potential benefits in
labour management.
1.4.3 Matrix Metalloproteinases
MMPs are zinc-dependent degradative enzymes secreted by both connective tissue
cells and leukocytes as pro-MMPs, which are then activated by proteinases such as
plasmin or indeed by other MMPs (Hulboy et al 1997). Endogenous inhibitors tissue
inhibitors of metalloproteinases (TIMPs) and a-macroglobulins form complexes
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with activated MMPs to inactivate them. ECM maintenance is reliant on the balance
between both MMPs and their inhibitors and matrix synthesis and disposition.
Control of their production is carefully timed throughout pregnancy and parturition
and regulated by cytokines, growth factors and hormones (Hulboy et al 1997).
Immediately prelabour the ripening process seems to accelerate with even more
proteolytic activity associated with an inflammatory cell infiltrate (Knudsen et al
1997).
The main role of MMPs is tissue remodelling by processing matrix proteins and
collagens. This is evident in many physiological inflammatory processes i.e.
menstruation, ovulation and wound healing. Pathological disease processes such as
cancer and fibrosis also require MMP activity. The same process may aid cell
migration by degradation of basement membrane constituent collagen type IV, and
this is particularly relevant in human reproductive tissues where migratory cells
accumulate at various stages within the reproductive cycle. Specific to the cervix
there is a leukocyte extravasation associated with labour (Junqueira et al 1980;
Stygar et al 2001; Young et al 2002; Osman et al 2003).
Classification of MMPs can be broadly divided into four categories:
1) interstitial collagenases (MMP-1, -8, -13); degrade intact collagen
2 ) gelatinases (MMP-2,-9); degrade proteoglycans, denatured
collagen I and III, collagen type IV, elastin, fibronectin
3) stromelysins (MMP-3,-7,-10,-11)
4) membrane-type MMPs (-14,-15,-16,-17).
The interstitial collagens (type I-III) are initially cleaved by interstitial collagenases,
predominantly MMP-8, MMP-1 and MMP-13. Then, after further denaturation to
gelatin, gelatinase (MMP-2 and MMP-9) activity results in small peptides which are
finally degraded by proteolytic enzymes (Hulboy et al 1997). Various studies have
reported increased levels of these enzymes in the cervix and lower uterine segment in
late pregnancy and labour (Junqueira et al 1980; Kitamura et al 1980; Rath et al
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1987; Rajabi et al 1988; Osmers et al 1990; Winkler et al 1999a; Stygar et al 2002;
Sennstrom et al 2003).
MMP-1 or fibroblast collagenase is secreted by both stromal cells and monocytes,
and degrades collagen I, II, III. MMP-1 degrades collagen type III 15-fold faster
than type I. MMP-8 or neutrophil collagenase is secreted by both neutrophils and
cytokine-activated fibroblasts and responsible for breakdown of fibrillar collagens.
MMP-8 is particularly efficient at collagen type I cleavage and also has substrate
specificity for gelatins and non-matrix proteins (Horwitz et al 1977; Hasty et al
1987).
The substrates of MMP-2 include fibrillar collagen, collagen IV, elastin and
fibronectin (Hulboy et al 1997). MMP-2 also activates MMP-1, -9 and -13. Of
particular interest is the capability of basement membrane degradation by MMP-2 as
this has been associated with pathological events involving monocytes and
specifically in tumour invasion (Sato et al 1994; Yoshizaki et al 2002). A similar
physiological process may apply in cervical ECM proteolysis during pregnancy. A
parallel can be drawn with the endometrium in menstruation where MMP-2 and
MMP-14 are upregulated with progesterone withdrawal (Zhang et al 2000).
MMP-9 produced by macrophages, neutrophils and cytokine stimulated fibroblasts
catalyses collagen types IV and V and elastin degradation (Winkler et al 1999b;
Winkler et al 1999a).
MMPs-1,-2,-8 and -9 have been studied in the human cervix and lower uterine
segment (Ledingham et al 1999a; Winkler et al 1999a; Denison et al 2000; Stygar et
al 2002; Sennstrom et al 2003). In the human cervix, neutrophils predominantly
produce MMP-8 and MMP-9, whereas MMP-1 is released by cervical stromal
fibroblasts both in early pregnancy and outwith (Yoshida et al 2001). Stygar et al
demonstrated by immunohistochemistry and reverse transcription-polymersase chain
reaction (RT-PCR) that in vivo, cervical MMP-9 was observed exclusively in
invading leukocytes perivascularly, and that this was up-regulated peripartum
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(Stygar et al 2002). The same study identified cervical stromal fibroblast cells and
smooth muscle cells as the main source of MMP-2 and this is supported by work
with cervical explants and isolated cervical fibroblasts from both non-pregnant and
first trimester samples (Ledingham et al 1999a). Denison et al immunolocalised
MMPs-1,-2,-8 and -9 in the first trimester cervix with increased stromal
immunostaining for all except MMP-2 after mifepristone treatment in vivo (Denison
et al 2000). Cervical MMP-2 and MMP-9 mRNA expression is up-regulated in
pregnancy at term, but there is no further increase seen after labour (Stygar et al
2002).
Watari demonstrated that cultured cervical smooth muscle cells express and secrete
MMP-1, -9 and -13 but it must be noted that these cells were derived outwith
pregnancy (Watari et al 1999). Combined, these studies suggest that MMPs have
multiple origins and whilst leukocyte infiltration may provide abundant supplies of
some MMPs, there is a role for resident cells in cervical MMP synthesis and
regulation. It is the interaction and individual activation of these differing cell types
that may hold the key to cervical changes in pregnancy, and it is this that makes it
extremely difficult to study in vitro.
Many studies have used the lower uterine segment as a proxy for the cervix, in view
of the ethical difficulties associated with obtaining cervical tissue in advanced
pregnancy or in labour. Rajabi did just this to confirm comparison baseline levels of
collagenase in cervical and LUS tissue outwith labour (Rajabi et al 1988). Analysis
of LUS biopsies in labour demonstrated a thirteen-fold increase in active and latent
collagenase levels but a specific collagenase or source was not identified, and there
were no cervical samples taken in labour. A similar study in 1999 revealed an
increase in both MMP-8 and MMP-9 in the LUS with increased cervical dilatation
and duration of labour (Winkler et al 1999a) and associated with increased IL-8
concentrations and neutrophil counts (Winkler et al 1999b).
Although cervical fibroblasts secrete MMP-1, preferentially degrading collagen III, a
cervical up-regulation of this particular MMP has not been shown in parturition
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(Osmers et al 1992). MMP-2, MMP-8 and MMP-9 are shown to increase throughout
gestation and even more so at the time of parturition, as the cervical collagen content
decreases (Uldbjerg et al 1983b; Rajabi et al 1988; Osmers et al 1992; Stygar et al
2002; Sennstrom et al 2003). Cervical MMP-8 and MMP-9 levels increase with
cervical dilatation and neutrophils counts yet no distinction can be made between
labour effects and those specific to cervical ripening due to the timing and grouping
of samples (Sennstrom et al 2003). MMP-8 may breakdown collagen whilst MMP-2
and MMP-9 also assists in leukocyte stromal extravasation by degrading basement
membrane.
MMPs exist either as free molecules, in complexes with TIMPs or complexed to a2-
macroglobulin, both of which are inhibitory; it is the balance between these
complexes that influences MMP activity and function. Regulation can occur at
transcription, post-transcription or post-translation as a result of pro-enzyme
cleavage or TIMP-binding. Tissue inhibitors of metalloproteinases (TIMPs- 1, 2 and
4) modulate MMP activity are also present in the cervix and increase with pregnancy
(Ledingham et al 1999a; Denison et al 2000; Sennstrom et al 2003). Alpa2-
macroglobulin inhibits MMPs by forming complexes inactivating them and is not
upregulated with parturition to the same extent as MMPs themselves. For example,
LUS collagenase concentration was 23-fold in labour compared to term whereas its
inhibitors increased only 2-fold in labour (Woessner 1991; Rechberger et al 1993).
MMP-2 and MT-MMPs are constitutive whereas most others require stimuli to
promote transcription. Such stimuli are cytokines, progesterone, oestrogen,
glucocorticoids and nitric oxide.
The regulation of MMPs is multifaceted but cytokines appear to induce production
and activation whereas progesterone is suppressive in cervical studies. Rabbit and
human cervical fibroblasts produce proMMP-9, proMMP-1 and proMMP-3 with
cytokine (IL-1 or TNFa) stimulus and these effects are inhibited by progesterone (Ito
et al 1991; Sato et al 1991; Sato et al 1996; Imada et al 1997). Similarly in the
human cervix in-vivo first trimester treatment with the antigestogen mifepristone
revealed an up-regulation in immunostaining for MMPs-1, -8 and -9, neutrophil
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elastase, CD45 (leukocyte common antigen) and CD68 monocyte marker (Denison
et al 2000). Untreated cervices showed a down-regulation of MMP-9 in early
pregnancy perhaps representing the protective effect of progesterone at this gestation
(Ledingham et al 1999a).
Human non pregnant cervical smooth muscle cells secrete increased MMP-1, MMP-
3 and MMP-9 in response to TNFa or IL-1 and IL-1 induced MMP-1 secretion has
been shown in early-pregnancy-derived cervical fibroblasts (Watari et al 1999;
Yoshida et al 2002). Both Osman and Young demonstrate increased cervical IL-1 (3,
IL-6 and IL-8 localised to leukocytes in association with labour providing a
mechanism for labour associated MMP upregulation (Young et al 2002; Osman et al
2003). Cultured cervical fibroblast IL-8 production is induced by cyclical
mechanical stretch designed to mimic the effects of pregnancy and labour (Takemura
et al 2004). Wang et al suggest that induction of MMP-14 and MMP-2 expression
by cyclical stretch is via TNFa and although this study was in cultured human
umbilical vein endothelial cells, it presents supportive comparisons to the body of
evidence within the cervix (Wang et al 2003).
PGF2a, NO and mechanical stretch all augment MMP-1 secretion from cultured
human cervical fibroblasts (Yoshida et al 2001; Yoshida et al 2002) and although
cervical MMP-2 and MMP-9 secretion was not altered with in-vivo NO donor
treatment, other MMPs may be influenced (Ledingham et al 1999b). Cervical NO
synthase isoforms, localised to the endothelium and leukocytes, are elevated in early
pregnancy with a further increase at term prelabour suggesting a role in the gradual
cervical changes seen throughout pregnancy rather than late cervical ripening
(Ledingham et al 2000). Cervical prostaglandin degradation is certainly decreased
as a late event in association with labour whereas COX-2 is unchanged, suggesting
prostaglandin effects are elevated at this time (Tornblom et al 2004). Progesterone,
NO, stretch, cytokines and prostaglandins all influence MMP regulation and based
on current evidence this chronological sequence of mediation effects appears likely.
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The interdependency of MMP function complex as each MMP provides substrate for
another in the stepwise process of ECM degradation. MMP-1 specific evidence is
based only on in-vitro findings. MMP-2 is thus far the most likely candidate
produced by cervical stromal cells to influence cervical remodelling in pregnancy.
MMP-2 activity is regulated in part by monocyte MMP-14. MMP-14 is a
membrane-type MMP (MT1-MMP) and activates MMP-2 though a prostaglandin-
cAMP pathway as has been established in activated monocytes (Shankavaram et al
2001). MMP-14 is membrane-bound and has wide substrate specificity for collagen
types I, II and III, elastin, fibronectin, gelatin, laminin and other proteoglycans. In
addition MMP-14 activates the inactive proform of MMP-13. Expression of MMP-
14 has been confirmed in activated fibroblasts, monocytes, endothelial cells, decidua,
fetal membranes, osteoclasts, trophoblast and cancer cell membranes (Fortunato et al
1998; Nakano et al 2001). In the human cervix the presence of MMP-14 has only
been demonstrated in squamous cell cancer but has not been evaluated in the context
of pregnancy or cervical ripening (Sheu et al 2003). However, MMP-14 is also
associated with leukocytes and the activation of proMMP-8 (Holopainen et al 2003).
As both MMP-2 and MMP-8 levels are increased in pregnancy and labour then
MMP-14, as a mediator of at least these two MMPs, would be expected to be present
in the human cervix and up-regulated in pregnancy or labour.
In addition to ECM maintenance MMPs also have the capability to alter the cellular
phenotype of tissues, thereby influencing proliferative, differentiating and apoptotic
functions (Hulboy et al 1997). It is pertinent to know whether the phenotype of any
of these cervical or migratory cells change during pregnancy. Indeed there has been
a myofibroblast-type differentiation seen within the human cervix in labour, where
these submucosal fibroblasts demonstrate desmin positivity and associated high
activity as shown by electron microscopy (Montes et al 2002). Active fibroblasts
have multiple potential secretory activities and could be central in orchestrating
cervical remodelling seen throughout pregnancy, labour and post-partum.
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1.4.4 Prostaglandins
Prostaglandins are eicosanoids, of which those believed to be most important in
human labour are of the 2 series, PGE2 and PGF2a. They are derived from the
cyclooxygenase (COX) metabolism pathway of arachidonic acid, obtained from
deesterified membrane phospholipids. PGs are locally acting paracrine regulators,
rapidly catabolised from the circulation in the lung, and also locally metabolised by
degradative enzymes, and so require prompt tissue response for any effect (Moore
1985; Kelly et al 1992). PGs are produced by many tissues, but notably by amnion,
chorion, decidua, placenta, cervix, leukocytes and platelets. There is no storage
mechanism so they are produced and released as required, and act through specific
G-protein coupled receptors (Geirsson et al 1990).
Prostaglandins induce many effects throughout all systems including
pro/anticoagulant properties, immunomodulation, vasoconstriction/dilation and
bronchoconstriction/dilation, hence their potency and potential for unwanted side
effects as well as desired attributes.
There are five groups of prostaglandins. Those involved in pregnancy are PGE2 and
PGF2a, prostacyclin (PGI2) and thromboxane, but in labour only the first two have
identified roles. PGE2 levels are known to increase in late pregnancy and early labour
whereas PGF2a rises in established labour (Moore 1985). See Figure 1.4
Many sources of prostaglandins have been identified in the cervix (Ellwood et al
1980), the uterus, placenta and fetal membranes. The amnion is particularly capable
of PGE2 synthesis (Keirse 1979; Mitchell 1987a; b) and it has been shown that
amniotic fluid prostaglandin levels gradually increase towards term with a sharper
rise in labour and as labour progresses (Steinborn et al 1995; Reece et al 1996; Gibb
1998). This is now known to be as a result of increased synthesis, rather than reduced
catabolism. As prostaglandins and their controlling enzymes (phospholipases,






























proved difficult to localise production sites, although high prostaglandin levels have
been reported in the amnion, decidua (PGF2a) and myometrium.
There are two cyclooxygenase enzymes, COX-1, a constitutive enzyme and COX-2,
an inducible enzyme that increases in labour (Bennett et al 1992; McLaren et al
2000; Whittle et al 2001). Particularly high levels of the prostaglandin inactivating
enzyme PGDH have been found in the chorion and trophoblast. Although placental
levels do not fall in labour, chorionic PGDH expression was seen to be lower in both
term and preterm labour compared to non labour (Whittle et al 2001). Another theory
is that with varying membranous PGDH distribution there may be regional variation,
most pertinently covering the internal cervical os, where the prostaglandin can
escape catabolism and traverse the membranes in order to effect cervical ripening
and myometrial activity (van Meir et al 1997; Van Meir et al 1997; Challis et al
1999). See Figure 1.5
Intrauterine prostaglandin levels, synthesis and catabolism have been extensively
studied with the consensus being that prostaglandin production is increased with
term and preterm labour (Mitchell 1987a; Olson et al 1992; Gibb 1998). Pro¬
inflammatory cytokines (IL-1, TNF-a) appear to enhance prostaglandin production
in many tissues including amnion, chorion, decidua and myometrium via the
inducible COX-2 pathway (Keelan et al 2001). The inflammation-associated
transcription factor NF-kB, activated by pro-inflammatory cytokines, is expressed
constitutively in amnion at term. This not only increases COX-2 expression but also
appears to negatively interact with the progesterone receptor facilitating 'functional
progesterone withdrawal' (Allport et al 2001). This combination of events then
triggers PG synthesis and activation of CAPs leading to labour. The possibility of
prostaglandin regulation of cytokines in an auto-regulatory loop has been suggested
as PGE2 stimulates cervical IL-8 release, but supportive data in the placenta and
membranes is lacking (Denison et al 1999).
Cervical biopsies taken after both at term and preterm delivery, with and without
labour confirm a reduced expression of PGDH when labour had occurred, suggesting
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Figure 1.5: Altered PGDHproduction in term andpreterm labour
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decreased prostaglandin degradation in association with parturition (Tornblom et al
2004).
Glucocorticoids increase amniotic COX-2 expression and decrease PGDH in the
chorion thereby promoting prostaglandin activity (Gibb 1998). It is possible that
PGDH expression may be varied in some areas by inflammatory cytokines as a result
of infection, and in others by progesterone and Cortisol competitively binding to their
steroid receptors. Cheng showed a reduction in endometrial PGDH with concurrent
increased PGE2 following treatment with the antiprogesterone RU486 (Cheng et al
1993). The PGE2 was localised to small blood vessels and this may aid leukocyte
infiltration, supporting the hypothesis of synergism between IL-8 and PGE2,
proposed by Colditz in rabbit skin (Colditz 1990). Immunostaining later confirmed
the perivascular location of IL-8 in non-pregnant endometrium (Critchley et al 1994)
consistent with this proposed role.
PGE2 is associated with a time-limited enzymatic collagen degradation, increased
protein synthesis and increased hyaluronic acid concentration (Rath et al 1987).
PGE2 increases newly synthesized GAGs in cultured cervical fibroblasts in a dose-
dependent manner (Carbonne et al 2000). Whether PGE2 exerts collagenolytic
effects directly is questionable as COX-2 inhibitors do not prevent these, and PGE2 is
likely act in concert with NO, cytokines and leukocyte recruitment.
Prostaglandin receptors are seven-transmembrane-G-coupled receptors divided into
five groups, specific to their prostaglandin. The EP group are specific to PGE and
are further subdivided into four isoforms; EP1 and EP3 stimulate the adenyl cyclase
system causing muscle relaxation, whereas EP2 and EP4 are inhibitory and cause
contraction (Arias 2000). EP2 and EP4 are present in cervical fibroblasts but only
EP4 mediates PGE2 stimulated GAG synthesis in a PKA-independent pathway
(Schmitz et al 2001).
Both PGE and PGF2a cause myometrial contractility whilst PGE2, in addition, has
specific effects on cervical ripening. Cervical PGE production increases at term and
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in labour and administration of PGE results in cervical changes akin to those seen
physiologically. Prostaglandins, which are known to increase physiologically at this
stage and are also effective therapeutically, are only one of several factors involved
in initiation of this process.
The antiprogestin mifepristone (Radestad et al 1990), oestrogen, cytokines and other
inflammatory mediators such as nitric oxide donors (Thomson et al 1998) are all
implicated in the cervical ripening process but the exact mechanisms of interaction
remain unclear. Prostaglandin E2 reproduces cervical ripening in vivo and in vitro.
However physiological or antiprogestin-induced cervical ripening is not suppressed
by indomethacin or specific COX-2 inhibitors (Chwalisz 1994; Shi et al 2000). NOS
and COX inhibitors combined are more effective in suppressing ripening than each
alone, suggesting that these two inducible systems function in parallel (Shi et al
2000). Therefore, PGE, cannot be the only pivotal pathway involved. One must then
ask how critical is the role of prostaglandins? And in clinical practice despite the
clear advantage of PGE2 use in induction of labour, this strategy has not been
sufficient to reduce the growing caesarean section rate.
1.4.5 Steroid Hormones
In humans, there is no systemic reduction in progesterone in association with late
gestation or labour (Anderson et al 1985). In any event, cervical ripening is a
prolonged preparatory process occurring before the initiation of labour and
myometrial activity. In fact progesterone levels do not fall until after the placenta is
delivered and the cervix begins to remodel to a more rigid non-pregnant state
(Garfield et al 1998). Yet antiprogestins do produce cervical ripening, but by what
mechanism? It is therefore possible that local progesterone or receptor changes
(Stjernholm et al 1997) may achieve a progesterone withdrawal effect to allow
cervical changes as seen when antiprogesterones are administered.
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Progesterone withdrawal is fundamental in parturition in small mammal physiology,
either by luteolysis or reduced progesterone action. There may be local changes in
progesterone metabolism or receptor activity in humans that mirror this.
Progesterone can inhibit cytokine release, suppress iNOS / COX-2 expression,
leukocyte migration and suppress MMPs (Ito et al 1994; Buhimschi et al 1996;
Denison et al 1999). These effects would inhibit cervical ripening, and provide a
mechanism of action for antiprogestin cervical ripening, as seen in animals and
humans.
Progesterone withdrawal (by antiprogestin administration) effects cervical ripening
in humans (Frydman et al 1988) and results in increased myometrial responsiveness.
Similar structural changes (collagen fibre dissolution, oedema, influx) as seen in
humans were described by Hegele-Hartung after studying progesterone antagonist
exposed guinea-pig cervices by electron microscopy (Hegele-Hartung et al 1989).
However progesterone agonists do not prevent antiprogestin-induced cervical
ripening, so there must be more than PR modulation in the stimulation of these
pathways (Shi et al 2000). Shi et al propose that progesterone and NO interact to
maintain pregnancy and showed that antiprogestins in combination with NOS
inhibitors stimulate labour in rats (Shi et al 2003).
E2 (17(3 oestradiol) increases myometrial activity in women and is associated with
cervical ripening, collagenolysis in guinea pigs and eosinophilic invasion in rats
(Pinto et al 1964; Rajabi et al 1991b; Luque et al 1998). P4 inhibits E2 stimulated
collagen degradation in vitro (Rajabi et al 1991a). Plasma DHEAS increased during
cervical ripening and increases procollagenase production in rabbit cervical
fibroblasts (Sakyo et al 1987), although neither E2 or DHEAS affected collagen
synthesis.
Cervical ripening in women is seen concurrently with a down-regulation of
oestrogen receptors. This altered ER:PR ratio is associated with proteoglycan change
and increased collagen solubility. Oestrogen and progesterone receptors are present
in human cervical tissue. Although mRNA is unchanged, human cervical ER and PR
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concentrations are reduced postpartum compared to term pregnant unripe cervices
(Stjernholm et al 1997). The same also applied to IGFBP-1. However IGFBP-1
mRNA increased four-fold from the non-pregnant state to term, so is there an
interaction between growth factor pathways and steroid receptors or do growth
factors stimulate MMPs? This may serve as a local receptor-mediated progesterone
withdrawal. PGE2 treatment of human cervices at term did not alter cervical ER/ PR/
IGF-1 concentrations or mRNA expression when compared with spontaneous
ripening, but mifepristone appeared to increase both ER and PR concentration so
perhaps differing mechanisms are at work (Stjernholm et al 1999). This would
support the role of prostaglandins and IGF-1 in spontaneous ripening, but does not
support the concept of receptor-mediated progesterone withdrawal. More recently
differing PR isoforms have been identified. PR-A and PR-B exist in myometrium
and have opposing effects. PR-A is a dominant repressor of PR-B and labour is
associated with raised PR-A in myometrium, with an increased PR-A: PR-B ratio
(Winkler et al 2002). So, again this may come back to receptor mediation as more is
discovered about individual isoforms, their expression, regulation and function.
1.4.6 Cytokines
Leukocytes appear to have a major role in cervical changes in pregnancy, akin to an
inflammatory response (Liggins 1981) perhaps orchestrated by the fibroblast with
increased local prostaglandins, a marked inflammatory neutrophil infiltration
(Junqueira et al 1980), increased vascularity and stromal oedema (see Figure 1.6).
The reduced collagen content seen in late pregnancy is a result of both proteoglycan
constituent variation and collagen breakdown from enzymatic degradation.
Cytokines are small secreted soluble proteins or glycoproteins which bind to specific
cell surface receptors, couple to intracellular signalling systems and act via second
messenger pathways. Cytokines can modulate cell function at nano-picomolar
concentrations through humoral regulation or autocrine and paracrine routes. They
are synthesized locally on demand and have short half-lives limiting the temporal
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effects. Examples are interleukins, chemokines, interferons, growth factors and
colony stimulating factors. Effects are achieved through altered gene expression,
binding with membrane receptors (IL-8) or ECM complexes, receptor modulation or
enzymatic cleavage to an active component. Cytokines are both pleiotropic and
redundant and are often produced in cascades, creating complex interactive
mechanisms of action. There are vast numbers of cytokines categorised by their
producing cells, target cells, receptors or function of immune, inflammatory or
haematopoietic regulation (see http://www.copewithcytokines.de/). All methods of
categorisation are problematic in view of the degree of overlap and cross-talk
between cytokine groups and receptors. An extremely select summary of a few
cytokines described in the human cervix, or cervical stromal cell, specific to
pregnancy and labour follows.
Pro-inflammatory cytokines stimulate immune cell proliferation and differentiation
and include IL-l(a and [3 ligands) and TNF-a, produced by many cell types. TNF-a
induces neutrophil chemotaxis, collagenase release, cytolysis, angiogenesis, and
prostaglandin release. IL-1 stimulates T-helper cells, activates neutrophils and
induces ACTFI release and immunoglobulin production. IL-6 is immunomodulatory
and acts on monocytes, macrophages and lymphocytes as a physiological regulator
of the acute phase reaction. IL-6 is raised in amniotic fluid of infected preterm
labour, stimulates decidual and amniotic PGE2 production and may be important in
the pathophysiology of chorioamnionitis (Romero et al 1990; Mitchell et al 1991).
Countless studies have shown that cytokines are produced in reproductive tissues,
some of which provide clear evidence of their role in parturition. Cervical and
uterine isthmic biopsies were found to produce far greater quantities of IL-1, TNFa,
IL-6 and IL-8 (Winkler et al 1998; Sennstrom et al 2000; Young et al 2002; Osman
et al 2003; Tomblom et al 2005) in labour and postpartum. The same was shown in
trophoblast and cervical secretions with raised IL-1 (3, IL-6, TNF-a, PGE2 and PGF2a
concentrations in labour (Steinbom et al 1995).
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Figure 1.6 Proposedfibroblast role in cervical ripening
Fibroblast
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Interleukin-8 (or neutrophil activating factor-NAF, neutrophil chemotactic factor-
NCF, monocyte derived neutrophil chemotactic factor-MDNCF) is a 99 amino-acid
non-glycosylated peptide which is cleaved to release a 72 amino-acid compound.
IL-8 is produced by monocytes, macrophages, endothelial cells, lymphocytes,
fibroblasts, choriodecidual cells and neutrophils. The main function of IL-8 is to
induce chemotaxis, activation and degranulation of neutrophils, releasing MMP-8
and elastase. IL-8 production is up-regulated by IL-1, TNFa, LPS, hypoxia and viral
or bacterial infection, and suppresssed by IL-10, dexamethasone and progesterone
(Kelly et al 1994).
IL-8 is produced in human cervices (Barclay et al 1993; Sennstrom et al 2000;
Young et al 2002), is chemotactic for neutrophils, is regulated by IL-1 (El Maradny
et al 1996) and can produce cervical ripening in rabbits (El Maradny et al 1994) and
guinea-pigs (Chwalisz et al 1994). The changes seen with these animals models are
increased water content, neutrophil influx, reduced collagen concentrations,
increased activity of collagenase, gelatinase, and elastase (El Maradny et al 1996).
Not all of these variations have been confirmed in PGE2 models and there is
speculation about a different mechanism of action or a synergism between IL-8 and
PGE2. Critchley et al confirmed the perivascular location of IL-8 in endometrium
and this is consistent with a proposed synergistic role with PGE2 in leukocyte
trafficking (Critchley et al 1994).
Using lower uterine segment biopsies as a substitute for cervical biopsies, later
studies confirmed this exaggerated IL-8 production in association with labour
(Osmers et al 1995; Winkler et al 1998) and this also correlates with raised MMP-8
and MMP-9 levels.
IL-8 produced by cervical fibroblasts has a dual function to induce neutrophil
activation and migration and cause degranulation to release collagenase. Other pro¬
inflammatory cytokines (TNFa and IL-1,) stimulate IL-8 and also have a similar
effect on PGE2 (Barclay et al 1993; Sato et al 2001). A synergistic action between
IL-8 and PGE has been proposed where PGE enhances vasodilation and vascular
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permeability for IL-8 augmented neutrophil recruitment. IL-8 is a potent neutrophil
chemo-attractant and MMP release (Ledingham et al 1999a) from the cervix is
known to be associated with IL-8, IL-1 and PGE (El Maradny et al 1996). Rabbit
cervices respond to local IL-8 application with increased neutrophil numbers,
reduced collagen content, increased total GAG and water content and cervical
softening (El Maradny et al 1994).
In cervical biopsies from labouring women, an increase in IL-8 gene expression and
protein release was seen in labour and postpartum (Sakamoto et al 2004 ; Tornblom
et al 2005), accompanied by increased neutrophil numbers, MMP-8 and MMP-9
concentrations (Winkler et al 1999b). This supports the chemotactic and proteolytic
role of IL-8. Indeed, animal models have produced cervical ripening using locally
applied IL-8 or IL-1 (3 (Chwalisz et al 1994; El Maradny et al 1994; 1996; Belayet et
al 1999). Whilst MMPs are produced by stromal cells and leukocytes, it seems that
cytokines also stimulate smooth muscle cell MMP release (Watari et al 1999). The
same cells produce IL-8 in response to LPS and may have a specific role in infection
associated parturition (Watari et al 2003).
Monocyte chemotactic/ chemoattractant protein-1 (MCP-1), alias MCAF/
monocyte chemotactic and activating factor, is a CC chemokine that attracts and
activates monocytes but not neutrophils, controls vascular smooth muscle cells, and
can modulate T helper cell cytokine production (Baggiolini et al 1995). MCP-1
plays a significant role in pathological inflammatory processes (e.g. atherogenesis,
SLE, psoriasis, immune response to microorganisms) and there are postulated roles
in pregnancy implantation, parturition and ovulation. In addition the presence of
MCP-1 has been shown in the human pregnant cervix (Denison et al 2000) in labour
(Tornblom et al 2005).
MCP-1, a 76 amino-acid protein with variable glycosylation, binds to receptor CCR2
which is coupled to a GTP binding protein (Carnevale et al 2001). MCP-1 is
produced by monocytes, pericytes, fibroblasts, endothelial cells, smooth muscle and
synovial cells (Yoshimura et al 1990) and is secreted by human endometrium and
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placenta (Kelly et al 1997). MCP-2 and MCP-3 share 62% and 71% homology with
MCP-1 and also specifically attract monocyte, basophils and T-lymphocytes but are
less potent (Uguccioni et al 1995; Proost et al 1996) and had not until recently been
identified in the human cervix (Takemura et al 2004).
LPS, IL-1, TNF-a, interferon-y and hypoxia induce MCP-1 synthesis via stimulation
of the transcription factor NFkB (Galindo et al 2001). MCP-1 is also autoinductive,
where migrated monocytes produce MCP-1, perpetuating further chemotaxis
(Vestergaard et al 1997). MCP-1 induces persistent directional monocyte migration
after only brief stimulation (15-30 mins) through interaction with CCR2 receptor
(Kito et al 2002). Glucocorticoids, IL-10 and progesterone are inhibitory whereas
17(3-oestradiol inhibits MCP-1 induced chemotaxis in vitro (Yamada et al 1996;
Kelly et al 1997).
Functions of MCP-1 include monocyte chemotaxis, angiogenesis, tumour
suppression, regulation of cytokine expression and immunomodulation (Conti et al
2001). In addition, MCP-1 triggers firm adhesion of monocytes to vascular
endothelium (Gerszten et al 1999) and induces transforming growth factor-(3 (TGF-
(3) and procollagen gene expression in rat lung fibroblasts (Gharaee-Kermani et al
1996).
MCP-1 upregulates both MMP-1 and TIMP-1 mRNA and protein synthesis via an
autocrine IL-1 a loop in human dermal fibroblasts (Yamamoto et al 2000). This may
provide a mechanism of action within the human cervix. MCP-1 has also been
shown to activate monocytes, stimulating arachidonic acid release and fibroblast IL-
1 production in human skin (Yamamoto et al 2000). The resident fibroblast is able
to initiate or amplify inflammatory responses by chemokines and cytokine release.
This is a potential direct mechanism of action of MCP-1 on cervical fibroblasts as it
could attract and activate monocytes, stimulate cytokine and matrix
metalloproteinase release and contribute to cervical remodelling.
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1.4.7 Nitric Oxide
Nitric oxide (NO) is a freely diffusible inflammatory mediator produced from L-
arginine by several NO synthases. Endothelial and neuronal NOS (e/nNOS) are
constitutive and Ca/calmodulin dependent whereas the inducible NOS (iNOS) is Ca-
indpendent. Inflammatory mediators regulate NO release via cGMP and NFkB. NO
behaves differently to many other inflammatory mediators as its diffusible nature,
and short half life, allows direct effects determined by chemical reactivity and site of
synthesis. NO effects are regulation of vascular tone, platelet aggregation, vascular
permeability, apoptosis and smooth muscle relaxation. NO also stimulates IL-8,
MMPs, LHRH, CRH and has a variable effect on COX-2.
The mechanism of action of NO involves intracellular GMP augmentation and
effects include smooth muscle relaxation (by myosin light chain dephosporylation),
increased vascular permeability and immunomodulation via IL-8 and MMPs. iNOS
synthesized NO acts via both cGMP and other immune and inflammatory pathways.
The myometrial effects are thought to be protective during gestation in maintaining
uterine quiescence.
NO also induces COX-2 and therefore PGE2. There are several similarities between
PGE2 and NO regulation in that both respond to cytokine induction and synthesis is
controlled by inducible enzymes present in inflammatory cells. Synthesized by
macrophages, myometrium, cervix, fetal membranes and other cell types such as
cardiac muscle, nitric oxide synthesis is stimulated by proinflammatory cytokines IL-
la, TNFa, IFNy and LPS, oestrogen and inhibited by dexamethasone. However
PGE2can have either influence, as can progesterone. The relationship between
progesterone and NO is particularly relevant as in concert they maintain uterine
quiescence and the feto-placental circulation, and with luteolytic progesterone
withdrawal in the rat this NO driven uterine inhibition is removed (Buhimschi et al
1996; Kublickiene et al 1997). However COX inhibitors do not block antiprogestin
induced cervical ripening, and perhaps this relates to the overlapping pathways of
NO and PGE2 synthesis. Where preterm labour is associated with infection,
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proinflammatory cytokines can directly induce iNOS, COX-2 and PGE2 without
affecting progesterone. And progesterone can also inhibit cervical ripening by
suppressing iNOS and COX-2 expression, cytokine release and MMPs.
There is conflicting evidence about the role of NO in labour, but several studies have
shown cervical ripening effects in humans and guinea pigs (Chwalisz et al 1997;
Thomson et al 1998; Facchinetti et al 2000). However these findings were in early
human pregnancy and mid-gestation in the guinea pig study, so similar effects would
have to be shown at term. It is possible that there are different mechanisms involved
in the initiation of term and preterm labour. See Figure 1.7
In rats, uterine and placental iNOS and NO production is seen to increase in
pregnancy and then down-regulate before term whereas cervical NO production is
the opposite (Buhimschi et al 1996; Chwalisz et al 1998). Buhimschi also showed
that onapristone (an antiprogesterone) suppressed uterine but increased cervical NO
production, whereas progesterone had the reverse effect. iNOS, eNOS and nNOS
are present in the rat cervix but only iNOS and eNOS in the uterus.
The same has not yet been clarified in humans as all three isoforms are present in the
myometrium yet myometrial and placental NOS activity was not reduced in labour in
comparison to those delivered electively (Thomson et al 1997a; Bao et al 2002).
Another study found myocyte iNOS expression increased in pregnancy prior to a
marked peripartum reduction (Bansal et al 1997). Human cervical NOS (iNOS,
eNOS and nNOS) expression increases thoughout gestation pre-labour with a
particular late rise in iNOS (Ledingham et al 2000). Localisation studies found
iNOS and eNOS in the vascular endothelium, nNOS in superficial epithelium in
early pregnancy and at term in stromal leukocytes (iNOS and nNOS) (Ledingham et
al 2000). The mechanism of action is still in doubt and although does not appear to
be via MMP-2/-9 could be via other MMPs, a role in apoptosis or interaction with
COX-2/ prostaglandin pathways. NO metabolites are increased in human cervical
fluid at term, after cervical ripening and with labour (Vaisanen-Tommiska et al
2003). NOS activity is seen in first trimester cervical endothelium, smooth muscle
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(adapted from Chwalisz and Garfield 1998)
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and in the connective tissue and NO donors inhibited contractility in-vitro (Ekerhovd
et al 1998). Cervical NO production is low in pregnancy, then upregulates toward
term, and NO donors are effective cervical ripeners in animal and first trimester
human studies (Chwalisz et al 1997; Thomson et al 1997b; Facchinetti et al 2000).
One suggestion is that the source of increased cervical NO (seen at term and with
labour) is likely to be leukocytes, a plentiful source of NO. An ingress of leukocytes
with cervical ripening has been established and iNOS expression is upregulated by
cytokines linked with cervical ripening. NO does appear to cause clinical cervical
softening in human and ECM changes seen by electron microscope in guinea pig
cervices, but perhaps in humans NO has an additive role in cervical smooth muscle
relaxation (Chwalisz et al 1997; Thomson et al 1997b; Ekerhovd et al 1998). This
would then act synergistically with the ECM degradation produced by PGs.
It must also be recognised that in vitro human cervical fibroblasts do produce iNOS
in response to IL-la, with a resultant increase in MMP-1 (Yoshida et al 2001).
Also, cervical iNOS mRNA augmentation occurs with advancing gestation and
labour (Ledingham et al 2000). Cultured human cervical fibroblast and explant
secretion of MMP-2 and MMP-9 respectively, were not altered by NO donor
treatment (Ledingham et al 1999a), although samples were from non-pregnant or
first trimester cervices. The lack of MMP-9 in cultured fibroblasts probably reflects
the likely bone marrow-derived cell of origin of this particular MMP. So the
mechanism of NO induced cervical ripening is still under investigation, whether
there be other factors to consider or there are gestation dependent changes not
revealed by this work.
Importantly NO also appears to have a significant role in maintaining the feto¬
placental circulation and so any therapeutic candidates would need to be specific to a
site of action. The benefit of NO donors for cervical ripening would be the absence
ofuterine activity as seen with PGE2.
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Systemic NO inhibits uterine contractility whereas local application appears to cause
cervical ripening. In vitro studies also reveal NO's capability to inhibit human
cervical contractile activity (Ekerhovd et al 1998) in addition to the biochemical
changes seen. Pharmacokinetic studies will be required to assess the effects at
different tissue concentrations. There may yet be a role for NO donors or NOS
inhibitors in the management of cervical ripening or prevention of preterm labour,
but further work is required on bioavailability studies and dose-finding.
1.4.8 Stretch
The presenting part of the fetus subjects the uterine cervix to cyclical mechanical
stretch in the later stages of pregnancy in the form of Braxton-Hicks contractions.
One of the effects of stretch is that it upregulates MMP-1 as shown in cultured
human cervical fibroblasts (Yoshida et al 2002). Takemura et al propose a direct
effect of stretch on chemotaxis of neutrophils and monocytes. Their model exposed
cultured cervical fibroblasts to cyclical stretch resulting in an increased IL-8 and
MCP-3 expression and secretion, a finding that was not replicated in skin fibroblasts,
suggesting this is a specific response in cervical fibroblasts (Takemura et al 2004).
Although this does not directly prove an effect on leukocyte infiltration, both IL-8




Decidualisation of the endometrium is a well described phenomenon, essential in
preparation for implantation and pregnancy. With persistently elevated progesterone
levels after ovulation, the superficial layer of the endometrium undergoes extensive
tissue remodelling. The epithelium becomes secretory and the stromal compartment
undergoes decidualisation during the late luteal phase. These events are regulated by
the action of progesterone on oestradiol-primed, fibroblast-like precursor stromal
cells and is coordinated through progesterone-dependent genes.
Decidualisation is initiated in the vicinity of blood vessels before spreading
throughout the endometrial stroma. This whole process prepares the uterus for
trophoblast invasion or, in the absence of pregnancy, menstruation. And so
disturbance of this mechanism may result in menstrual disorders or subfertility.
Decidual stromal cells (DSC) are differentiated endometrial stromal cells and form
the main elements of decidual stroma, together with bone-marrow-derived uterine
natural killer (NK) cells. There is controversy about the origin of DSC. Some
rodent-based evidence suggests that DSC may originate from bone marrow-derived
stem cells (Kearns et al 1982; Lysiak et al 1992), but the obligate presence of the
nuclear progesterone receptor in precursor stromal cells would seem to refute this, as
this is not a feature of haemopoietic-derived cells.
The decidual reaction, which occurs in vivo under the influence of prolonged
progesterone exposure, occurs more readily in-vitro with endometrial stromal cells
sensitised to progesterone by elevated cAMP levels (Brosens et al 1996; Brar et al
1997; Brosens et al 1999). In vivo, decidualisation coincides with local release of
PGE2 and relaxin, and prolactin (PRL) is first detected in the endometrium at day 10
post-ovulation. This is an environment with sustained high progesterone levels.
This process may be seen much earlier in vitro where typical patterns of PRL and
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IGFBP-1 production is seen from 48 hours (Brosens et al 1999; Gellersen et al
2003). Many in vitro studies have identified the intracellular second messenger
cAMP as a putative key factor in the decidualisation process (Tang et al 1993; Lane
et al 1994; Richards et al 1995; Telgmann et al 1997; Brosens et al 1999) and this is
further supported by the fact that the phosphodiesterase inhibitor, relaxin, is also an
initiator of decidualisation. Intracellular second messengers function by transmission
and amplification of cell signals. Cyclic AMP alters gene transcription by activation
of the PKA pathway (Telgmann et al 1997). Activators of adenyl cyclase (e.g.
PGE2via EP2 or EP4 receptors) increase ATP conversion to cAMP, and PDE
inhibitors (e.g. rolipram, relaxin) prevent cAMP breakdown, thereby maintaining
high cAMP levels (Bartsch et al 2001).
The decidual phenotype is recognised by a rounded morphology, with enlarged
endoplasmic reticulum, abundant glycogen stores and cell projections (Lane et al
1994). Decidual stromal cells appear to acquire myofibroblasts characteristics
(Oliver et al 1999). Characteristic gene expression and protein production is also
evident (Tang et al 1993; Richards et al 1995; Telgmann et al 1998). Figure 1.8.
Prolactin (PRL) and Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) are
both expressed by decidual stromal cells and are reliable markers of decidualisation
(Telgmann et al 1998). Prolactin is vital for lactation in the human, and is produced
by the anterior pituitary, reproductive tissues and various leukocytes. There may be
a local immuno-regulatory role for prolactin in reproductive tissues and steroid
interaction is clearly important. Decidual PRL is known to increase to a maximum
in amniotic fluid at week 20 of gestation, before a gradual decline to term, but the
role of PRL in decidua remains uncertain (Clements et al 1977). IGFBP-1 levels rise
in both serum and amniotic fluid during pregnancy to a peak in the mid trimester.
IGFBP-1 is a good marker of decidualisation and is thought to influence trophoblast
invasion by modulating IGF bioavailability (Gibson et al 2001).
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Figure 1.8 Decidualisation markers













Decidualisation encompasses morphological and biochemical alterations. At a
molecular level there are many changes in cell function resulting in altered steroid
metabolism, cytokine, growth factor and enzyme expression and ECM remodelling.
Extracellular matrix reorganisation at the time of decidualisation is vital for
trophoblastic invasion. Fibronectin, desmin, laminin and (^-microglobulin are
induced in human endometrial decidualisation (Aplin et al 1988; Loke et al 1989;
Komatsu et al 1998) and MMP variation occurs in response to progesterone
modulation (Lockwood et al 1998). Matrix protein deposition is essential for
implantation and there is evidence of increased expression of desmin, laminin and
fibronectin in both human and rodent models (Glasser et al 1987; Can et al 1995;
Korhonen et al 1997; Oliveira et al 2000).
In addition to endometrial decidualisation various ectopic sites of decidual foci have
been reported including the cervix and ovary (Massi et al 1995). Indeed extrauterine
decidual-like cells have been identified in the human cervix, uterine tube and ovary
during pregnancy (Rutanen et al 1991). These were identified morphologically and
were stain-positive for IGFBP-1 antibody by immunohistochemistry. However the
potential for decidual transformation of stromal cells outwith the endometrium has
not been further investigated.
The cervical stromal fibroblast cell is possibly a key regulator in the process of
cervical connective tissue remodelling throughout pregnancy and labour. Very little
is known about how this cell population may change in pregnancy in response to the
same sex steroids that initiate decidualisation in the endometrium. Cervical ripening
has often been compared to an inflammatory reaction with increased vascularity and
enzymatic collagen degradation (Liggins 1981; Sennstrom et al 2000) through matrix
metalloproteinases (Yoshida et al 2002), and more recently associated with an
ingress of leukocytes (Junqueira et al 1980; Denison et al 2000). The stromal
fibroblast is the most likely source of collagen and matrix protein production in the
cervix, and as a source of chemokines, prostaglandins, and other inflammatory
mediators, so these cells may have a key role in cervical remodelling (Sato et al
1991). If these stromal cells also differentiate to a decidual phenotype, a new
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appraisal of their role in pregnancy and in cervical function throughout gestation is
appropriate.
1.5.2 Progesterone Role in Decidualisation
The decidual reaction, for which progesterone is critical, occurs in vivo under the
influence of prolonged progesterone exposure. In-vitro this process occurs more
readily in endometrial stromal cells sensitised to progesterone by elevated cAMP
levels (Brosens et al 1996; Brar et al 1997; Brosens et al 1999).
Progesterone receptors are members of the superfamily of ligand-inducible
transcription factors, and have been identified in human cervices (Gorodeski et al
1987; Stjernholm et al 1999; Remoue et al 2003). There are two isoforms, PR-A and
PR-B with differing N terminals (Kalkhoven et al 1996). Transcriptional activities
are dependent on the target cell. In general PR-A is less active and inhibits PR-B
transcription activity. PR-A is dominant in decidua and in cultured endometrial
stromal cells, where there is an initial increase with cAMP/MPA stimulus, and a later
prolonged down-regulation with sustained exposure (Brosens et al 1999).
Stjernholm et al demonstrated a reduction in cervical PR concentration in advanced
pregnancy and postpartum but the isoforms were not distinguished (Stjernholm et al
1997; Stjernholm et al 1999).
Decidualisation requires the presence of progesterone receptors and as such is
restricted to reproductive tissues. It is likely that human cervical stromal cells
express the progesterone receptor (PR) as shown in lower uterine segment stromal
cells (Perrot-Applanat et al 1994; Winkler et al 2002), and as such may play a role in
the cervical changes seen during pregnancy, such as the increased vascularisation.
The elusive "progesterone withdrawal" may be an effect of alteration in PR status or
function. There is little evidence of specific cellular localisation of PR receptors (A
and B) in the human uterine cervix, and in particular in pregnancy, but this is due to
difficulty in obtaining such specimens. Previous immunohistochemical studies have
81
identified the presence of PR within fibroblasts in the cervical stromal compartment
in pregnancy, using the lower uterine segment as a proxy (Winkler et al 2002).
Progesterone results in a reduction in MMP-1 and MMP-3 (lytic enzymes) and thus
an increase in matrix synthesis with decidualisation (Lockwood et al 1998).
Progesterone withdrawal also results in up-regulation of these key proteolytic
enzymes in vitro and would therefore provide the ideal mechanism to induce
menstruation, in the absence of pregnancy.
Progesterone levels are thought to restrict excessive neutrophil entry and this has
been well described in a sheep model (Staples et al 1983). Progesterone antagonism
increases PGE2, chemotactic agents, leukocyte numbers and vascular permeability,
which in combination promote significant controlled leukocyte infiltration. VEGF
may be partly responsible for the vascular permeability changes in the pregnant
cervix as in the endometrium, as expression of VEGF and its receptor is up-regulated
in human decidual cells (Sugino et al 2002).
It is known that PGE2 levels increase in pregnancy, but it must also be remembered
that PGE2 catabolism by PGDFI is also progesterone dependent (Cheng et al 1993).
PGE2 and relaxin have both been used to elicit cervical ripening and both are
associated with endometrial decidualisation. Alteration of the PGE, cAMP and
progesterone pathways have been shown at different stages in pregnancy in uterine
tissues. It seems likely that interaction between these pathways provides a
physiological decidual stimulus via cAMP up-regulation in association with a
progesterone rich environment. Progesterone withdrawal then results in endometrial
menstruation and a similar mechanism in the cervix may contribute to the cervical
remodelling associated with late pregnancy and labour.
The stages that comprise early implantation are apposition and adhesion of the
blastocyst to the uterine lumen, penetration of the epithelium, enhanced
decidualisation of the stromal cells and trophoblastic invasion into the stromal
vasculature. The fact remains that although many cellular, biochemical and
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molecular associations with endometrial decidualisation have been confirmed, the
purpose and function of this decidual phenotype is still largely unknown. It appears
that MMP and matrix protein modulation occurs in concert with tissue and vascular
remodelling and angiogenesis effecting appropriate trophoblast invasion and fetal
cell migration. Insufficient invasion results in miscarriage or pre-eclampsia and
excessive invasion results in the highly dangerous condition of placenta percreta.
The specific functional role of IGFBP-1 or PRL remains unclear and the control
mechanisms are unknown. Prolactin, produced by human DSC could activate
receptors on uterine large granulated lymphocytes potentially influencing their role
in post-implantation uterine function (Gubbay et al 2002) whereas IGFBP-1 is
thought to influence trophoblast invasion by modulating IGF bioavailability (Gibson
et al 2001).
All the above considerations lead to the question: does cervical "decidualisation"
exist and is it a pre-requisite for successful pregnancy and appropriate gestation-
dependent cervical remodelling? Parallels may be drawn, but there are also contrary
functions in these two tissues. In particular the cervical stroma is not required to
accommodate trophoblast invasion or the extent of vascular remodelling seen in the
cervix. Could the decidual response be a reproductive stromal cell state that
becomes tissue specific dependent on other factors such as receptor status and
transcription factors? The cervical "decidual" response could be distinct. Here
cytokine, growth factor, matrix protein production and MMP modulation may render
the cervical stroma sensitive to other triggers such as cyclical stretch and functional
progesterone withdrawal at term.
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1.6 SUMMARY
Cervical remodelling associated with pregnancy and labour is a complex
physiological process and there are many contributory factors. Current clinical
interventions are limited by gaps in our knowledge of the process and by difficulty in
and limitations of administering cervical ripening agents. A series of clinical studies
with the needleless injector were planned but did not progress beyond the first proof
of principle study (see Chapter 3). Further study of the role of the cervical fibroblast
in pregnancy is the major focus within this thesis as a result of this change in
direction. Human cervical tissue is notoriously difficult to obtain, but further studies
must address the detail of cervical function with respect to the different cell types
present in the cervix and their interactions. The aims of this work are to explore the
hypothesis that the human cervix undergoes a preparatory phase in gestation akin to
endometrial decidualisation, that the key cell involved is the cervical fibroblast and
that the fibroblast may facilitate leukocyte recruitment by an MMP-14 induced
proMMP-2 activation pathway.
1.6.1 Hypothesis
The proposal is that the cervical fibroblast/ stromal cell has a central role in cervical
remodelling witnessed throughout pregnancy and in labour. Central to cervical
ripening is the rearrangement of the stromal ECM and therefore stromal tissue
distribution of active drug is essential. Reliable and efficient drug administration
could be improved by direct administration to this target area. A novel method of
needleless injection to the cervix may provide this if stromal penetration is achieved.
Evidence supports the fact that the cervical fibroblast has the capability to respond to
cytokines and steroids, the capacity to produce collagen, cytokines, chemokines,
MMPs and thus play a key role in tissue remodelling. Cervical fibroblasts do appear
to behave differently in pregnancy and are progesterone responsive. What is not yet
clear is whether there is phenotypic variation in the cervical fibroblast of pregnancy,
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as is seen in endometrial stromal cells. If this were so then this phenotype must
assessed in order to appreciate subsequent responses and functions in pregnancy and
labour. In addition MMP-14, as an activator of MMP-2 and MMP-8, may have a
specific role in cervical remodelling when one considers the potentiation of
leukocyte recruitment.
1.6.2 Aims of this thesis
1. To assess a needleless injection method for drug delivery to the cervix.
2. Assess the response of the cervical fibroblast to decidual stimuli.
3. Characterise any cervical fibroblast decidualisation-like response.
4. Investigate MMP-14 expression in the human cervix.
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RPMI 1640 culture medium
Tissue culture flasks
Neutral Buffered Formalin (NBF)
70% Ethanol
Sigma-Aldrich Co Ltd, Poole, UK
Costar Ltd, High Wycombe, UK
See appendix II
TISSUE CULTURE MATERIALS
RPMI 1640 culture medium
Fetal calf serum (FCS)






















6/12/24 well culture plates
Sigma, Poole, UK/ PAA Laboratories







Control Therapeutics, East Kilbride, UK
Sigma, Poole, UK
Sigma, Poole, UK
From Dr D Philibert, Roussel-UCLAF
Affiniti Research Prods. Ltd, Exeter, UK
Sigma, Poole, UK
Peprotech Ltd, London, UK
R&D Systems, Oxford, UK
Sigma, Poole, UK
R&D Systems, Oxford, UK





Costar Ltd, High Wycombe, UK
Costar Ltd, High Wycombe, UK
CELL LINES
U937 cells European Collection of Cell Culture
HS27 cells European Collection of Cell Culture
RNA EXTRACTION
Tri Reagent Sigma, Poole, UK
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Eppendorf AG, Hamberg, Germany
BDH Laboratories Supplies, Poole, UK
Sigma- Aldrich, Poole, UK








Applied Biosystems, Warrington, UK
See appendix II
Sigma, Poole, UK
Taqman Polymerase Chain Reaction kit
0.6ml PCR tubes
96 well optical plates
Optical cap strips
18S primer/probe set
All other primer/probe sets
Stratagene, Amsterdam, Netherlands
Applied Biosystems, Warrington, UK
Applied Biosystems, Warrington, UK
Applied Biosystems, Warrington, UK
Biosource, Nivelles, Belgium




















IL-8 capture antibody (mouse monoclonal) R&D Systems Ltd, Oxford, UK
IL-8 recombinant standard R&D Systems Ltd, Oxford, UK
IL-8 biotin-labelled detection antibody R&D Systems Ltd, Oxford, UK
IL8 KIT ELISA
Quantikine human IL-8 immunoassay R&D Systems Ltd, Oxford, UK
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MCP-1 ELISA
MCP-1 capture antibody R&D Systems Ltd, Oxford, UK
MCP-1 standard R&D Systems Ltd, Oxford, UK
MCP-1 biotin-labelled detection antibody R&D Systems Ltd, Oxford, UK
IGFBP-1 ELISA
IGFBP-1 capture antibody R&D Systems Ltd, Oxford, UK
IGFBP-1 recombinant standard R&D Systems Ltd, Oxford, UK
IGFBP-1 biotin-labelled detection antibody R&D Systems Ltd, Oxford, UK
PROLACTIN ELISA
Delfia Prolactin kit Perkin Elmer Applied Biosysytems
FACS
CD 10 phycoerythrin labelled antibody Beckman Coulter, High Wycombe, UK
NEEDLE-FREE INJECTOR STUDIES
Needle-free injector devices Weston Medical Ltd, UK
Methylene blue dye Sigma-Aldrich





All uteri with cervices (n=6) were obtained intact from healthy non-pregnant women
(aged 31-45yrs) undergoing total hysterectomy for benign pathology. All were
parous and had had at least one previous vaginal delivery. The Lothian Research
Ethics Committee and the Lothian University Hospitals NHS Trust approved the
study and use of facilities. Written informed consent was obtained from each subject
after consideration of an information leaflet.
Uteri were collected fresh from theatre, transferred to the laboratory and returned to
theatre within 60-90 minutes where they were fixed in formalin and processed
normally through the pathology laboratory.
2.1.2 Cervical Biopsies
Cervical biopsies were obtained from both pregnant and non-pregnant women. For
both groups, Lothian Research Ethics Committee and Lothian University Hospital
NHS Trust management granted approval. Women were approached in the out¬
patient setting and given information leaflets to consider before written informed
consent was obtained on admission.
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Non-pregnant women
Healthy non-pregnant pre-menopausal women aged 32-47 years undergoing total
abdominal hysterectomy for benign pathology, were approached. Samples were
obtained on day 3-20 although a few cycle stages were unidentifiable due to erratic
bleeding. Non-pregnant samples were obtained immediately post-operatively in the
Department of Obstetrics and Gynaecology, Royal Infirmary of Edinburgh. Cervical
biopsies (n=20) were retrieved from uteri immediately post hysterectomy. A thin
(~2mm) section was cut longitudinally through the anterior lip of the uterine cervix
and placed in RPMI 1640 medium (Sigma, Poole, Dorset, UK) on ice for transport.
Initial biopsies were processed for cervical stromal cell culture only. Later biopsies
were divided and:
1. Processed for cervical stromal cell culture (n=12).
2. Placed in 10% Neutral Buffered Formalin (NBF) at 4°C to fix overnight,
then transferred to 70% ethanol for storage until routine paraffin
embedding (n=12).




Healthy pregnant women (aged 18-34yrs) at 7-12 weeks gestation as determined by
last menstrual period and/or ultrasound scan, attending for surgical termination of
pregnancy under general anaesthetic, were approached. All required a negative
smear history and were chlamydia negative. Seven of the thirteen had received
misoprostol priming as per department protocol, but these samples were only used
for cell culture. The brief exposure to misoprostol (l-3hrs) was not likely to have a
prolonged effect in view of the length of time required for culture prior to
experimental protocol.
Cervical biopsies (n=13) were taken from the anterior lip of the cervix immediately
prior to termination, using Shumaker biopsy forceps and placed in RPMI 1640 on ice
for transport (Denison et al 2000). Shumaker biopsy forceps produce a sample
approximately 5mm diameter.
Initial biopsies were processed for cervical stromal cell culture only. Later biopsies
were either used for one of the below, or divided if large enough:
1. Processed for cervical stromal cell culture (n=8).
2. Washed with PBS, minced and placed in trireagent for whole tissue RNA
extraction (n=6). None in this group had received misoprostol priming.
3. Placed in 10% Neutral Buffered Formalin (NBF) at 4°C to fix overnight,
then transferred to 70% ethanol for storage until routine paraffin
embedding (n=8). Due to time constraints these samples were never
processed for paraffin embedding, hence planned immunohistochemistry
studies were not performed.
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2.2 TISSUE CULTURE
2.2.1 Cervical stromal cell culture preparation
Both pregnant and non-pregnant cervical biopsies were twice washed in PBS, then
dissected into small fragments with scalpel blades and replaced into RPMI complete
medium Tissue was then placed in complete culture medium (RPMI 1640
supplemented with 10% FCS, 20|ig/ml gentamicin, lOOIU/ml penicillin, 100p.g/ml
streptomycin and 2mM L-glutamine), in 25cm2 tissue culture flasks, at 37°C for 95%
air : 5% CO, incubation. This resulted in outgrowth of cervical fibroblast-like cells
within 7 days and with medium exchange every 3-4 days, the cells grew to
confluence. After transfer into 75cm2, then 162cm2 flasks the cells had grown to
confluence within a maximum of 21 days.
Cervical stromal cells were split 1:5 with standard trypsin:EDTA and were used up
to passage 7. Passages varied due to differing sample collection times, culture times
per sample, and a need to achieve adequate cell numbers concurrently for the
proposed treatment protocols. Passage variation within each study was kept to a
minimum. Culture times and passage numbers are consistent with other investigators
(Yoshida et al 2001; Yoshida et al 2002; Takemura et al 2004).
Cultured stromal cells were morphologically of fibroblast cell type and responded to
monoclonal anti-fibroblast antibody (Oncogene Research Products), which
recognises a fibroblast specific surface antigen. Culture conditions used were similar
to those for the extensively studied endometrial stromal cells in these laboratories.
Cervical stromal cell storage
Where appropriate cells were frozen in liquid nitrogen using a cryopreservative
medium (FCS with 10% dimethylsulfoxide (DMSO). Cervical stromal cells grown
to confluence in a large flask, and not for immediate use were washed with PBS,
then trypsinised to free them from the plastic surface. A small volume of RPMI was
93
added and after centrifugation at 1700rpm for 3 minutes a cell pellet was obtained.
On ice, the supernatant was then removed and 4-5mls of cryopreservative medium
added to re-suspend. Aliquots of 1ml of suspended cells per cryovial were placed at
-70°C in a slow freeze apparatus, and after at least 24 hrs the cryovials were
transferred to a liquid nitrogen container. On retrieval, cells were recovered in
complete medium and grown to confluence within 7-11 days.
2.2.2 U937 monocyte cell line
Undifferentiated U937 cells (ECACC) were used as a model to investigate cytokine
and matrix metalloproteinases release. U937 cells are a myeloid-derived
"immortalised" cancer cell line. They are pro-monocytic, display many monocytic
characteristics and can be induced to macrophage differentiation in vitro. These cells
were cultured in complete medium as maintenance and used at a cell density of
lxl05 cells/ml for treatment regimes.
94




lml Tri-reagent was added to treatment flasks or wells of cultured cells, after the
removal of supernatant. RNA was extracted by transferring the Tri-reagent to pre-
spun (6000rpm for 2 minutes) phase lock gel-tubes (Eppendorf). They were then
placed on ice for 5 minutes to allow lysis. 200pl of chloroform was then added and
mixed vigorously, before pre-cooled centrifugation at 14000rpm for 20 minutes at
4°C. The phase lock gel migrates to separate phases of an aqueous/organic
extraction; the aqueous layer above the gel contains RNA and the layer trapped
below the gel contains DNA and protein. The RNA aqueous phase is transferred to a
clean eppendorf 1.5ml tube and mixed by inversion, after the addition of 500(ll of
100% isopropanol. A further incubation at 4°C for at least one hour is followed by a
second spin at 14000rpm for 15 minutes. This produces an RNA pellet from which
the supernatant is removed and lml of 70% ethanol to resuspend. This is centrifuged
at 14000rpm for 5 minutes at 4°C. The ethanol is removed and the RNA pellet
resuspended in 25|ll RNA storage buffer (Ambion).
Whole tissue RNA extraction
Cervical biopsies from both pregnant and non-pregnant women were washed twice
in PBS and dissected into small fragments with scalpel blades. This was then placed
in Tri reagent, homogenised and frozen at -70°C until RNA extraction completed, as
above.
Cervical stromal cell culture RNA extraction
At the end of any treatment period, after removal of medium, cultured cells were
washed with PBS and then Tri-reagent added to each well/ flask. This was then
transferred into phase-lock eppendorfs with chloroform, spun and followed by
precipitation with isopropanol. The concentration of total RNA in the samples was
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quantitated by UV spectrophotometry (Biotech, WPA, Cambridge, UK) and each
sample was then diluted to lOOng/pl. and either reverse transcribed to cDNA or
stored at -70°C.
U937 cell RNA extraction
As undifferentiated U937 cells are non-adherent and remain in suspension, cells in
medium are collected and spun at 1700rpm for 3 minutes before resuspension in Tri-
reagent and RNA extraction as detailed above.
RNA quantification
A 5(lx1 aliquot of each sample was diluted in 2mls diethylpyrocarbonate-treated water
(depc H20) and thoroughly mixed. Quantitation was by UV spectrophotometry and
all samples diluted to 100ng/p.l as follows. The optical densities measured at 260nm
and 280nm determined the concentration and purity of RNA present. A blank was
used to zero the machine (2.5|il RSB with 2ml depc H20) with each set of samples.
The 260:280 ratio determined the purity with a value of 1.8 or higher indicating a
pure RNA sample. RNA concentrations were calculated by multiplying the 260 OD
value by the dilution factor and then a factor of 40 (as an OD value of 1 at 260nm is
equivalent to 40p.g/ml of mRNA). For example if 5ju.l RNA is diluted in 2mls depc
H20 (dilution factor 400), then:
RNA concentration (ng/|al) = 260 OD value x 400 x 40
Diluted RNA samples were then stored at -70°C for subsequent use.
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2.3.2 Reverse Transcription
Generally, 4(0.1 of template mRNA (at 1 OOng/jol) was reverse transcribed using 16|il
of Taqman reverse transcription reagents (AB Applied Biosystems). The RT mix
contained random primers, MgCl2 (5.5 mmol/1), dNTPs (1 mmol/1), random
hexamers (2.5|imol/l), RNase inhibitor (0.4 IU/p.1) and multiscribe reverse
transcriptase (1.25 IU/jol). This 20(il mix was covered with mineral oil to prevent
evaporation, and incubated sequentially at 25°C for 20 minutes, 48°C for 60 minutes
and 95 °C for 5 minutes (Omnigene PCR machine, UK). The resulting single-
stranded cDNA was then diluted with xl.5 volumes (30pl) of TE buffer and stored at
4°C for imminent use, or at -20°C for later use.
The precision of the RT reaction was calculated within the department by Elena
Faccenda (laboratory research support). An mRNA sample was taken and 8 RT
reactions set up in 8 separate tubes. A single PCR run on one primer/ probe set
compared them and found precision to be 3.65%.
DNA contamination is a major concern as PCR cannot discriminate between RT
synthesized cDNA and genomic DNA, thereby risking false positives.
Contamination is be minimised by extraction techniques and primer design but can
also be easily detected by "no RT" control PCR as follows. The control mRNA
samples from each experiment were assessed for possible genomic DNA
contamination by (3-actin signal detection without prior reverse transcription. A (3-
actin signal above 27 cycles indicates no major genomic DNA contamination. 27
cycles has been defined as threshold as this represents 3 standard deviations from a
mean of samples (King et al. 2000) without major genomic DNA content. Any
samples with a value below 27 indicating contamination were excluded from
analysis.
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2.3.3 Quantitative Real Time Polymerase Chain reaction
The polymerase chain reaction is a primer-directed in-vitro enzymatic reaction used
to amplify a specific DNA fragment. Primers are paired and flank a nucleotide
sequence of interest. There are three steps involved:
1. thermal denaturation of the target DNA (heat to 94°C)
2. primer annealing of synthetic oligonucleotide primers
3. extension of the annealed primers by DNA polymerase
This cycle is then repeated and with each repitition the number of product fragments
is approximately doubled. Because there is an accumulation of the product fragment,
there is a plateau beyond which there will be no amplification, because the enzyme
required is of a finite supply. PCR thermocyclers automate the entire procedure.
The result is a logarithmic amplification of the target sequence.
Reverse transcriptase-PCR uses messenger RNA (mRNA) rather than DNA, is very
accurate and sensitive allowing quantification of very low levels of mRNA. The
mRNA is reverse transcribed to produce a copy of the original DNA in single
stranded form, called complementary DNA (cDNA). This cDNA is mixed with
oligonucleotide primers, probes and enzymes and sequentially heated and cooled to
achieve the processes described above. Thermal cycling conditions commence with
a 2 minute hold at 50°C, followed by 10 minutes at 95°C. This provides a single
stranded template. Thereafter each cycle of 40, heats to 95°C for 15 seconds and
holds at 60°C to anneal. A specific labelled oligonuleotide probe will identify its
complementary sequence. Real-time quantitative PCR detects gene expression of a
particular target at the same time as it is amplified.
The amount of specific DNA at the end of each PCR run does not correlate to the
target copies in the original sample, but the cycle number at which a threshold
amount of product is seen reflects the original amount mRNA present.
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The measurement of PCR product is by detection of released fluorescent reporter
dye. Forward and reverse primers recognise the sequence of target DNA whilst a
dual-labelled probe recognises a particular sequence located between the annealing
sequences of the two primers. The labelling is with two distinct fluorescent dyes.
One is the reporter dye and the other a quencher dye (TAMRA). The reporter dye
fluorescence is suppressed by the quencher dye in the intact probe, as they are in
close proximity. During amplification the taq polymerase cleaves the probe, thus
separating the quencher dye from the reporter dye and releasing fluorescence, which
can be measured. The fluorescence is only detected if the probe target sequence is
cleaved, so non-specific amplification is not recognised (see Figure 2.1).
Ribosomal 18-S is used as the internal control. 18-S is constant to the relative
amount of cDNA present, and as the endogenous control, is then related to the
amount of specific amplicon to normalise variations in cDNA content between
samples. A negative control without RNA (depc H20) was used in each reaction.
Ribosomal 18-S and specific amplicons can be measured at the same time as each
reporter dye emits a different wavelength. The reporter dye on 18-S is VIC and most
specific amplicons use FAM (6-carboxyfluorescein) as the reporter dye.
PCR master mix contained Stratagene Brilliant Quantitative PCR Core Reagent Kit
(Amsterdam, Netherlands) (2x PCR buffer, 7.2mM MgCl2, 1.6mM Stratagene dNTP
mix, 1.6mM Boehringer dNTP mix, 0.05U/|ll sure-start taq polymerase, 0.06%
reference dye diluted in depc H20). All primer/ probe sets were purchased from
Biosource (Belgium) and diluted to 250)lM (primers) and 50|lM (probes) in TE
buffer. The mixture was then divided into 45pl (for two replicates) or 67.5(il
(triplicate) aliquots per tube. 5pl or 7.5|il (dependent on no. of replicates) of sample
cDNA was then added to each tube and mixed. 24pl aliquots were then transferred
to a 96 well PCR plate in duplicate or triplicate. A no template negative control
(depc H20) was also run on each plate. Plates were then sealed with optical caps and
the PCR run on ABI Prism 7700 Taqman sequence detector under standard
conditions.
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PCR data analysis was performed by use of the 2"AACt formula. Ct refers to the cycle
number that the fluorescent signal crosses the threshold. ACt is the difference
between the specific amplicon (FAM) and the 18-S (VIC) Ct values and enables the
amplified signal to be normalised against the total mRNA content. The mean ACt
between the duplicates on the plate was calculated. AACt then relates each samples'
ACt value to its own within experiment control. Therefore, the amount of target
mRNA is standardised to the amount of 18-S RNA, and is then compared to its
control. This gives a value relating to the fold increase in amount of target mRNA
compared to its own control.
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Figure 2.1:
Stage 1 shows the probe annealed to the target sequence with the reporter
and quencher dyes in close proximity suppressing fluorescence.
Stage 2 shows the forward primer extending along the template and
displacing the reporter dye as it reaches the probe.
Stage 3 Taq polymerase (as^hdonuclease) cleaves the probe separating
the two dyes and increasing the free reporter dye, and therefore
fluorescence.
Stage 4 Polymerisation is complete. The fluorescence signal is proportional
to the amount of amplicon (PCR product generated), thereby reflecting the
initial quantities of the target sequence.
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The primers and probes used were designed using the PRIMER express computer
program and sequences are listed in table 2.1.
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To determine the specificity of each primer/probe set, BLAST nucleotide database
searches were performed for each primer and probe
(http://www.ncbi.nlm.nih.gov/BLAST/). The returned results constitute a list of
'hits' or DNA sequences found to contain the target sequence. Each 'hit' is
accompanied by a 'E' Value (expect rate) which indicates the number of hits
expected to be found by chance during the search. The results of the BLAST
searches showed that for all sequences of interest, the primer and probe sets used
were unlikely to amplify fragments from an inappropriate gene, thereby confirming
specificity.
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Primers and probe sets were validated by assessing the linearity of the response in a
serial dilution of a standard pool of RNA. The log of total RNA (in ng) was plotted
against the mean ACt value of three replicates and then a regression line attained.
The slope of regression line (y) required was <0.1 in order that the primers and probe
be validated. All primer and probes were validated and intra-assay variation
calculated as a precision value (based on the mean and relative standard deviation of
6 replicates of identical cDNA in the same run) and expressed as a percentage.
See Figure 2.2.
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y = 0.0217x + 6.574
1.3 0.7 0.4 0.1 -0.2
log ng total mRNA
-0.51
An example of a linearity plot for the primer/ probe sets used in Q RT-PCR. This figure
represents the plot for the fibronectin primer and probes. The y value for this particular plot
is 0.02 and is an indication of the linearity.
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Table 2.2 Validation andprecision valuesfor the primer andprobe sets
















Tissue Factor -0.17 9.7
vEGF 0.081 1.7
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2.4 ENZYME LINKED IMMUNOSORBENT ASSAYS (ELISA)
2.4.1 ELISA is a technique whereby the concentration of a protein in solution can
be calculated by comparison with a standard curve created from prepared solutions
of known concentrations. Two main methods of ELISA are commonly used; the
Two Site ELISA and the Competition ELISA. Both types run on Maxisorp 96-well
plates. Method files for each ELISA were constmcted in Assay Zap with the range
of standards used, producing a standard curve against which any samples can be
measured.
1. Two Site ELISA (eg. IL-8)
This method involves using paired antibodies. A capture antibody coats the plates
and biotinylated detection antibody is used to detect the bound substance, which is
then quantified by adding streptavidin peroxidase. The peroxidase is then measured
by a colour reaction.
96 well plates are initially coated with a coating antibody specific to the protein of
interest. Blocking medium minimises non-specific binding and reduces background
recordings. The samples, standards, quality controls and non-specific binding wells
are then incubated. The target analyte of measurement is recognised and bound at a
specific site by the coating antibody. Excess media is then discarded and washed
away. The detection antibody recognises the target analyte but is bound by a
different specific site. The detection antibody is also biotin-labelled, which is bound
by streptavidin peroxidase, when added. Another wash removes any unbound
streptavidin peroxidase conjugate. Substrate added then detects the peroxidase,
which converts the tetra methyl benzidine into a coloured product (see figure 2.3).
The reaction is stopped by the addition of 2N sulphuric acid, before the colour
measured. The end result is that your target analyte is sandwiched between two
specific antibodies, one of which is biotinylated, binding peroxidase which is
detected by the substrate and quantifiable by EIA 450nm plate reader. These values
are then compared against the standard curve created to calculate the amount of
target substance present in the solution measured.
108
Figure 2.3 Two site sandwich ELISA
A.Coating antibody on plate Y.
B.Target substance X _2_
C.Biotinylated detection antibody. J.
□.Peroxidase link
E.Sub3trate
A.Plate coated with capture antibody
B.Target substance bound to capture antibody
C.Biotin labelled detection antibody bound to target substance
D.Streptavidin peroxidase links to biotin labelled detection antibody
E.Peroxidase produces measurable colour on addition of substrate.
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2. Competition ELISA (eg. PGE2)
96 well plates are coated with the purified donkey anti-rabbit antibody (Sapu,
Scotland, UK) and then blocked. This removes non-specific binding. A PGE2 anti-
sera raised in rabbit is added to the wells which will bind to PGE2. The solution
containing unknown amounts of the analyte is added with anti-sera and link
(biotinylated PGE2). The anti-sera binds with both the recombinant protein and the
analyte. The result is competition, between the link-bound PGE2 and the sample
PGE2, for the anti-sera. Therefore if there are high concentrations of the analyte,
more of the link is displaced and less colour displayed (see figure 2.4). Low
concentrations of analyte produce high levels of link bound to anti-sera, and a high
optical density reading. A secondary antibody binds to a separate site on the anti-
sera, which is then identified by the detecting system, to give a colour reaction. High
levels of sample PGE2 increase competition displacement of the biotin labelled link,
giving a lower concentration of coloured measurable product.
A standard curve and quality controls are generated to calculate sample
concentrations.
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Figure 2.4 Stages andprinciples ofa Competition ELISA (PGE2)







Antisera with rabbit anti PGE2 antibody
DAR antibody
Competition displacement ELISA. Higher levels of sample PGE2 result in
increased displacement of the biotin labelled link and so a lower
concentration of coloured measureable product.
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2.4.2 Interleukin-8 ELISA
IL-8 release was assayed by ELISA with matched pairs of capture and biotin-labelled
detection antibodies for IL-8. Plates were coated with capture antibody (2pg/ml) at
lOOpl/well overnight at 4°C. After a single wash, blocking solution was added at
400pl/well for 30 minutes at room temperature. Plates were either washed once and
used immediately or, after removal of the blocking solution, air dried and stored with
a dessicant at -20°C.
lOOpl/well of samples and standards were added, standards ranging from 2000-3.9
pg/ml, and samples in duplicate. The plates were incubated overnight at 4°C or at
room temperature for 3 hours on an orbital shaker, washed again, and then detection
antibody added (50ng/ml; 100pl/well). A further incubation period of 60-90 minutes
at room temperature with shaking was followed by a further wash and addition of
streptavidin peroxidase (lOOpl/well). The final wash was followed by the addition of
substrate (200pl/well) before quenching with 50pl/well 2N H2S04
Within 30 minutes of quenching, absorption was read at 450nm. Values are then
compared against the standard curve produced, to calculate the amount of IL-8 in
each sample. Intra and inter-assay precisions were 9.1% and 22% R.S.D.
respectively with a detection limit of 15pg/ml (Denison et al 1997).
R&D Quantikine Human IL-8 Immunoasssay
This kit employs the sandwich technique using a specific IL-8 monoclonal antibody
pre-coated on the plate. IL-8 in samples and standards is then sandwiched between
the immobilized coating antibody and the enzyme-linked polyclonal antibody




IGFBP-1 was measured by a two-site sandwich ELISA with matched pairs of capture
and biotinylated detection antibodies for IGFBP-1. Diluent used was PBS. The
IGFBP-1 capture antibody (lOOpl/well) was added at 2pg/ml, and plates prepared as
in the IL-8 ELISA method.
The plates were washed prior to use and a standard curve (4ng/ml to 0.06ng/ml)
added in single wells to each plate. lOOpl NSB and quality control wells (at
700pg/ml) were added in quadruplicate. Samples (lOOpl) were added in duplicate,
sealed and incubated at room temperature on an orbital shaker for 2 hours. After
washing (x4) and tapping dry, detection antibody (O.lpg/ml; lOOpl/well) was added
for a further 2 hour incubation on the plate shaker. After further wash and dry cycle
as before, streptavidin peroxidase conjugate (0.125U/ml; 100pl/well) was added, to
incubate for 20 minutes, before washing and developing with substrate (lOOpl/well)
and quenching with 2N sulphuric acid (50pl/well). The optical density was then
determined by a plate reader set at 450nm. The computer programme AssayZap was
used to analyse the results and construct a standard curve against which the samples
were then compared. The within assay precision was 1.7% (relative standard
deviation) and all assays were analysed on the same run.
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2.4.4 Prolactin Fluoroimmuonassay
A Wallac DELFIA prolactin kit (Perkin Elmer™ Life Sciences) was used to assay
prolactin release in culture medium. The kit is designed for use in human serum and
is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich
technique. The two antibodies are directed against two separate antigenic sites on
the hPRL molecule, the first immobilises the sample hPRL while the other is
europium-labelled. Enhancement solution dissociates europium ions from the
labelled antibody into solution and forms fluorescent chelates with them. The
fluorescence measured is proportional to the hPRL concentration in the tested
sample.
Reagents and samples were brought to room temperature before use. A 96 well
plate, pre-coated with solid phase anti-hPRL IgG is supplied with each kit.
Europium-labelled antibody (mouse monoclonal) at 200|il/well was added, and then
standards and samples were added in duplicate. Standards are supplied in the kit and
range from 0-250ng/ml. Expected concentrations in culture medium were at the
lower end of these standards so sample volume was multiplied by a factor of eight
and results then divided accordingly. A 90 minute-incubation at room temperature,
on orbital shaker was followed by washing prior to the addition of enhancement
solution (200jnl/well) and shaking for 5 minutes. Fluorescence is then measured
within 30 minutes on a time-resolved fluorometer (VICTOR).
The analytical sensitivity (the value which is 2 standard deviations above the mean
of the zero standard measurement values) is reported as "typically better than
0.04ng/ml". The within assay variation was 7.5% (r.s.d) and all samples were
analysed on the same run.
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2.5 FLUORESCENCE ACTIVATED CELL SORTER (FACS)
This method is based on flow cytometry (Coulter ® EPICS ® XL™). Flow
cytometry is used to optically quantitate components or structural features of cells,
which are individually counted but rapidly processed so thousands of cells can be
measured in seconds. The cells are passed through a laser beam as single cells in
suspension, and registered as events. The light then scatters; forward scatter is
related to cell size and side scatter relates to cell granularity. Cells also emit
fluorescent light when excited by the laser. Different probes, which fluoresce at
different wavelengths, can be used to quantify specific components of cells
recognised by labelled antibodies. The three measurements of cell size, granularity
and fluorescence combine to illustrate the distinct populations of cells present and
the percentage of fluorescent gives the percentage of antigen-positive cells in a
sample.
2.5.1 Fibroblast Cell Purity
Human cervical stromal cell cultures were assessed for purity with a human
monocloncal anti-fibroblast antibody Ab-1 (Oncogene).
Cultured cells were trypsinised and resuspended in medium before being split into
three 1.5ml eppendorf tubes. To one tube 2[ll fibroblast antibody was added and all
three tubes were placed on ice for 30 minutes. Tubes were then spun at 4000rpm for
1 minute to pellet and resuspended in CSM (cell separation medium). Two further
washes were performed. To two tubes, 100|il CSM and 1 OjllI anti-mouse IgG whole
molecule with FITC conjugated (Sigma) was added and then cells re-suspended.
The remaining tube was a blank. The tube exposed only to the anti-mouse IgG is the
negative isotype-matched control. Tubes wrapped in foil to prevent light exposure
and kept on ice for 30 minutes. Tubes washed as before and re-suspended in 500|il
FACS buffer. The cells were the passed through cell strainers (Becton Dickinson
Labware Europe, France) to ensure single cell suspension, and the passed through the
FACS machine.
A typical FACS report is shown is shown in Figure 2.5
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Figure 2.5 A representative example ofa FACS reportfor thefibroblast purity of
cultured cervical stromal cells
A) Isotype-matched negative control
B) Sample with fibroblast antibody
The y axis is log of forward scatter and x axis is the log of side scatter.
Graph i) total no. of counts is illustrated and the region within the green line
represents the gated area of cell analysis. Remaining points outside this are likely to
be cell debris and are excluded from analysis.
Graph ii) the y axis represents the total cell count and the x axis is FITC value -
the total level of fluorescence detected within the gated region in i). The red line
indicates those positive for FITC.
Note the FITC value is minimal in A) the negative control, but in B) where the
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Cells were trypsinised and resuspended in cell separation medium to achieve a cell
density of 4-8 x 105/ml. This suspension was then centrifuged at 4000rpm for 1
minute to form a pellet before resuspension in FACS buffer (sterile PBS with
1%FCS and 0.1% azide). A repeat spin was followed by resuspension in 1 OOju.1 of
FACS buffer. To this 20pl of CD 10 phycoerythrin labelled probe (human anti
mouse) was added and incubated for 30 minutes on ice and protected from light. A
blank and an isotype (mouse IgG) control was also prepared for each cell line. For
each treatment there were 3 vials:
1. Control
2. Isotype control labelled
3. CD 10 phycoerythrin labelled probe
All samples were then washed, spun and resuspended three times in FACS buffer to
a final volume of 1ml. Cells were then analysed by flow cytometry in a Beckman
Coulter FACScan. Fluorescence intensity was then plotted against number of events.
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Statistical analysis
Significant differences of PCR and ELISA results were determined by analysis of
variance (ANOVA; Statview 3.0).
Data normalised to control was analysed by non-parametric methods. The Kruskal-
Wallis analysis of variance was used and Dunn's multiple comparisons test was used
to assign significance to treatment. For comparisons of RNA in pregnant or non¬
pregnant cervical biopsies, the Mann-Whitney U test was used.
Statistical differences are indicated on graphs by the use of symbols above the
relevant bars. P values relating to the symbols used are detailed in the figure legends.
P<0.05 was taken as being significant.
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CHAPTER 3




Cervical ripening is essential to the normal progress of labour. It is known that
approximately 20 % of pregnancies in the UK currently undergo some therapeutic
intervention to initiate labour. Prostaglandins are the most commonly used agents,
currently administered vaginally or intracervically in the form of a gel, tablet or
hydrogel polymer. This method relies on variable drug absorption and can have
significant side effects. A needleless injector may provide a route of administration
whereby a precise dose can be given directly to the target tissue producing a more
rapid and controlled response.
Cervical ripening is a complex process culminating in the softening and restructuring
of the cervical connective tissue in preparation for cervical dilatation throughout the
process of labour. There are many mediators involved in this but the most
therapeutically exploited to date are prostaglandins. Prostaglandins of the E and F
groups are known to have a physiological role (Gibb 1998) and have been used
successfully for cervical ripening, not only for labour but also for termination of
pregnancy and other procedures requiring access to the uterine cavity (Calder et al
1993).
Prostaglandins E and F do not only affect cervical tissue but also cause the
myometrium to contract and this is one of the major concerns, as it occasionally
results in hyperstimulation. Rarely the catastrophic complication of uterine rupture
may occur (Bennett 1997). In fact, when given systemically, prostaglandins can
produce gastro-intestinal, respiratory and cardiovascular side effects and this is one
of the reasons that intravenous, oral, extra-amniotic and intramuscular use now is
largely avoided.
The current favoured agent is dinoprostone (PGE2), but many formulations require
special storage and cost is a limiting factor in developing countries. With
pharmaceutical developments, local administration became far more popular
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reducing the side effect profile significantly and vaginal/ intracervical gels /tablets
and vaginally administered hydrogel polymers are now widely used (Keirse 1992;
Calder et al 1993; Arias 2000). There is little to choose between these formulations
in terms of efficacy, but patient satisfaction scores were slightly better for the
hydrogel polymer which is left in-situ for up to 12hrs, when compared with vaginal
gel where repeat examinations and drug administration may be required within that
time (Tomlinson et al 2001). However the improved satisfaction scores related to
labour rather than the induction process.
As knowledge of the cervical ripening process continues to expand, so therapeutic
options may increase. Drug delivery for this purpose is felt to be more appropriate
locally, as systemic administration, particularly of prostaglandins, which are most
commonly used in this scenario, can cause significant side effects. Currently we rely
on absorption through the vaginal/ cervical epithelium for any drug to take effect and
this results in administration of an excessive dose to achieve absorption of the
required amount. It is increasingly suggested that the internal cervical os is the site
of initiation of cervical ripening (Van Meir et al 1997; Challis et al 1999) and is
notoriously difficult to target, due to the anatomy and the very dense structure of the
cervix. It is considered that by bypassing the absorption requirements, a more direct
delivery may allow lower dosage administration and may achieve a more rapid
response. The needleless injector form of drug delivery is currently used for
subcutaneous and intradermal administration (usually of hormones eg. growth
hormone and insulin), and may provide an attractive alternative to current cervical
ripening therapeutics.
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Figure 3.1 Anatomicalfeatures with local drug delivery
A) vaginal gel B) needleless intracervical injection
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Hypothesis
The needleless injector has been used to deliver compounds both subcutaneously and
intradermally. The cervical stroma is the target tissue for cervical ripening agents.
One problem in drug administration to the cervix is the stratified squamous
epithelium through which diffusion is relatively slow, and another is the dense nature
of the fibrous cervix. Absorption after vaginal application is variable and requires
excess drug to be administered to achieve the desired effect. Some compounds
cannot be delivered in this manner due to molecular size or hydrophilic nature. In
these cases it would be desirable to bypass the epithelial barrier, by injection
technique, and it is supposed that avoidance of needle use is attractive for users. In
addition the diffuse distribution of drugs using injection of a liquid stream may be
beneficial for subsequent diffusion. This form of delivery system has not been
assessed with cervical tissue and so this study aimed at preliminary assessment of
suitability. Does the needleless injector breach the cervical epithelium and penetrate
the cervical stroma?
Needle free injector device
The device uses a compact nitrogen gas source to propel a quantity of liquid through
a tiny aperture (0.3mm), thereby breaching the epithelial barrier, and penetrating the
underlying tissue. There is a gas spring and trigger mechanism and a capsule
containing the liquid. Once the safety band is removed, pressure is applied against
the target until the trigger latch disengages. On activation the ram is pushed forward
by the compressed gas. This pushes the piston down the drug capsule, expelling the
solution in less than 60 milliseconds.
Needle free injector devices have been successfully used in dental practice and for
self administration of subcutaneous insulin. Differing designs are on offer (reusable
or disposable) and compression gases vary (eg. C02) have been used.
(See www.syrijetinc.com/public/intro.html or www.jtip.com/luersys.htm)
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Weston needle-free injection device
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The Weston intraject device is a single use, disposable, needle-free injection system
for the delivery of liquid drugs. It uses compressed nitrogen as an energy source and
once filled, delivers a pre-measured quantity of drug to the site chosen. The liquid
drug is held in a glass capsule contained within an outer clear plastic sleeve. The
device cannot be used on a second occasion as there is no residual energy after use.
This also means that the device can be easily and safely disposed of as there is no
needle and no residual energy.
Aims:
1. To assess a needleless injector device as a delivery system to the
cervix.
2. To measure depth of penetration of dye administered by a
needleless injector.
3. To obtain histological evidence of dye penetration.
4. To obtain histological information about degree of tissue trauma.
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3.1 METHODS
Uteri were obtained as described in chapter 2. Six cervices were used in the study
with a proposed two injections per cervix. See details in table below. All women
were undergoing surgery for benign disease and were pre-menopausal.
Table 3.1
Age Parity Vaginahcaesarean delivery Operation
1 32 2 1:1 TAH
2 37 2 2:0 TAH
3 32 4 4:0 TAH
4 31 2 2:0 VH
5 45 2 2:0 TAH





The needle-free injector devices (Weston Medical Limited, UK) were filled prior to
use with 0.2mls methylene blue dye (lmg/ml) in sterile phosphate buffered saline.
Each uterus and cervix was collected from theatre and injected within 30 minutes of
removal from the subject. The site of injection was the ectocervix of the anterior and
posterior cervical lip with the direction of injection towards the uterine body. After
each injection a coronal or sagittal incision was made, measurements performed and
photographs taken (see Figs 3.3-3.6). The camera used was Nikon D4 with a
Tamron macro lens. Each picture contained a scale in millimetres. The main
outcome measure was the mean depth and lateral spread of dye injected.
Measurements of depth and lateral spread included any evidence of blue dye spread
from the site of injection, both intense and lesser degree of staining.
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After all measurements were recorded and photographs completed each sample was
returned to theatre, and placed in formalin. After overnight fixation, specimens were
examined macroscopically, dissected, and tissue blocks taken from the cervix and
processed by routine methods. Haematoxylin and eosin stained sections were made
and examined microscopically. In addition, unstained sections were mounted on
glass slides and examined microscopically for traces of dye.
The last sample received one injection from a needle-free injector device and one
from a conventional needle and syringe filled to the same volume. It was felt that
depth of injection cannot be compared as the needle must penetrate the tissue to
some degree before injection thereby falsely increasing the measurement of depth of
spread. This was to allow a comparison of the pattern of distribution i.e. is there a
more diffuse pattern of distribution with a needle-free injector reflected by a greater








The results are shown in the tables below (Tables 3.2 & 3.3). The needleless
injector penetrated a mean depth of 5.6mm with a mean lateral spread of 10.3mm.
This is sufficient to breach the cervical epithelium and deliver an agent directly to
the cervical connective tissue. This would avoid the problem of variable
absorption in vaginally delivered gels. One sample was taken at the time of
vaginal hysterectomy, the indication for the procedure being uterocervical
prolapse, which is felt to be associated will some form of collagen dysfunction.
This sample resulted in the greatest measurements for depth of penetration and
may be related to deficient collagen and lower tensile strength of the tissue. If this
is the case one might assume that greater penetration may occur in pregnant
cervices as the process of cervical connective tissue remodelling begins early in
pregnancy and accelerates in the final few weeks.
Pathology
After routine processing for histology, no trace of dye was seen microscopically in
any of the six specimens, neither on haematoxylin and eosin-stained sections, nor on
the unstained sections of cervix. It is believed that the dye dispersed during
processing. However, in none of the specimens was there any evidence of tissue
trauma secondary to the injection procedure. The use of an alternative dye that
persists throughout fixing and routine preparation for microscopy would have been
beneficial and corroborated the gross findings and given us a more accurate
assessment of distribution. Suggested alternatives might be toluidine blue or india
ink.
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Table 3.2 Depth ofpenetration












Table 3.3 Lateral spread







Needle comparison: depth 16mm, lateral spread 8mm.
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3.4 DISCUSSION
These findings support the hypothesis that needle-free injectors breach cervical
epithelium when used on ex-vivo uteri. This may warrant further investigation for
the application of drug delivery to the cervix. Initial assessment confirms that this
delivery system would penetrate the cervical epithelium, thereby reaching the target
immediately and possibly shortening the duration of the ripening process. This
would also enable more accurate dosage regimes and as a local delivery system,
minimise systemic side effects of any proposed agent. Not only might his be used
for cervical ripening agents but also to administer local anaesthetic agents for
colposcopic or other gynaecologic procedures.
Cervical ripening is the preparatory connective tissue remodelling prior to labour to
enable the cervix to dilate. The cervix is a very dense fibrous structure out with
pregnancy (Danforth 1947) and through the majority of pregnancy, but there is a
gradual change in cervical connective tissue which accelerates immediately prior to
labour (Ekman et al 1986). The end result of this process is a remodelled structure
with reduced collagen content, increased water content and a change in relative
quantities of different glycosaminoglycans. This then causes disassociation of the
collagen fibrils, and with a neutrophil influx, an increase in degradative enzyme
activity.
Cervical fibroblasts may be central to the ripening process. There is now interest in
several other inflammatory mediators thought to have some role in cervical ripening
(Sennstrom et al 2000). The premise here is that leukocytes are recruited to the
cervix by some inflammatory mediator released from the fibroblast. The activated
leukocytes then participate in the inflammatory process of ripening by releasing
collagenases and matrix metalloproteinases, which in turn remodel the connective
tissue resulting in reduced collagen content, increased water content and a softer
cervix (Liggins 1981; Romero et al 1991; Ledingham et al 1999a).
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Whatever agent is considered for cervical ripening there may be significant benefits
in the proposed delivery method, ideally to promote cervical ripening without
inducing myometrial activity until this process is complete. The attraction of
delivering the required compound directly to the cervical connective tissue (largely
collagen fibrils and fibroblasts), thereby avoiding variable absorption rates with
unpredictable responses, and acting directly on the target tissue is considerable.
The use of an alternative dye that persists throughout fixing and routine preparation
for microscopy would have been beneficial, corroborated the gross findings and
given us a more accurate assessment of distribution. This was an unintentional yet
significant short-fall in this study and I suggest that more appropriate dyes might be
toluidine blue or india ink.
Having used these devices on postoperative organs in non-clinical set-up it would be
important to trial their use in-vivo without active agent, largely to assess practical
issues such as device trigger pressure, ease of use, and user and patient acceptability.
The needle-free injector may provide efficient drug delivery to the cervix for
gynaecological outpatient procedures as well as induction of labour and pre-surgical
termination of pregnancy cervical preparation. There are considerations in device
design to consider, such the trigger pressure required to fire the device. Currently
this requires forward pressure against the chosen target until a threshold is reached
that automatically fires the gas release. Perhaps this threshold pressure would need
alteration for particular tissue targets or the incorporation of a manual trigger would
be beneficial. A threshold pressure set too low would be potentially dangerous if
triggered before correct placement, and too high would be impractical for clinical use
as the cervix would require to be immobilised. This would cause further discomfort
and negate the potential benefit of needle-free injection. However, significant design
alterations were not an option in these circumstances as a single device design was
available. Also because of the anatomical site of the cervix, the existing device
would require an extension to allow use with a speculum. With good visualisation of
the cervix a simple lengthening of the handle would suffice and it is unlikely that
introduction of an angle along the handle would be a significant improvement. The
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sound of gas release with firing the device is something that cannot be prevented and
with adequate pre-procedure counselling is unlikely to be a handicap.
In summary this shows the needle-free injector delivery system is effective in
traversing the cervical epithelial barrier and may therefore successfully deliver
compounds unsuitable for other methods of administration. This study confirms the
viability of use of such a device with regard to tissue penetration, but it remains to be
seen whether this would offer a clinical benefit. The anticipated benefit would be
accurate, reliable and anticipated reduced drug dosing. A potential benefit would be
speed of subsequent distribution with a shorter interval to effect. An improved
efficiency of any drug delivery method for labour induction could shorten the
process for those that currently require repeated administration of vaginal gel over
24-48 hours.
To assess clinical benefit of a needle-free injector, a trial would require comparison
against standard drug delivery methods (i.e. vaginal gel). Initial further assessment
would require placebo use of the device in women to assess acceptability and safety.
It was my intention to proceed to this but several significant delays were encountered
postponing tissue collection in the first instance and later device supply was
withdrawn as re-design issues were dealt with. Initial delays were awaiting Ethics
Committee and Trust Management Approval. Although applications were submitted
early and there were no concerns with study design, I encountered significant delay
as a result of legal discussions regarding Intellectual Property Rights and publication
issues between the Trust R&D, University department and Ardana Biosciences. As
this was the first such collaboration locally there were unforeseen issues that required
clarification and communication between the relative departments was laboured. In
addition to these delays, subsequent postponement of research activity was inflicted
as the clinical department, and later the research unit were relocated to a new site
causing major disruption and down-time on each occasion. As a result the
subsequent plans for a clinical assessment study were abandoned and further work
concentrated on in-vitro cervical fibroblast studies.
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There is no evidence to suggest that this method would be preferable than injection
with a dental syringe as is routinely used in colposcopic practice and both these
methods require lithotomy positioning, speculum examination and good lighting.
Either injection technique is much more cumbersome than current induction
procedures where a simple vaginal examination is suffice, but while practical, the
inadequacies of current induction techniques should not be ignored. Only if the
induction process were sufficiently improved in terms of duration from induction to
delivery or outcomes would this more invasive method seem justified.
At present optimal dosage studies of current vaginally administered induction agents
are in progress and may offer significant improvement in terms of safety and
efficiency. Although this device offers theoretical benefit for cervical ripening drug
delivery, I have several concerns about the practicalities in clinical use and therefore
I do not feel that further investigation is merited. With regard to outpatient
gynaecological procedures the examination procedure would not change but there are
minimal difficulties with dental syringe use and so little to be gained with the added
expense of device purchase.
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CHAPTER 4
DECIDUALISATION OF CERVICAL STROMAL CELLS
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4.1 INTRODUCTION
Although the uterus and cervix have distinct anatomy and disparate roles they do co¬
exist in physical continuity with similar exposures. The process of endometrial
decidualisation is essential for successful pregnancy and this transformation of the
endometrial stromal cell is dependent upon progesterone response mediated by the
progesterone receptor. The capacity for the cervical stromal cell to respond to
decidual stimuli in a manner similar to it's endometrial counterpart has not been
explored despite previous identification of decidual-like cells in the human cervix
(Rutanen et al 1991). Decidualisation follows activation of a series of progesterone-
dependent gene sets (Tabanelli et al 1992). This provides a window of opportunity
for blastocyst implantation and trophoblast invasion. In the absence of pregnancy
falling progesterone levels leads to vascular disruption and the superficial
endometrium is shed.
Previous in vitro studies in decidualisation conclude that progesterone is critical and
that cAMP augments the response via sustained protein kinase A activation (Brar et
al 1997; Telgmann et al 1997; Gellersen et al 2003). Although in laboratory practice
this involves treating with cAMP analogue, as cAMP does not cross cell membranes
with ease, this could be achieved through various mechanisms physiologically either
via the PGE2 receptor pathway or by alteration of cAMP synthesis/ catabolism. An
example would be to influence phosphodiesterase activity, with specific PDE
inhibitors or with relaxin, which has also been shown to have this effect (Bartsch et
al 2001). EP2 is known to be the dominant PGE receptor in pregnant baboon
cervices (Smith et al 1998) and provides a mechanism of cAMP regulation via the
EP2 receptor/ PGE2 pathway (Brar et al 1997). In-vitro endometrial decidualisation
studies traditionally use a decidualisation mix including progesterone, cAMP and
oestradiol based on the observation in-vivo that the progesterone response
necessitates oestradiol-primed stroma (Huang et al 1987; Telgmann et al 1998). The
dramatic effect seen with progesterone and cAMP combined confirms their critical
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role. An oestradiol-specific effect is not apparent from in-vitro studies and questions
the need for oestradiol in these models.
Known decidualisation markers from the body of work on human endometrium are
many but the most reliable are PRL and IGFBP-1 (Tabanelli et al 1992; Lane et al
1994; Brar et al 2001). The precise function of the decidualised cell is still
undetermined but key functions would appear to include regulation of extracellular
organisation, cell migration, angiogenesis and haemostasis. Decidual IGFBP-1 has a
high affinity for IGFs altering their bioavailability and thereby inhibiting local
actions (Lane et al 1994; Gibson et al 2001).
Endometrial stromal cells express both PR isoforms (Brosens et al 1999) and are
sensitised to PR-mediated progesterone effects by raised cAMP levels and sustained
PKA activation. Persistently elevated PR levels inhibit decidualisation (Brosens et al
1999). Prolonged progesterone exposure downregulates PR reversing PR-mediated
IGFBP-1 inhibition, possibly limiting decidual phenotype expression. PR isoforms
are also present within the human cervix and so phenotypically similar cervical cells
have the potential to respond in a similar manner (Stjernholm et al 1997; Stjernholm
et al 1999).
Decidua has a basement membrane-like structure with increased intercellular space
rich in matrix proteins such as fibronectin, laminin and collagen. These upregulated
matrix proteins interact with placental integrin receptors forming the fetomaternal
interface. Fibronectin is thought to have a particular role in cell migration during
implantation, embryo and fetal development (Duband et al 1990), and is upregulated
by progesterone via the PR (Zhu et al 1992; Brar et al 2001; Tseng et al 2003).
Laminin, desmin and tissue factor are other identified decidual products (Tabanelli et
al 1992; Lockwood et al 1993; Brar et al 2001). Desmin, typically expressed by
myofibroblasts, is not seen in decidual precursors but has been identified in DSC
(Glasser et al 1986; Oliver et al 1999). Human DSC also express CD 10 antigen, an
endopeptidase associated with haematopoietic cells, yet ultrastructural studies concur
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with the mesenchymal origin of DSC (Montes et al 1996; Oliver et al 1999; Kimatrai
et al 2003).
This experimental work aims to establish whether there is evidence of decidual-like
changes within the human cervix in early pregnancy, by assessment of
decidualisation marker mRNA expression, primarily prolactin and IGFBP-1. In view
of the limited availability of cervical whole tissue, particularly in pregnancy, a
proposed model is suggested to evaluate the cervical fibroblast/ stromal cell and its
response to decidual stimuli. Endometrial decidualisation evolves from the
perivascular stromal cell (Kelly et al 2002) and so, should a similar mechanism exist
within the cervix, the fibroblast is a likely contender. The fibroblast is a cell of
multiple functions and may prove to be central in orchestration of the events seen
throughout pregnancy and labour. It is of particular interest to explore its response to
a pro-decidualisation environment. Phenotypic alteration would have significant
implications for the subsequent functions of this cell type.
It is critical to compare the influence of progesterone and cAMP individually in this
process, and whether a combined approach demonstrates true synergism as is
suggested from the endometrial data. Pregnancy-derived and non-pregnancy derived
cervical samples and stromal cells are compared in their response to decidual stimuli.
Decidual-like transformation may be an inherent property of all fibroblasts with
appropriate stimulation. A comparison will be made with a non-reproductive cell
line (foreskin fibroblasts) on the assumption that this capacity is peculiar to
reproductive tissues in possession of nuclear progesterone receptors.
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Hypothesis
This work aims to prove the hypothesis that human cervical stromal cells undergo a
phenotypic alteration akin to decidualisation in pregnancy and that this can be
induced in-vitro by a combination of progesterone and cAMP.
Aims:
1. To compare gene expression of decidualisation markers in pregnant
and non-pregnant cervical biopsies.
2. To apply decidual stimuli in vitro to cervical stromal cells from both
pregnant and non-pregnant women and compare the response in terms
of;
a) Morphology
b) Gene expression of markers of decidualisation
c) Protein release of decidualisation markers
d) Receptor status
e) Surface marker expression





Cervical stromal cells were isolated from both non-pregnant (n=6) and pregnant
(n=7) cervices as described in chapter 2.
A foreskin fibroblast cell line (HS27 obtained from the European Collection of Cell
Culture) was used to compare the decidualisation response in a non-reproductive
fibroblast cell line.
Cervical biopsy mRNA studies
Both pregnant and non-pregnant samples were homogenised in Tri reagent for RNA
extraction from untreated cervical biopsy tissue.
Tissue culture/ storage
All cervical fibroblasts were cultured as described in Chapter 2. Cells used were
from passage 2-7.
HS27 cells are foreskin fibroblasts and were used as a non-reproductive cell
comparison. These cells were supplied at passage 23, were incubated in an identical
manner as in complete medium and treated at passage 24-25.
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Treatment regimes
All cells were plated at 5 x 104/ ml complete medium in 6 well plates and grown to
confluence over 72hrs before treatment commenced. Following a PBS wash
treatments were prepared with 2% FCS supplemented RPMI (with 20|Lig/ml
gentamicin, lOOIU/ml penicillin, 100|J.g/ml streptomycin and 2mM L-glutamine):
1. Control
2. 8-bromo-cAMP 250(iM (cAMP)
3. Medroxyprogesterone acetate 10"6M (MPA)
4. Decidualising Mix (8-bromo-cAMP 250(lM + MPA 10"6M + oestradiol 10"7M)
The combined treatment of MPA, cAMP and oestradiol will be referred to as
decidualisation mix (DM). Treatment periods were for 6 or 10 days, with medium
changes every 3 or 4 days (pregnant cell lines n=5, non-pregnant n=6). Medium was
collected in duplicate at the end of each treatment period and stored at -20°C for
protein assay at a later date.
Decidualisation mix containing cAMP, MPA and oestradiol was used based on
previous experience in the local laboratory with endometrial decidualisation.
Oestradiol could therefore have a confounding effect as this was not compared alone.
In view of the potential confounding factor of oestradiol, a comparison experiment
was perfonned using Decidualising Mix with and without oestradiol (n=4):
1. Control
2. 8-bromo-cAMP and MPA
3. DM (8-bromo-cAMP 250pM, MPA 10"6M and oestradiol 1CT7M)
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Real time-PCR
RNA extraction was performed using Tri Reagent and Phase-lock tubes according to
detail in Chapter 2, followed by precipitation with isopropanol. All RNA samples
were quantified by UV spectrophotometry before dilution to 100ng/fxl. Generally,
4|ig of total RNA was reverse transcribed, and the resulting single-stranded cDNA
was then analysed by quantitative, real time, Taqman PCR using a Model 7700
Sequence Detector.
Primers and probes were designed using the Primer Express© program (Applied
Biosystems). Sequences used in are shown in Table 2.1.
All PCR reactions were run in duplicate, with 18-S as an internal endogenous control
to normalise variations in cDNA content between samples. To determine genomic
DNA contamination the (3-actin signal was measured without reverse transcription in
all samples. The criterion for exclusion was a measurement greater than 3 standard
deviations below the mean, from a population of 66 samples; this translates to a [3-
actin FAM signal with a Ct below 27 cycles. Samples used had a mean (3-actin FAM
Ct of 34.6 ± 0.4 and the minimum was 29.1.
To examine the gene expression of known decidualisation markers in untreated
cervical biopsies, RT-PCR was carried out for PRL, IGFBP-1, laminin, fibronectin
and VEGF. Phosphodiesterase type 4 was also measured as a potential marker for
physiological cAMP regulation. Receptor expression status was evaluated for
progesterone receptor (PR) prostaglandin receptor types EP2 and EP4.
Where cultured CSC were treated, decidualisation markers PRL and IGFBP-1
mRNA expression was compared with control. In these groups progesterone, EP2
and EP4 receptor expression was evaluated.
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Enzyme Linked Immunosorbent Assays
Secretion of PRL and IGFBP-1 proteins were evaluated in medium collected at the
end of each treatment period. All samples assayed in duplicate. PRL estimation was
performed using a PRL kit as described in Chapter 2 but with a 10-fold increase in
sample volume relative to standard volume, corrected during analysis. The
analytical sensitivity is 40pg/ml and the within assay variation was 7.5% (relative
standard deviation). All samples were analysed in the same assay.
The IGFBP-1 assay was performed as described in Chapter 2 with a lower limit of
sensitivity of 62.4pg/ml and a within assay variation of 1.7% (relative standard
deviation). Again, all samples from each experiment were analysed on the same
assay.
Fluorescence Activated Cell Analysis
FACS for anti-fibroblast antibody: for details see Chapter 2
Cervical stromal cells were grown to confluence and treated with trypsin EDTA,
washed and resuspended in PBS/BSA medium. The cell suspension was treated with
monoclonal anti-fibroblast antibody (Oncogene Research Products), which
recognises a fibroblast specific surface antigen. Cells were then washed and treated
with fluorescein labelled sheep-anti-mouse serum. Cells were analysed in a
Beckman Coulter instrument and fluorescence intensity was plotted against number
of events.
FACS for CD 10 surface marker: for details see Chapter 2
A repeat experiment was run for 10 days comparing control pregnant (n=2) and non¬




4.3.1 Cervical biopsy data
Cervical biopsy samples from pregnant and non-pregnant women were homogenised
and RNA extraction performed. Due to limited tissue samples RT-PCR was
performed on pooled RNA for some markers (PRL and IGFBP-1), and individually
for others with a mean and s.e.m calculated (range shown in table 4.1).
PRL and IGFBP-1 mRNA were both found to be raised in pregnant samples relative
to non-pregnant samples (14-fold and 53-fold respectively), but this was on pooled
RNA so there are no error margins. However this demonstrates the possibility of
decidual-like changes in cervical tissue as has been shown in the endometrium.
EP2, EP4, PR, PDEIV and VEGF message was not significantly altered between
groups. Laminin appears to be increased in the pregnant group, but this is due to a
single greatly elevated result. There was a wide variation in data for all the results in
the biopsy data.
Table 4.1 RNA expression in untreated cervical biopsies; mean ± s.e.m (range)
Non pregnant n=6 Pregnant n=6
PRL 1.0 14.6 pooled RNA
IGFBP-1 l 52.8 pooled RNA
PR 1.1 ± 0.2 (0.6-2.6) 2.3 ±0.3 (1.6-4.1)
EP2 2.5 ± 0.9 (0.2-8.4) 3.6 ±1.7 (0.4-16)
EP4 3 ±2 (0.1-13) 5 ±3.6 (0.1-23)
PDEIV 3.3 ±1.9 (0.04-12.4) 5.1 ±3.1 (0.1-17)
Laminin 2.7 ±1.1 (0.1-8.9) 14.9 ±9.1(0.2-81)
Fibronectin 2.1 ±0.6 (0.1-5.4) 2.8 ±1.3 (0.2-10.2)
VEGF 2.1 ± 1.3 (0.2-8.3) 3.6 ±2.7 (0.3-17)
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4.3.2 Cervical Stromal Cell response to decidual stimulus
a) Morphology
Spindle-shaped fibroblast-like cells grew out of cervical tissue from both pregnant
and non-pregnant women. These will be referred to as cervical stromal cells (CSC)
throughout the commentary. The fibroblast identity of these cells was confirmed by
FACS analysis. The percentage of cells that possessed this marker was between 95
and 98 % of the total (Figure 4.1).
Cervical stromal cells treated with progestin and 8-bromo cAMP for six or ten days
had a plumper morphology than untreated cells cultured in the same way (Figure
4.2). This represents a change characteristic of "decidual" transformation achieved
in a relatively short period. Morphological decidual change in endometrial stromal
cells exposed to progesterone alone in vitro can take 14 days or more to occur (Lane
et al 1994) although local experience suggests a response in decidualisation markers
within 48 hours as is shown in other studies (Gellersen et al 2003). Addition of
cAMP is known to accelerate this response.
There was no observable difference between pregnant and non-pregnant cell lines
and the light micrograph demonstrates the morphological change between control
and DM regimes after 10 days in pregnant CSC.
There was no difference in morphology between those CSC stimulated with DM
(cAMP, MPA, oestradiol) or those with cAMP and MPA combined, without
oestradiol.
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Figure 4.1 FACS Analysis CSC with fibroblast specific antibody (oncogene)
FACS analysis of undifferentiated cultured human cervical stromal cells to confirm fibroblast
nature.
Y axis = forward scatter
X axis = fluorescence intensity denoting specific fibroblast marker.
Cells positive for the fibroblast marker are shown in grey = 98% of cells
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Figure 4.2 Morphological change in pregnant CSC with decidual stimuli
A
B
Cervical stromal cells grown for 10 days in (A) culture medium or (B) in the presence of 8-
bromo-cAMP and MPA. Photomicrograph of cultured cell appearance after 10 days. Note
cells treated with decidual stimuli are much more rounded in appearance.
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b) Gene expression of decidualisation markers
These cervical stromal cells responded to stimulation, with cAMP and MPA, by
expressing PRL and IGFBP-1 message (Figure 4.3). Both pregnant and non¬
pregnant CSC showed an increase in decidual marker gene expression, but the
pregnant CSC response was much more marked.
Pregnant CSC (n=5) cultured with DM for six days effected a significant 26-fold (± 5
s.e.m, p< 0.01) increase in PRL mRNA expression, where cAMP alone produced a
four-fold (± 0.8 s.e.m) increase above control.
The same experiment with non-pregnant CSC gave a much more modest effect. The
cAMP group resulted in a 3.9-fold increase (s.e.m ± 0.9) above control, compared
with DM (6.4 ± 3.8; ns).
IGFBP-1 mRNA expression was increased 559-fold (s.e.m ± 282) and 8-fold (s.e.m
± 4.3) with DM, relative to control in pregnant and non-pregnant CSC respectively.
The effects of either progestin alone or cell-permeable cAMP analog (8-bromo-
cAMP) alone were minor and not significant. However combined treatment
produces significant effects consistent with a decidual-like response.
The addition of oestradiol to cAMP +MPA as a treatment regime did not alter the
mRNA expression of the two major decidualisation markers in pregnant CSC (n=4),
when compared to cAMP + MPA. IGFBP-1 mRNA expression was upregulated
148-fold (± 73 s.e.m) with cAMP and MPA, and was not significantly different with
DM (including oestradiol) at 252-fold relative expression (± 85 s.e.m). PRL mRNA
expression increased 12.6-fold (+ 5.8 s.e.m) following cAMP + MPA exposure,
compared to 16.1 ± 7.8 with the addition of oestradiol. See figure 4.4.
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Figure 4.4 Prolactin and IGFBP-1 mRNA expression in pregnant CSC treated

























Comparison between cAMP+ MPA ± Oestradiol, where DM = cAMP + MPA + Oestradiol.
Results shown as mean ± s.e.m. There is a significant (p<0.05) difference with DM relative
to control, but here is no significant difference between the two treatment arms, therefore
oestradiol has a negligible effect on the mRNA expression of the major decidualisation
markers after 6 days.
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c) Protein release of decidualisation markers
Cervical stromal cells release more PRL and IGFBP-1 protein, following treatment
with DM, than after treatment with cAMP or MPA alone. (Figure 4.5)
Pregnant CSC treated with DM produced 0.35ng/ml/72hrs (± 0.06 s.e.m.) PRL
protein compared to control (0.1ng/ml/72hrs, p<0.01). Neither cAMP nor MPA
alone had a significant effect, suggesting the combination is essential. Non-pregnant
cells were not compared. See later for comparison of decidualisation regimes in both
pregnant and non-pregnant CSC.
In pregnant CSC, IGFBP-1 protein release was significantly synergistically enhanced
with DM (1.5ng/ml/72hrs ± 0.72) compared to control (0.06ng/ml/72hrs, p<0.01).
Again, no effect is seen with either cAMP or MPA alone and there was negligible
release in non-pregnant CSC in all treatment arms and control.
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Control BrcAMP MPA DM
Prolactin and IGFBP-1 protein release, as measured by ELISA after a 6 day treatment
period with cAMP, MPA, or DM. Results expressed as ng/ml/72hrs and shown relative to
control as mean ± s.e.m. Significance is shown p< 0.01 relative to control.
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d) Receptor status
The decidualised cells showed an increase in progesterone receptor mRNA
expression in accord with observations in endometrium (Tseng et al 1997). Pregnant
CSC (n=5) cultured with DM expressed a four-fold increase PR mRNA relative to
control (p< 0.05) with no significant difference with cAMP or MPA treatment alone,
(see Figure 4.6)
Non-pregnant CSC (n=6) showed no significant increase in PR mRNA with any
treatment group compared to control (results not shown).
Accompanying changes in decidualisation, were increases in agents that might
maintain a high intracellular cAMP such as the PGE2 receptor type2 (EP2). Again
pregnant CSC (n=5) responded synergistically when exposed to both cAMP and
MPA with a 5.6-fold increase in EP2 receptor mRNA expression, p< 0.05. (see
figure 4.6)
Comparatively, non-pregnant CSC (n=6) under the same conditions did not show the
same synergistic response with slightly raised EP2 mRNA expression (2 to 3-fold) in
all treatment groups. There was no significant difference between groups with wide
variation within groups.
EP4 expression did not vary following 6 days treatment with cAMP, MPA or DM
(control 1.01 ± 0.01; DM 0.77 ± 0.33) in pregnant CSC.
Similarly, the previously demonstrated rise in PR and EP2 receptor expression was
consistent with DM or cAMP + MPA stimulation alone, suggesting no significant
oestradiol effect. See Figure 4.7.
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*
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Control cAMP +MPA DM
Both PR and EP2 are upregulated in response to cAMP + MPA (PR 1.63 ± 0.31; EP2 5.46 ±
0.23), but this is only significant for EP2 (p<0.05) relative to control. The addition of
oestradiol had no additional significant effect (PR 2.2 ± 0.24; EP2 5.05 ± 1.01) in either
group. Results are expressed as mean ± s.e.m.
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e) Surface marker expression
The CD 10 surface marker, as determined by FACS analysis, was found to be present
in both pregnant and non-pregnant CSC as controls. Following identical culture
conditions for 10 days a variation in CD 10 expression was seen after DM treatment
depending on origin of CSC.
In non-pregnant CSC control CD 10 expression was 42% (as mean of two cell lines,
st.dev 5.4%) whereas CSC treated with DM for 10 days resulted in a decreased
CD10 expression of 15.5% (st.dev 1.8%).
Alternatively, in pregnant CSC control CD 10 expression was 25.9% (as a mean of
two cell lines, st.dev 14.1%) and increased non-significantly to 35.2% (st.dev 20.3%)
following DM stimulation.
Examples of the FACS results are shown in Figure 4.8 and 4.9. This represents the
proportion of each cell population positive for the CD 10 marker. The example
shown is a pregnancy-derived cell line cultured as control in Figure 4.8 and
following 10 day DM treatment in Figure 4.9.
Results of both pregnancy and non-pregnancy-derived cells are summarised in
Figure 4.10.
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Figure 4.8 FACS Analysisfor CD10 in cultured controlpregnant CSC
MRC EDINBURGH
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Stats: Normalized, Listgating: Disabled
Color equations
Hist Reaion ID % Count Mn X Mn Y PkPosX PkPosY PkCnt FPCVX FPCVY
1 A A 85.3 10000 85.2 31.3 66.5 32.4 86 48.06 48.44
4 F1 F 35.8 3576 0.699 2.52 0.665 1.37 44 14.38 61.42
F2 F 0.17 17 1.05 1.70 1.02 1.02 2 3.54 38.34
F3 F 63.4 6336 0.744 0.271 0.768 0.102 169 12.04 64.30
F4 F 0.71 71 1.05 0.372 1.02 0.374 5 5.47 49.55
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The CD10 positive (phycoerythrin-labelled) cells are represented by the green line E in
histogram 3. The same data is underlined in green in the lower table, as a percentage of the
cell population. These results represent pregnancy-derived CSC in control culture
conditions for 10 days prior to FACS.
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Figure 4.9 Pregnant CSC exposed to decidual stimuli - FA CSfor CD10
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1:
|
The CD10 positive (phycoerythrin-labelled) cells are represented by the green line E in
histogram 3. The same data is underlined in green in the lower table, as a percentage of the
cell population. These results represent pregnancy-derived CSC in DM culture conditions
for 10 days prior to FACS.
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Figure 4.10 FACS Analysis ofCD10 expression in cervical stromal cells
FACS for CD10 expression
Non pregnant Pregnant
Graph shows FACS analysis for CD10 in both pregnant (n=2) and non-pregnant (n=2) cell
lines. The above applies to cultured CSC after 10 day treatment with control or DM medium.
White bars represent the blanks, black bars the isotype controls and blue bars the proportion
of the cell population positive for CD10. Decidualisation stimuli produced a reduction in
CD10 expression in non-pregnancy-derived cell lines, whereas the opposite was seen in
pregnancy-derived cells. Results are expressed as mean - s.e.m.
CD 10 expression in the control non-pregnant cell lines (n=2) was mean 42%(range38-46%),
and decidual stimulus resulted in a significant reduction to mean of 15.5% (range14-17%).
Significance; unpaired Mann-Whitney U two-tailed p value <0.0000.
In the pregnancy-derived cell lines (n=2) CD 10 expression was a mean of 26% (range16-
36%) in the control group compared to 35% (range 21-50%) in the treated group (ns).
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4.3.3 Comparison to non-reproductive cell line
HS27 fibroblasts did not produce the same response to decidual stimulus in identical
culture and treatment conditions.
The response of the HS27 cells to DM incubation was a reduction in IGFBP-1
message and no change in PRL message. There was no increase in PR or EP2
receptor expression in the foreskin cell line on exposure to decidual stimuli, as
shown with the cervical stromal cells. (See Figure 4.11)
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Figure 4.11 Comparison ofpregnant CSC with HS27 (foreskinfibroblast cell line)
















Control cAMP MPA DM
EP2 mRNA Prolactin mRNA
Control MPA
Control cAMP MPA DM
Identical culture and treatment regimes were used for both pregnant CSC and HS27
(foreskin fibroblast) cell lines. The purple bars represent pregnancy-derived CSC and the
white bars represent HS27 cells.
Previously shown significant increases in decidualisation markers, PRL and IGFBP-1 mRNA
expression in CSC, are not duplicated in HS27. Similarly PR and EP2 receptor mRNA
expression did not vary in treatment arms with HS27. This confirms a response particular to
a reproductive fibroblast cell line.
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4.4 DISCUSSION
Changes in the consistency of the cervix can be detected in early pregnancy
(Uldbjerg et al 1990) but little is known about the contribution of the various cell
types within the cervix to such a change. The stromal cell of the cervix has been
considered an important contributor to physiological changes, both in early
pregnancy and at the time of parturition. These cells respond to steroids and initiate
collagenolytic pathways (Sato et al 1991; Ito et al 1994; Carbonne et al 2000;
Schmitz et al 2001) and since they have progesterone receptors, they may play a
sentinel role in altering cervical morphology in response to hormone changes.
However if these cells respond to prolonged exposure to progesterone with a change
in phenotype, as do cells in the endometrium, then this modified cell may be critical
in the maintenance of normal cervical function in pregnancy. In support of this
hypothesis I have shown that human cervical stromal cells have the capacity for a
phenotypic alteration akin to decidualisation in pregnancy and that this can be
induced in-vitro by a combination of progesterone and cAMP.
The cervical biopsy data suggests an increase in both PRL and IGFBP-1 mRNA
expression in first trimester cervical tissue relative to non-pregnant cervical tissue.
As has been shown, the wide variation seen with biopsy samples can make analysis
difficult. This could be for many reasons including age, parity, gestation or stage in
menstrual cycle. The limited tissue available limits the number of investigations one
can perform. In addition, although the biopsies were all taken in an identical fashion,
it is impossible to ensure equal contribution from differing cell types. For these
reasons pooled RNA was used to evaluate the presence of a trend for further
exploration. To investigate this further with particular emphasis on the cervical
fibroblast, cervical stromal cell cultures were established for in vitro studies of the
response of these cells to decidual stimuli.
These primary cells were identified as fibroblasts by a fibroblast specific antibody.
Another method of fibroblast identification is by immunocytochemical staining for
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vimentin, a typical marker for fibroblasts or mesenchymal cells which is absent on
epithelial cells (Brar et al 2001). Other investigators have demonstrated 99%
vimentin positivity in cultured human cervical fibroblasts after similar culture
conditions and use of passage numbers, with <1% of these cells possessing cx-smooth
muscle actin (Yoshida et al 2001; Yoshida et al 2002; Takemura et al 2004).
I show here that both pregnancy and non-pregnancy-derived cervical stromal cells
respond to progestins in the presence of cAMP by undergoing "decidual" changes, as
seen in endometrial stromal cells. Morphologically this is primarily represented by a
change in cell shape to a more rounded form. Both of the major decidualisation
markers, PRL and IGFBP-1, are up-regulated significantly with a combination of
cAMP and MPA. Oestradiol does not appear to influence these changes. This has
been shown by both mRNA expression and protein release and is particularly marked
in the CSC derived from pregnant women. Perhaps this is due to pregnancy
associated phenotypic alteration in vivo prior to culture conditions. In support of
these changes we also see increased PR and EP2 receptor mRNA expression (Tseng
et al 1997).
Of significance is the finding that fibroblasts derived from foreskin do not produce
the same response. There is mild prolactin stimulation but no IGFBP-1 effect as has
been reported in skin fibroblasts (Richards et al 1996).
Although progesterone appears to be sufficient for the decidual change in vivo, cells
in vitro need to be sensitised by elevated intracellular cAMP levels (Brosens et al
1999). These findings confirm the same to be true for cervical stromal cells. In vivo,
raised intracellular cAMP levels can be brought about by prostaglandin E acting
through either EP2 or EP4 receptors to activate the stimulatory G-protein (Gs) or by
relaxin inhibiting the enzyme responsible for the catabolism of cAMP,
phosphodiesterase (Bartsch et al 2001). Since one effect of raising cAMP is to
stimulate expression of phosphodiesterase both of the above pathways will work
together in a synergistic fashion to maximise cAMP levels. Other agents involved in
decidualisation may also affect phosphodiesterase activity since epidermal growth
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factor inhibits the activity of an isoform of PDEIV by ERK-2 dependent
phosphorylation (Hoffmann et al 1999).
The cervical biopsy data supports the presence of up-regulated PRL, IGFBP-1
mRNA expression in first trimester cervical tissue, but clearly this is not comparative
as these results are from whole tissue biopsies and are therefore widely variable and
include other cell types and possible interactions. The wide variation seen in biopsy
RT-PCR results for laminin, fibronectin and VEGF as other markers of
decidualisation should also be assessed in the controlled CSC model, or by
immunolocalisation.
The CD 10 surface marker reported in decidual stromal cells (Montes et al 1996;
Oliver et al 1999; Kimatrai et al 2003) did not show consistent changes in pregnancy
and non-pregnancy derived cells, with a trend to up-regulation in CD 10 expression in
pregnant CSC after decidual stimulus, but a down regulation in non-pregnant CSC.
This effect may be due to length of exposure to decidual stimulus, in that the
pregnancy-derived tissue will have been exposed physiologically for several weeks
before culturing without decidual stimuli. This is then followed by re-exposure in-
vitro where a temporarily interrupted phenotypic alteration may re-establish. It is
possible that the duration of exposure required for CD 10 expression as a decidual
marker is longer than 6 or 10 days in those non-pregnant CSC not previously
exposed. The surface-expressed zinc dependent metalloproteinases, CD 10 and
CD 13, were expressed on 95% of cultured preDSC whereas no group of cervical
cells studied here reached that degree of expression. Perhaps the origin of cervical
and endometrial stromal cells are different, or perhaps the cyclical local environment
of ESCs predisposes a heightened response.
It would be of paramount importance to confirm these findings in-vivo and
immunohistochemical confirmation in cervical biopsies would be ideal. Localisation
studies would provide information on the functional contribution of differing cell
types and it would be of particular interest to explore varying gestational stages.
Detailed localisation of these "decidualised" fibroblasts may reveal a spatial
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relationship with the blood vessels as has been reported in the endometrium (Kelly et
al 2002). The exact purpose of decidualisation in the endometrium is still a mystery
but angiogenic changes are clearly important and may also apply to the cervix.
Although decidualisation of the cervical fibroblast has not hitherto been recognised,
ectopic decidua has been reported on cervix and ovary during pregnancy (Zaytsev et
al 1987; Massi et al 1995). There has always been doubt whether this was a
manifestation of otherwise unrecognised endometriosis. The identification of the
decidual marker IGFBP-1 immunolocalised to decidual-like cells of extrauterine
sites, including the cervix, supports the potential demonstrated in this in vitro model
(Rutanen et al 1991).
The cervical fibroblast has the potential to orchestrate tissue remodelling in all stages
of pregnancy, or even in menstruation. What is not clear is the function of these
phenotypically altered cells. Gene expression and protein secretion resemble
endometrial DSC, yet the function of this endometrial transformation is unknown. It
is essential for successful implantation and trophoblast invasion, and appears to
involve MMP modulation, angiogenesis and vaso-reaction. Menstruation occurs
with progesterone withdrawal once endometrial stromal cells have undergone
decidualisation (Lockwood et al 1998; Warren et al 1999). It is possible that
decidualised cervical stromal cells of pregnancy are therefore primed to respond to a
localised functional progesterone withdrawal towards term, with the effect of
cervical ripening. The mechanism of local progesterone functional withdrawal in
human parturition is unclear but the concept is favoured as a necessary step (Allport
et al 2001; Mesiano et al 2002). This raises the possibility of altered function of
these cervical cells at differing stages of pregnancy. The implications of this vary
from providing cervical integrity for the majority of pregnancy to a change in status
resulting in cervical ripening, whether this occurs physiologically at term, preterm or
in response to infection. Not only are the characteristics of this altered cell-type
important, but the influence on surrounding cells, blood vessels and extracellular
matrix. Understanding the interaction between other resident and migratory cells
will be paramount in appreciating the role of the "decidualised" cervical fibroblast.
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These functions may include recruitment and activation of leukocytes, paracrine
communication between cells and cAMP modulators or initiation of the matrix
remodelling cascade.
These findings on the decidual-like changes in cervical stromal cells open a new area
for the study cervical function throughout pregnancy. Any advances in the
knowledge of physiological cervical changes in pregnancy can be exploited in
attempts to manipulate events in preterm labour or prolonged pregnancy.
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CHAPTER 5




The ability of cervical stromal cells to undergo a decidual-like reaction in the same
manner as endometrial stromal cells suggests that these altered cells may have a
specific role in cervical function in pregnancy. The physiological mechanism of
decidual stimulation may be complex but progesterone is critical and varied
mechanisms resulting in cAMP elevation are certainly effective in vitro and present
during pregnancy (Gellersen et al 2003).
Implantation is associated with significant vascular changes and leukocyte influx
(King et al 2000). Another marker of endometrial decidualisation is tissue factor, a
membrane-bound inhibitor of bleeding, thought to control haemorrhage at the time of
vascular remodelling as the trophoblast invades the maternal spiral arteries
(Lockwood et al 1993). Localised angiogenesis may be regulated by TF-enhanced
autocrine VEGF stimulation (Lockwood et al 2002). Clearly, cervical trophoblast
invasion would not occur in normal circumstances, but structural and vascular
changes do occur even early in gestation and VEGF may be partially responsible
(Sugino et al 2002). Increased vascular permeability may promote controlled
leukocyte infiltration. Progesterone levels are thought to restrict excessive
neutrophil entry and this has been well described in a sheep model (Staples et al
1983). Progesterone antagonism increases PGE2, chemotactic agents and leukocyte
numbers. PR present on DSC are therefore key in this role. VEGF may be partly
responsible for the vascular permeability changes in the pregnant cervix, as in the
decidualisation reaction, as expression of VEGF and its receptors is up-regulated in
human decidual cells (Sugino et al 2002).
Fibronectin, laminin, (32-microglobulin and desmin have been described as potential
markers of endometrial decidualisation, and alteration of these components can be
seen in tissue remodelling (Aplin et al 1988; Loke et al 1989; Komatsu et al 1998).
Evaluation of cervical biopsy whole tissue in the first trimester did not demonstrate a
similar induction in mRNA, but there was wide variation in these samples. Further
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assessment of these markers will be undertaken in purified cervical stromal cell
culture conditions.
Myofibroblastic characteristics have been identified in human DSC and in the human
cervix at term (Oliver et al 1999; Montes et al 2002; Kimatrai et al 2003). These
include the presence of cytoskeletal filaments desmin and a-smooth muscle actin and
evidence of contractility or ultrastructural features consistent with the phenotype.
The presence of desmin and smooth muscle actin strongly suggests a contractile
function, inhibited by progesterone and activated by cytokines (Kimatrai et al 2003).
Rat cervical fibroblasts display high cytoskeletal desmin intensity but not until late in
pregnancy in association with ultrastructural appearances of secretory myofibroblasts
(Varayoud et al 2001).
Cervical changes in labour are dramatic and associated with pro-inflammatory
changes, in particular leukocyte infiltration and cytokine upregulation. IL-8 has been
shown to be induced in cervical tissues in labour (Barclay et al 1993; Winkler et al
1998; Winkler et al 1999b; Sakamoto et al 2004) and has been used in animal
models to produce cervical ripening as has been discussed in Chapter 1 (Chwalisz et
al 1994; El Maradny et al 1994; 1996). It is postulated that there is a synergism
between PGE and IL-8 in the mechanism of cervical ripening, with a combined
effect of vaso-reaction and chemotaxis. In concert, this activates an inflammatory
cascade, triggering ECM remodelling via proteoglycan reorganisation and enzyme
degradation of collagen and matrix proteins.
If IL-8 is a significant player in cervical ripening at term, then an evaluation of its
production by cervical stromal cells exposed to pro-decidual influences is of
relevance. Other investigators have established a recognised up-regulation of
cervical IL-8 production in late pregnancy and labour (Winkler et al 1999b;
Sakamoto et al 2004; Tomblom et al 2005). It is pertinent to assess the relative IL-8
expression in non-pregnant and first trimester cervical tissue and then assess the
response with the CSC model and decidual stimulus.
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Many in vitro models use 8-bromo-cAMP, an analogue resistant to PDE with
increased potency. Alternative mechanisms for the physiological induction of
decidual differentiation are likely. Cyclic AMP is required in in-vitro studies to
effect decidualisation changes and progesterone is essential. There is potential
convergence of the progesterone and prostaglandin pathways during stromal
transformation, at the level of the EP2 receptor, stimulated by both PGE2 and
progesterone, effecting raised cAMP levels. Intracellular cAMP plays a central role
in decidualisation via PKA signalling. Physiological cAMP stimulating agents
include PGE2 relaxin and phosphodiesterase inhibitors. EP2 is known to be the
dominant PGE receptor in pregnant baboon cervices (Smith et al 1998). Cyclic AMP
catabolism is mediated by phosphodiesterase, which is up-regulated with raised
cAMP levels. Inhibitors of this enzyme (relaxin, rolipram) will prevent catabolism
and thereby maintain raised cAMP levels (see Figure 5.1). Studies have shown that
PDE inhibitors such as rolipram have a profound effect on decidualisation (Bartsch
et al 2004). A combination of PGE2, acting via cervical EP2 receptors, and rolipram
should therefore mimic the cAMP effect, and in combination with progesterone,
cause decidualisation.
Other factors involved in PGE synthesis and catabolism such as the COX enzymes
and PDGH are relevant in physiological cAMP regulation. It must also be
remembered that PGE2 catabolism by PGDH is also progesterone dependent (Cheng
et al 1993). PGE2 and relaxin have been used to elicit cervical ripening (MacLennan
et al 1986; Calder et al 1993; el-Refaey et al 1994; Brennand et al 1997; Stjernholm
et al 1999; Witter 2000), and have been associated with endometrial decidualisation
(Huang et al 1987; Lane et al 1994; Bartsch et al 2001). The effects of PGE2on the
cervix will be dependent EP2 expression, phosphodiesterase activity and on
progesterone status, mediated by PR expression.
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It is hypothesized that interaction between these pathways provides a physiological
decidual stimulus via cAMP up-regulation in association with a progesterone rich
environment. The aims of this section are to explore the potential consequences of
the decidual-like changes seen in CSC by assessing phenotypic markers and relate
this to mechanisms of cervical change in pregnancy.
Hypotheses:
1. Decidualised CSC will express decidual markers tissue factor and VEGF
and demonstrate matrix protein induction as seen in the endometrium.
2. Cervical "decidualisation" down-regulates stromal IL-8 in early gestation
providing a mechanism for IL-8 stimulation in labour when functional
progesterone withdrawal occurs.
3. Cyclic AMP-elevating factors provide a physiological basis for decidual
stimulus resulting in cervical stromal cell decidual-like reaction.
Aims:
1. Evaluate markers of decidualisation in CSC and compare to cervical
biopsy findings, by RT-PCR.
2. Assess the response of CSC to decidual stimuli with respect to IL-8
expression and protein release.
3. To apply an alternative decidualisation regime (PRM) providing indirect




Tissue collection, culture, RNA extraction and RT-PCR processes were as described
in Chapter 4.
Untreated cervical biopsy samples were homogenised and RNA extraction
performed as before. Pregnancy (first trimester) and non-pregnancy-derived samples
were compared by Q RT-PCR for gene expression of decidualisation markers,
prostaglandin metabolism en2ymes and IL-8.
For cell culture experiments, all cells were plated at 5 x 104/ ml complete medium in
6 well plates and grown to confluence over 72hrs before treatment commenced.
Following a PBS wash treatments were prepared with 2% FCS supplemented RPMI
(with 20|lg/ml gentamicin, lOOIU/ml penicillin, lOOjlg/ml streptomycin and 2mM L-
glutamine).
Treatment regimes
RNA extracted from treatments groups in Chapter 4 was used to perform RT-PCR
for other markers of decidualisation and matrix modulators:
1. Control
2. 8-bromo-cAMP 250|lM (cAMP)
3. Medroxyprogesterone acetate 10"6M (MPA)
4. Decidualising Mix (DM)
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To explore the potential physiological process of prostaglandin and progesterone
interaction an alternative decidual stimulus treatment was with PRM; PGE2 (10~6M),
Rolipram (10"6M) and MPA (10~6M). For this comparison both pregnant cell lines




Treatment periods were for 6 or 10 days, with medium changes every 3 or 4 days.
Medium was collected in duplicate at the end of each treatment period and stored at -
20°C for protein assay at a later date as previously described.
Quantitative Real Time-PCR
RNA extracted from cervical biopsies as in Chapter 4, was used for Q RT-PCR to
assess mRNA expression of IL-8, COX-1, PGDH.
Following in-vitro studies with decidual stimuli in Chapter 4, all medium was
removed, RNA extraction and Q RT-PCR was performed as previously described.
To examine the gene expression of other known decidualisation markers in cultured
CSC, RT-PCR was carried out for tissue factor (TF), desmin, laminin, fibronectin
and (^-microglobulin, phosphodiesterase type 4 (PDEIV), COX-1, COX-2, IL-8 and
vascular endothelial growth factor (VEGF) in control and treatment groups.
Experiments were repeated under identical conditions with the alternative proposed
decidual stimulus, PRM. Medium was stored and RNA extracted prior to Q RT-PCR
for PRL, IGFBP-1, PR, fibronectin, laminin, and IL-8.
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Enzyme Linked Immunosorbent Assays
Protein release estimation was performed in duplicate for all samples as previously
described.
Prolactin protein release was measured using a PRL kit as described in Chapter 4.
The IGFBP-1 assay was performed as described in Chapter 2 with a lower limit of
sensitivity of 62.4pg/ml and a within assay variation of 1.7% (relative standard
deviation). Again, all samples were analysed on the same assay.
IL-8 protein release was measured by ELISA, with matched pairs of capture and
biotinylated-detection antibodies for IL-8 as described in Chapter 2.
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5.3 RESULTS
5.3.1 Gene expression of decidualisation markers in treated CSC
The following results relate to pregnant CSC unless otherwise stated. Treatment
arms are either control, cAMP, MPA or DM as described in Chapter 4.
Tissue factor, a further decidualisation marker, mRNA expression is significantly
increased with DM treatment relative to control (mean 12.6 ± 5.6 s.e.m; p<0.05).
This effect is not seen with cAMP or MPA alone. (Figure 5.2)
The effects of either progestin alone or cell-permeable cAMP analog (8-bromo-
cAMP) alone were minor and not significant. An exception to this was the
stimulation of VEGF message by 8-Br-cAMP which was evident in the absence of
progesterone. DM treatment resulted in induction of VEGF message relative to
MPA alone (2.6 ± 0.8; 0.7 ± 0.1, p< 0.01). See Figure 5.2
Similarly PDEIV message also increased significantly with DM, but this is likely to
be a cAMP effect that did not reach significance, and is comparative to MPA and not
the control group (2.5 ± 0.3; 0.7 ± 0.2, p< 0.05) (see Figure 5.2).
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All cells were originally derived from the cervix of pregnant women (n=5). Note the increase
in expression of the prostaglandin receptors EP2 (but not EP4). Also shown are changes in
progesterone receptor, vascular endothelial growth factor (VEGF), phosphodiesterase type
IVb, fibronectin, tissue factor and IL-8 message. Significant differences are denoted as
follows: difference from control with p <0.01** and p <0.05*, and difference from
progesterone alone p<0.01ee, p<0.05®.
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Matrix modulators fibronectin, desmin, laminin and (3-2microglobulin were not
significantly up-regulated with decidualisation stimuli, as is seen in endometrial
stromal decidualisation (see Figure 5.2 and Table 5.1). In pregnant CSC treated with
DM, fibronectin expression was not significantly altered from control (0.66 ± 0.08
s.e.m) but was suppressed relative to progesterone (1.4+0.12 s.e.m, p< 0.01). Non¬
pregnant CSC demonstrated increased fibronectin mRNA with MPA (1.9 ± 0.28;
control 1+ 0.001) but a trend to relative suppression with DM (1.56 ± 0.37, ns). In
summary CSC exhibit progesterone-dependent stimulation of fibronectin expression
with attenuation by cAMP.
Desmin follows a similar pattern with a trend toward suppression with DM in both
cell types relative to control. This only reached significance in pregnancy-derived
CSC (p< 0.05). (table 5.1 and Figure 5.3)
Laminin expression displays a non-significant trend to stimulation with combined
DM stimuli in both pregnant and non-pregnant CSC (table 5.1).
There was no change in [3-2microglobulin mRNA expression in either cell type with
either cAMP, MPA or combination treatment (table 5.1).
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Table 5.1 RNA expression response to DM (pregnant n=5, NP n=6)
Message Mean relative to control - sem Significance
Cyclo-oxygenase 2 2.1 -0.61 ns
0.31 -0.1 (NP) ns







0.81 -0.06 (NP) ns






Control cAMP MPA DM
Desmin mRNA expression after 6 day treatment period in both pregnancy and NP-derived
CSC. Results expressed as mean ± s.e.m. Significance is shown in DM treated pregnancy-
derived CSC relative to control, where desmin message is reduced.
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5.3.2 Prostaglandin metabolism enzymes in cervical tissue and stromal cells
Accompanying changes in decidualisation markers seen in cervical stromal cells,
were increases in agents that might maintain a high intracellular cAMP, such as an
increase in COX-1. Moreover, the increase in phosphodiesterase (in this instance
Type IVb) seen after stimulation with cAMP is attenuated by progesterone (Fig 5.2).
Cycloxygenase-1 is the ubiquitous PGE synthesis enzyme. COX-1 message appears
to be suppressed in the cervix in pregnancy (Figure 5.4). There was a wide variation
in data for all the results in the biopsy data and although the mean for the non¬
pregnant biopsies was 37 (s.e.m 34) compared to 2.9 (pregnant biopsies), the result
was skewed by one result of 200. This again reflects the difficulties in interpreting
whole tissue biopsy samples.
By comparison, in treated CSC, decidual stimuli produced a significant increase in
COX-1 message in both pregnant (3 ± 1.1) and non-pregnant (3.3 ± 0.5) groups,
relative to control. There were no significant changes in COX-2 (the inducible
enzyme) expression in either group (table 5.1).
Prostaglandin dehydrogenase (PGDH) message was found to be increased (p< 0.01)
in untreated pregnant cervical biopsies relative to non-pregnant cervical biopsies
(mean 38.8 ± 21.7sem ; 2.3 ± 1.2sem, n=6 both groups). However during culture the
PGDH message diminished and minimal message was found in treated and untreated
cultured cervical stromal cells.
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Figure 5.4 Cervical biopsy mRNA expression in untreated samples
COX-1 mRNA in cervical biopsies
Non pregnant Pregnant
PGDH mRNA in cervical biopsies
Non pregnant Pregnant
mRNA expression in non-pregnant (n=6) versus pregnant (n=6) whole tissue
cervical biopsies. Samples were washed and homogenised prior to RNA
extraction and RT-PCR. Results are expressed as mean ± s.e.m. COX-1 and IL-
8 results are non-significant due to wide variation, but PGDH* indicates p<0.01.
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Figure 5.5 Relative expression ofCOX-1 mRNA in pregnant and non-pregnant CSC
COX-1 mRNA
Control cAMP MPA DM
■ Non preg
■ Pregnant
Results expressed as relative expression to control group, mean ± s.e.m. Significance is
reached for both pregnancy and NP-derived CSC after DM treatment relative to control
groups in each cell type.
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5.3.3 IL-8 message and protein in whole cervical tissue and stromal cells
There was wide variation in IL-8 mRNA expression between individual biopsies, but
there was a trend to mRNA expression up-regulation in pregnant tissue (Figure 5.6).
Pooled mRNA produced a ratio of non-pregnant 1: pregnant 11, reflecting the non¬
significant trend seen with individual analysis (NP mean 3.2 ± 1.6 s.e.m: pregnant
15.7 ±7.2).
This is at variance with findings from cultured fibroblasts under decidual stimuli.
Combined cAMP and MPA treatment in pregnant CSC resulted in significantly
decreased IL-8 message (0.39 ± 0.04, p<0.01), relative to control (Figure 5.2).
IL-8 protein release was also decreased by decidual stimulus of pregnancy-derived
CSC; control 10.1 ± 2.8 ng/ml per 72 hours and DM 3.5 ± 1.4; p< 0.01 (paired data),
reflecting the reduced IL8 mRNA expression in pregnant CSC. (Figure 5.7).
Non-pregnant CSC demonstrated no difference in IL-8 between control and all
treatment arms.
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Figure 5.6 IL-8 message in untreated whole tissue cervical biopsies
mRNA expression in non-pregnant (n=6) versus pregnant (n=6) whole tissue cervical
biopsies. Samples were washed and homogenised prior to RNA extraction and RT-PCR.
The y-axis depicts relative expression. Results are expressed as mean ± s.e.m and do not
reach significance.
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Figure 5.7 IL-8 protein releasefrom treatedpregnant cervical stromal cells
IL-8 protein
Control cAMP MPA DM
IL-8 protein release from pregnant CSC after a 6 day treatment period, as measured by
ELISA detailed in Chapter 2. Results expressed as mean ± s.e.m. Significance is shown for
DM (3.5 - 1.4 ng/ml/72hrs) relative to control (10.1 - 2.8). This mirrors the IL-8 mRNA
expression in the above treatment groups, as shown in Figure 6.2.
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5.3.4 Comparison of decidual stimuli
Morphology
Comparison of the PRM and DM treatment groups did reveal some differences as
shown in Figures 5.8 & 5.9. Pregnant CSC treated with DM revealed a plumper
morphology as shown previously, and this effect was not so marked with the non¬
pregnant CSC.
However the PRM treatment showed a more dramatic effect in the non-pregnant
group, when compared with the pregnant CSC. Non-pregnant CSC exposed to PRM
demonstrated an altered cell shape in a proportion of cells with visible cell
projections.
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Figure 5.8 Comparison ofdecidualisation regimes in A) pregnant CSC
Photomicrographs (magnification x 10) of pregnancy-derived cultured CSC after 10 day
treatment with either:
i) DM (cAMP, MPA and oestradiol) or
ii) PRM (PGE2, Rolipram, MPA)
Control groups no shown here as comparison made in Chapter 5. Both DM and PRM
produce similar plumper cell morphology that control groups.
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Figure 5.9 Comparison ofdecidualisation regimes in B) non-pregnant CSC
Bi)
Photomicrographs (magnification x 20) of non-pregnancy-derived cultured CSC after 10 day
treatment with either:
i) DM (cAMP, MPA and oestradiol) or
ii) PRM (PGE2, Rolipram, MPA)
Control group not shown. DM produces more rounded ceil morphology, but PRM stimulation
produces cell projections in these non-pregnancy-derived CSC.
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Gene expression
Cells derived from pregnant women differed in their decidualisation pattern from
those obtained from non-pregnant women, when comparing DM with PRM (PGE +
Rolipram + MPA). Both treatment regimes produced a distinct increase in IGFBP-1
mRNA expression and protein release, but to differing degrees.
After 10 days treatment with either DM, IGFBP-1 expression was 10 times higher in
the pregnancy-derived cells than in the non-pregnancy cells. With PRM treatment
IGFBP-1 message increases strikingly from control, but only 1.3 times as high in
pregnancy-derived cells compared to NP (Table 5.2).
Pregnant CSC demonstrated greater IGFBP-1 expression and protein release with
DM, whereas the non-pregnant CSC response was more pronounced with PRM over
DM. (Figure 5.12)
Table 5.2 10 day decidualisation with different regimes, pregnant n-6, NP n=5
Treatment Control DM PGE+Rolipram+MPA
Expression of IGFBP-1 message re lative to control (-sem)
Pregnant 1 751±242 354±181
Non-pregnant 1 63±31 264±120
Release of IGFBP-1 pg/ml/72 hours (-sem)
Pregnant 66±3.5 1423±812 227±113
Non-pregnant 63 136±102 663±136
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Figure 5.12 Comparison ofIGFBP-1 response to DM vs PRM treatment








































□ NONpreg □ Pregnant
10 day treatment period. Results expressed as mean ± s.e.m. Significance expressed
relative to each control for IGFBP-1 mRNA/ protein. There was no statistically significant
difference in IGFBP-1 mRNA between DM and PRM groups in either pregnant/ non¬
pregnant CSC. IGFBP-1 mRNA is significantly increased in pregnant CSC with DM and non¬
pregnant CSC with PRM, relative to control (both p<0.01). IGFBP-1 protein release is
increased relative to control (p<0.05) in pregnant CSC with DM, but with PRM in non¬




IGFBP-1 protein release is significantly increased with both treatment regimes.
Prolactin protein release with these two differing decidual stimuli followed a similar
pattern of variation as IGFBP-1 stimulation, with pregnant CSC responding to DM
but non-pregnant CSC responding to PRM. Significance was reached with DM in
pregnant CSC (p<0.01) and with PRM in non-pregnant CSC (p<0.05) relative to
control, but there was no statistically significant difference between the two
treatment arms in either cell type, despite the visible trend. See Figure 5.13.
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Figure 5.13 Prolactin protein releasefrom CSC in response to DM and PRM










□ Non preg □ Pregnant
10 day treatment period: results expressed as mean ± s.e.m. Significance relative to
individual control groups. Again a greater response is seen in pregnancy-derived CSC with
DM relative to PRM, whereas non-pregnancy-derived CSC release greater quantities of
decidualisation markers with PRM.
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Receptor status
In non-pregnant CSC, PR mRNA expression increased significantly with PRM, but
not with DM (p<0.05).
Pregnant CSC produce a varied response with no significant variation of PR
expression between the two treatment groups (Table 5.3).
Matrix modulators
PRM stimulation down-regulates fibronectin mRNA expression (p< 0.05), but
increases laminin (p< 0.01) in NP-derived CSC. IL-8 mRNA is reduced following in
the non-pregnancy-derived group following PRM treatment (p< 0.01).
Pregnant CSC produce a varied response with no significant variation of IL-8, PR or
laminin expression with either DM or PRM, but a reduction in fibronectin expression
in association with DM (p<0.05).






PR NP 1.97 ±0.37 4.07 ± 1.97* *p<0.05
Preg 1.07 ±0.26 6.67 ±5.44
IL-8 NP 0.55 ±0.03 0.14 ±0.04** **p<0.01
Preg 1.16 ± 0.38 0.86 ±0.27
Fibronectin NP 0.74 ± 0.12 0.46 ± 0.07* *p<0.05
Preg 0.52 ±0.12* 1.31 ±0.64 *p<0.05
Laminin NP 3.07 ±0.32 3.92 ± 0.75** **p<0.01
Preg 1.36 ±0.35 4.44 ±3.19
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Overall, PRM appears to stimulate effects in non-pregnant CSC that are not seen in
pregnancy-derived cell lines. The variants in this experiment are the method of
cAMP elevation and origin of tissue. This confirms that there are multiple factors
involved in the regulation of this decidual-like response dependent upon the means
of cAMP regulation. The two methods of cAMP elevation are handled differently by
pregnancy and non-pregnancy derived cells. This implies that there is some inherent
difference in the response of these two cell types to specific stimuli, supporting the




The cervical fibroblast may change during pregnancy in response to progesterone
and as the commonest cell type in the human cervix, an altered phenotype would
have huge implications on cell function throughout gestation. I have shown in vitro
evidence of decidual marker expression and protein release in cultured cervical
fibroblasts exposed to decidual stimuli, with an upregulation of the requisite PR.
Further characterisation of this response supports this finding where TF and VEGF
are also upregulated in CSC in vitro. Decidual cells under progesterone stimulation
produce tissue factor (Lockwood et al 1993). Tissue factor has a putative role as an
inhibitor of bleeding at the time of implantation and trophoblast invasion. It is
known that uterine and cervical vasculature is increased in pregnancy and with
proposed angiogenesis and tissue remodelling, tissue factor may be involved in
regulating this. In addition to TF stimulation, VEGF message is also increased after
decidual stimulus, and although this would appear to be largely a cAMP effect,
significance was only reached when progestin and cAMP in combination were used.
Again this may indicate some role in vascular reorganisation. In the endometrium,
decidualisation is initiated perivascularly before spreading throughout the stroma,
and so a similar mechanism may be suggested in the cervix although cannot be
proven without immunolocalisation studies. The decidual transformation in
endometrium is also associated with an increased production of the angiogenic agent
VEGF and its KDR receptor (Sugino et al 2002) and this process may be responsible
for the increased vascularisation of the cervix that is seen during pregnancy. The
increase in the EP2 receptor may also facilitate VEGF release since PGE stimulates
VEGF through the EP2 receptor in synovial fibroblasts (Ben-Av et al 1995).
Although there are likely to be other cellular sources of EP receptors in the pregnant
cervix, experiments in the baboon show that the EP2 type is predominant (Smith et
al 1998) although its expression decreases during labour (Smith et al 2001).
Other decidualisation markers reported in endometrial stromal cells (fibronectin,
desmin, laminin, (32-microglobulin) did not show significant stimulation in CSC.
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This is not consistent with endometrial findings, but the very different roles of these
tissues impacts on the specific functions required at various gestations and their
regulation. In fact, an apparent inhibition of fibronectin was seen in CSC under
decidual stimulus, and this appears to be a cAMP effect. These findings agree with
those suggested by the cervical biopsy mRNA expression assessed in Chapter 4.
Desmin expression was reduced in both CSC types after treatment with DM (and not
cAMP or MPA alone), but only to significance in pregnancy-derived cells. Perhaps
this is not surprising as the increased endometrial expression of these matrix proteins
is in association with implantation, a phenomenon not normally seen in the cervix.
The assessment of PDEIV mRNA expression in pregnant CSC confirms an induction
with cAMP as expected and the significant result seen with DM is likely due to
variation, as no effect is seen with MPA. The effect of DM is no greater that that of
cAMP, but has smaller error margins.
Prostaglandin dehydrogenase (PGDH) mRNA, the enzyme responsible for PGE2
catabolism, is significantly increased in first trimester whole cervical tissue.
Although this information must be treated with some caution in view of variation, it
suggests that there may be up-regulation of the PGE catabolic pathway in the cervix
in early pregnancy. Further assessment could not be obtained from this model as the
PGDH message diminished in stromal cell culture and this is consistent with the
paucity of data on PGDH expression in cell culture. It is possible that an alternative
cell type is responsible for the PGDH expression demonstrated in the biopsy data. In
whole tissue there appeared to be greater COX-1 message in non-pregnant samples
but there was a wide variation and significance was not reached. The CSC model
showed evidence of moderate COX-1 stimulation with combined cAMP and MPA in
both cell types although, surprisingly, no changes were seen for COX-2.
Interestingly, a significant suppression in IL-8 mRNA expression and protein release
is apparent after decidual stimulation in cultured cells. It could be that the
phenotypic changes seen in early pregnancy differ to that which may be observed in
late pregnancy, and that "decidualised CSC" have a suppressive role in terms of
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immunomodulation to preserve cervical integrity. First trimester pregnancy-derived
biopsy samples however revealed a trend to IL-8 up-regulation when compared to
non-pregnant tissue. In particular the contradictory IL-8 result, in whole tissue
compared to CSC, can be explained by the presence of other cell types capable of IL-
8 expression, such as epithelial and migratory cells. This influence is then lost in
isolated stromal cell culture. Progesterone suppresses IL-8 production so the culture
results after prolonged progesterone exposure are to be expected (Ito et al 1994). IL-
8 is produced by the cervix in increasing amounts during labour, is associated with
chemotaxis and has been used to induce cervical ripening in animals (Barclay et al
1993; Chwalisz et al 1994; El Maradny et al 1994; Osmers et al 1995; Osman et al
2003; Sakamoto et al 2004). It is logical that IL-8 suppression throughout gestation
would be an essential function of the phenotypically-altered CSC of pregnancy.
Removal of this blockade in labour by the localised functional progesterone
withdrawal at the receptor level in the human cervix (Stjernholm-Vladic et al 2004)
then provides the mechanism for IL-8 production and subsequent inflammatory
response of labour (Sakamoto et al 2004).
Moreover, when DM is compared with the prostaglandin, rolipram and progestin
combination, the same changes in decidualisation markers are seen. The
combination of prostaglandin and PDE inhibitor mimic cAMP administration and in
concert with progesterone, provide a similar environment to that used to induce
decidual changes in endometrial stromal cells. It has been shown that this
combination (PRM) stimulates decidual-like changes in CSC in vitro studies as seen
with DM. PRM produces the same induction of PRL, IGFBP-1 and PR message and
protein release as shown with DM. There is also a similar pattern of fibronectin and
IL-8 inhibition. Pregnancy provides high progesterone levels and localised
prostaglandin changes are seen in vivo. PDEIV inhibition helps to maintain a high
cAMP environment by reducing its inactivation. These influences are present in
pregnancy and may provide a physiological stimulus to encourage this decidual-like
transformation.
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It is interesting to observe the differing response between both cell types (pregnant
and non-pregnant CSC) and the two regimes used (DM and PRM). The response to
DM is much more dramatic in pregnancy-derived CSC than in non-pregnancy-
derived cell lines as one might expect due to duration of exposure pre-culture.
However, non-pregnant cell lines appear to have an enhanced response to PRM and
this suggest a differing mechanism of action or ability to respond, possibly to due to
change in cellular phenotype.
Further assessment of prostaglandin metabolism, by estimation and localisation of
specific enzymes and metabolites would provide essential information in evaluating
the potential influence of differing cell types. There may be compartmentalised
prostaglandin metabolism that would explain the differences seen in whole tissue and
cell culture. Similarly, the same would apply to any factor influencing matrix
modulation, inflammatory mediators or angiogenesis.
Endometrial progesterone withdrawal results in menstruation, and this raises the
possibility of altered function of these cervical cells at differing stages of the
menstrual cycle and pregnancy. Clearly this may involve interaction with other
resident and migratory cells, but the "decidualised" fibroblast may modulate the
activity of local leukocytes, facilitate communication between cells and cAMP
modulators, or influence the ECM remodelling cascade or angiogenic pathway. The
interaction between progesterone and prostaglandin pathways provides a
physiologically plausible and self-maintaining mechanism whereby a pro-decidual
influence may be present in pregnancy.
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CHAPTER 6
MMP-14 IN THE HUMAN CERVIX
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6.1 INTRODUCTION
Migratory inflammatory cells and matrix metalloproteinases appear to have
significant roles in cervical remodelling and immune cell trafficking is evident in the
cervix and myometrium throughout pregnancy.
Evidence of increased leukocyte numbers in mouse (Yellon et al 2003) and human
uteri (Thomson et al 1999; Winkler et al 1999b) and cervices (Bokstrom et al 1997)
have been shown in advanced pregnancy and labour (Osman et al 2003) as discussed
in Chapter 1. In humans, the predominant migratory cells seen in the cervix are
neutrophils and monocytes in association with labour, although Bokstrom identified
a pre-labour leukocyte recruitment with no subsequent increase thereafter.
Concurrent increases in collagenolytic and proteolytic enzymes at term have been
demonstrated (Rajabi et al 1988; Osmers et al 1990) with varied identified sources of
these enzymes including stromal cells, smooth muscle cells and leukocytes (Osmers
et al 1992; Ledingham et al 1999a; Stygar et al 2002).
Some chemotactic signal is likely to trigger this neutrophil infiltration, and
chemokines are produced by cervical tissue with up regulation at term and with
labour (Winkler et al 1998; Denison et al 1999; Sennstrom et al 2000). Adhesion
molecule up-regulation has also been observed (Winkler et al 1998; Denison et al
1999; Sennstrom et al 2000; Ledingham et al 2001b; Winkler et al 2003). The initial
chemotactic signal may originate from resident cells or monocytes, which then
produce cytokines and pro-MMPs thereby promoting the inflammatory cascade and
contributing to extracellular matrix remodelling.
Monocyte chemotactic protein -1 (MCP-1) is a small protein beta-chemokine,
chemotactic for leukocytes and secreted by differing cell types including monocytes,
fibroblasts and endothelial cells. MCP-1 recruits and activates leukocytes, can
influence fibroblast activity and stimulates collagen synthesis and matrix deposition
during inflammatory processes and fibrosis. In human dermal fibroblasts MMP-1
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and MMP-2 gene expression and protein synthesis are upregulated by MCP-1 in
vitro (Yamamoto et al 2000). MCP-1 is produced by human cervical tissue in early
pregnancy and mifepristone significantly increased its release with a concurrent
increase in monocyte numbers (Denison et al 2000). This is a potential mechanism
of action of MCP-1 in cervical remodelling as it may stimulate leukocyte migration
and matrix metalloproteinase activity.
Neutrophils infiltrating cervical tissue are known to be a plentiful source of MMP-8
(Osmers et al 1992) and MMP-9 (Uldbjerg et al 1983a) whereas cervical resident
cells, particularly stromal fibroblasts, have been identified as the primary sources of
MMP-1 and MMP-2 in non-pregnant, early pregnant and term pregnant cervical
biopsies (Ledingham et al 1999a; Denison et al 2000; Stygar et al 2002; Yoshida et
al 2002). MMP-2 and -9 upregulation has been confirmed in late pregnancy (Stygar
et al 2002) and MMP-8 with labour (Sennstrom et al 2003), but no conclusion can be
drawn regarding cervical changes pre-labour as specific groups with ripe and unripe
cervices have not been compared.
MMP cleavage is required from its pro-form for activation. MMP-14, a membrane-
type MMP (MT1-MMP), mediates the activation of MMP-2 on the cell surface and
is therefore essential for MMP-2 function. MMP-14 is thought to act through a
prostaglandin-cAMP dependent mechanism (Shankavaram et al 2001). Activators of
adenyl cyclase (e.g. PGE2via EP2 or EP4 receptors) increase ATP conversion to
cAMP. PDE inhibitors such as rolipram or relaxin prevent cAMP breakdown,
thereby maintaining high cAMP levels (Bartsch et al 2001). Phosphodiesterase
enzymes promote cAMP catabolism and their inhibitors therefore maintain high
cAMP levels. A combination of PGE2 and a phosphodiesterase inhibitor (eg.
rolipram; type IV PDE inhibitor) could act synergistically in the regulation of MMP-
14. As both MMP-2 and MMP-8 levels are increased in pregnancy and labour then
MMP-14, as a mediator of at least these two MMPs, would be expected to be present
in the human cervix and up-regulated in pregnancy or labour.
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Hypothesis
The hypothesis is that MMP-14 is produced by the normal non-pregnant human
cervix, specifically the cervical fibroblast and that it is up-regulated by prostaglandin
via a cAMP mechanism as in other cell types.
In order to assess the expression of MMP-14, and its origin within the human cervix,
MCP-1 and PGE2 treatments were compared with control in cervical explants,
cultured cervical fibroblasts and cultured monocytes. Where PGE2 was shown to
have an effect, combination therapy with a phosphodiesterase inhibitor was assessed.
Aims:
1. To measure MMP-14 mRNA expression in non-pregnancy derived
cervical biopsies.
2. To evaluate MMP-14 mRNA expression in cultured human cervical
fibroblasts (non-pregnant and pregnant) in response to PGE2 and MCP-1.
3. To assess the expression of MMP-14 in a monocyte cell line in response
to treatment with PGE2, MCP-1 or phosphodiesterase inhibitor type-IV,
and the effect of combination therapy.
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6.2 METHODS
Human cervical biopsies (n=2) were taken from non-pregnant women at the time of
elective hysterectomy for benign reasons. Biopsies were divided into 2-3mm3




After 24hrs the supernatant was removed, the explants were homogenised and placed
in 1ml trireagent for total RNA extraction and RT-PCR.
Cultured human cervical fibroblasts (n=8, passage 2-4) from non-pregnant tissue
were plated in small flasks or 6 well plates at a density of 1 x 105 cells /ml in




All treatments were in duplicate for a period of 24 hours at which point the
supernatant was removed and RNA extracted for MMP-14 mRNA estimation by RT-
PCR.
The same was repeated with pregnancy-derived cervical fibroblasts (n=4, passage 2)
with identical culture and treatment conditions.
A monocyte cell line (U937, passage 8-39) was used to study the effect of
prostaglandin, MCP-1 and rolipram on MMP-14 gene expression. Cells were
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cultured in complete medium and plated at a cell density of 4 x 105 per ml prior to
treatment. These cells remain non-adherent unless differentiated to an adherent
phenotype. All treatment regimes including the controls were with LPS to activate
the monocytes.
Treatment regimes were as follows:
1. Control




6. PGE2 + rolipram
The treatment period was 24 hours. U937 cells remained in suspension throughout
the treatment period, were spun down to allow for supernatant collection and RNA
extraction by adding 1ml tri-reagent to each pellet. RNA extraction was performed
as detailed in Chapter 2. Reverse transcription was then performed prior to RT-PCR
as previously described in Chapter 2.
RT-PCR was performed for MMP-14 in all the above treatment arms.
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6.3 RESULTS
Human cervical explants (n=2) expressed MMP-14 mRNA after 24hr incubation
with complete medium. Those treated with PGE2 revealed a four-fold increase in
MMP-14 mRNA expression (4.13 ± 2.18), but this is not significant in view of the
small sample size. There was no significant change with MCP-1 treatment (1.7 ±
0.58). (Figure 6.1)
In cultured human cervical fibroblasts, PGE2 produced no variation in MMP-14
mRNA expression relative to control, in pregnant (n=4) or non-pregnant (n=8) cell
lines (0.69 ± 0.14, 0.76 ± 0.1 respectively). Incubation with MCP-1 did not alter
MMP-14 expression in either cell line (1.5 ± 0.39, 0.8 ± 0.15) relative to control.
(Figure 6.2)
In the U937 cell model, MMP-14 mRNA expression was found to be increased
above control in PGE, treated groups and PDEIV inhibitor groups, and an apparent
although not statistically significant synergistic rise was observed in the combination
group. MCP-1 treatment demonstrated no appreciable effect, and rolipram alone
almost doubled MMP-14 mRNA expression (1.92 ± 0.28) but this was not
significant. PGE2 alone produced a five-fold (5.14 + 0.55) increase in MMP-14
mRNA expression with a non-significant further increase when combined with
MCP-1 (5.33 ± 0.45) or rolipram (6.44 ± 1.05). (Figure 6.3)
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Figure 6.1 MMP-14 expression in treated cervical explants (non-pregnant) n=2




Results shown as mean ± s.e.m. Non significant increase in MMP-14 mRNA expression
with PGE2 treatment of whole tissue cervical explants.
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Results shown as mean ± s.e.m. No change in MMP-14 mRNA expression in treated
cervical fibroblasts, relative to control. p<0.05 for the difference between PGE2 and MCP-1
treated groups. The same was repeated for pregnancy-derived cervical fibroblasts (n=4)
with no change in MMP-14 expression (PGE2 0.77 ±0.1, MCP-1 0.8 ± 0.15).
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Control PGE2 MCP-1 PGE2 + Rolipram PGE2 +
MCP-1 Rolipram
Results shown as mean ± s.e.m. n varied for treatment groups due to availability of cultured
cells: n=9 for control and PGE2, n=7 for MCP-1± PGE2, n=5 for rolipram, n=4 for PGE2 +
rolipram.
U937 cell MMP-14 mRNA expression was significantly increased with PGE2 alone and any
treatment group including PGE2 relative to control, and with PGE2 relative to MCP-1
(p<0.05).
**
p<0.001 relative to control, * p<0.05 relative to control.
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6.4 DISCUSSION
This study shows that in the context of the human cervix MMP-14 mRNA is
expressed and is induced in non-pregnant cervical explants incubated with PGE2.
More specifically MMP-14 mRNA expression has been shown in cultured human
cervical fibroblasts derived within and outwith pregnancy, but in this specific cell
population the proposed hypothesis that PGE2 induces fibroblast derived MMP-14 is
not supported.
This implies that the PGE2-induced MMP-14 expression must originate from
migratory cells in the cervix or possibly other resident cells, such as epithelial cells.
This study supports the hypothesis that the monocyte expresses MMP-14 and that
PGE2 stimulates activated monocytes to increase MMP-14 expression. These
findings are in agreement with those of Shankavaram which conclude that MMP-14
expression is induced by LPS activation in monocytes, and further augmented by
prostaglandin (Shankavaram et al 2001).
However from this data it cannot be excluded that another resident cervical cell
population may be responsible for this. To do so would require further study of
cervical cell populations and localisation of MMP-14 expression, ideally by
quantitative immunohistochemistry. Nor can I draw any conclusions regarding
gestation dependent variation in cervical MMP-14 expression as samples were only
obtained in early pregnancy or outwith pregnancy. It is regretful that there was not
enough pregnancy-derived tissue for the explant protocol in addition to fibroblast
culture. It is perhaps of significance that there was no difference in response to PGE2
between pregnancy and non-pregnancy derived fibroblasts. A different response
might be expected if the fibroblast phenotype has changed in any way during early
pregnancy, but it is also possible that unless this change is irreversible, any effect
may be lost in subsequent culture.
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In-vivo the PGE2 or monocyte-associated regulation of MMP-14 is likely to be a late
gestation event in the cervix and may contribute to the leukocyte infiltration and
collagenolytic activity seen at term in labour. These findings emphasise the cross¬
talk occurring between cell types, both resident and migratory, to achieve tissue
remodelling. The hypothesis is that monocyte-produced MMP-14 then activates
proMMP-2 released from other resident cells to its active form MMP-2. MMP-2 is
substrate specific for collagen type IV in basement membranes, where disruption will
assist in further leukocyte infiltration and degranulation. With leukocyte invasion
towards term, monocytes are also activated, by PGE2, to release degradative enzymes
contributing to the dissolution of ECM and collagen fibrils.
The balance between MMPs and their respective TIMP has been thought to be key in
the mechanism of extracellular matrix remodelling. Since this work was done an
exception to this has been identified where a surface bound form of MMP-8 on the
neutrophil is not inhibited by TIMPs (Owen et al 2004). This then complicates the
potential mechanisms at play in tissue remodelling between cell types and regulators
of matrix modulation, but confirms that there are situations where the regulatory
effect of TIMPs on MMP activation may be minimised.
The main source of MMP-8 is the neutrophil, but on activation by inflammatory
mediators these cells release only a small proportion of their MMP-8 capacity and
this is in its latent pro-form. Incubation of activated neutrophils with collagen type I
(the major substrate of MMP-8) produces pericellular collagenolysis as a result of
membrane-bound MMP-8, which has been shown to be resistant to TIMP inhibition.
This neutrophil membrane bound MMP-8 also has enhanced stability relative to
soluble MMP-8 (Owen et al 2004). Further exploration may demonstrate a similar
mechanism with other MMPs, where soluble or membrane-bound forms of a
particular MMP differ in their activity and resistance to local inhibitors. In
particular, pericellular collagenase activity has been shown in the guinea-pig cervix
surrounding cervical fibroblasts after treatment with antiprogestins (Hegele-Hartung
et al 1989).
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Unfortunately, it was impossible to perform other studies on pregnant cervical
explants due to a limited supply of pregnancy-derived tissue, but ideally one would
assess this at differing gestation and further explore sites of production with
immunohistochemical studies.
MCP-1 did not appear to have a significant effect in these culture conditions or in the
explant study, but none of these conditions accurately represent physiological
conditions where the attraction and activation of monocytes is possible. A role for
MCP-1 cannot be excluded as it is likely that the interaction between fibroblasts and
monocytes is relevant. Outwith in-vivo studies, then further explant studies or co-
culture with fibroblasts and monocytes would be essential to assess this aspect of
cervical ripening.
PGE2 and rolipram in combination do appear to have some synergism in monocyte
MMP-14 mRNA up-regulation, but this was not statistically significant and again
does not represent the physiological situation where differing cell types can be
recruited and activated in unison.
It can be concluded that MMP-14 is certainly expressed in the human cervix, cervical
fibroblast and monocyte. MMP-14 mRNA expression is up-regulated in monocytes
by PGE2 alone or in combination with a phosphodiesterase inhibitor. The influence
of this MMP stimulation in-vivo is uncertain, but this particular MMP is known to
activate MMP-2 and proMMP-8 (Holopainen et al 2003). These are two key
enzymes released by stromal cells and neutrophils respectively, that in combination
would have a significant effect on local collagenolysis. The presence of increased
uterine prostaglandin and cAMP is a physiological finding toward late pregnancy
and peripartum, and particularly in association with preterm labour. This proposed
mechanism is pertinent in cervical remodelling as the cervical fibroblast may
modulate not only collagen reorganisation but also BM degradation thereby aiding
leukocyte extravasation.
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Distinction of MMPs and their various forms appears to be in its infancy, as their
activation mechanisms, interdependencies, substrate specificities, resistance to
inhibitors and relative tissue stabilities are now seen to be extremely complex. The
key role of MMPs in cervical ripening cannot be doubted, but the initiation process
and relative contribution of the fibroblast and the leukocyte remains unknown.
Further elucidation of the mechanisms of activation, site of action, stability and
inhibition of MMPs is essential, but it must always be remembered that this is the
end-stage in the cervical ripening process. Whilst for the purposes of artificial
initiation of cervical ripening this may be an appropriate level to aim interventions,
where prevention of abnormal preterm cervical remodelling is desirable, effective






7.1 SYNOPSIS OF RESULTS AND GENERAL DISCUSSION
Within the literature review current methods of cervical ripening were reviewed and
as a result of this a novel drug delivery method was assessed. Particular issues with
drug administration to the cervix are the epithelial barrier, variable absorption and
increased tissue density. Also the cervical site and environment preclude certain
drug administration methods such as patches. With regard to cervical ripening, the
proposed target is ideally the internal os (Van Meir et al 1997; Challis et al 1999)
and as extracellular matrix reorganisation is a major factor (Uldbjerg et al 1983b;
Uldbjerg et al 1983a), stromal tissue distribution of active drug is essential. Initial
assessment of a needle-free injector device demonstrates that the device can breach
the epithelium and penetrate the cervical stroma. The potential additional benefits of
this are to provide a reliable dosage directly to the target area. This could reduce the
administration to effect interval and the drug dosage required. It is accepted that this
provides evidence by proof of principle only as this was performed on uteri removed
at hysterectomy, and there remains many issues relating to clinical practicalities,
clinical use, safety and patient acceptability in the context of obstetrics and
gynaecology. Unfortunately due to time constraints as a direct result of delays
incurred by legal issues and departmental relocation, further placebo clinical studies
were postponed. Later withdrawal of the device supply for design issues made it
impossible to pursue this project further and the direction of my research changed
significantly at an advanced time-point in my MD program.
The focus then turned to the cervical fibroblast and it's role in pregnancy, the
hypothesis being that an altered decidual-like cervical stromal cell may exist in
pregnancy as is seen in the endometrium. Cervical stromal cells are exposed to the
same progesterone-rich environment for a prolonged period, these cells are known to
possess nuclear progesterone receptors and are responsive to progestins and
antiprogestins in both animal and human models in-vitro and in-vivo (Hegele-
Hartung et al 1989; Chwalisz et al 1994; Stjernholm et al 1999; Denison et al 2000;
Stjernholm-Vladic et al 2004).
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It would appear from this data that there is the potential for morphological and
phenotypic alterations in the cervix and specifically the cervical stromal cell
population. Whether this decidual-like transformation occurs in vivo is uncertain,
and indeed the cervix has its own specific role in reproduction, distinct from the
uterus. The propensity for CSC to differentiate in this manner may be a pre-requisite
for maintenance of cervical integrity until such times as delivery is appropriate.
Pregnancy-derived cervical biopsies demonstrate an up-regulation of PRL and
IGFBP-1 mRNA expression, relative to non-pregnant tissue. Evidence for in-vitro
transformation to a decidual-like phenotype is shown morphologically and by
induction of decidualisation markers prolactin and IGFBP-1 in cultured human CSC.
This occurs in both non-pregnancy and pregnancy-derived CSC, although much
more marked in the latter. These findings are seen in response to a combination of
both 8-bromo-cAMP and MPA, also resulting in PR and EP2 receptor mRNA
stimulation.
Tissue factor and VEGF, previously described markers of endometrial
decidualisation, were also stimulated as a result of cAMP effect (Lockwood et al
1993; Lockwood et al 2002) and supports this hypothesis. Tissue factor, an inhibitor
of bleeding may have a haemostatic role during proposed angiogenesis and tissue
remodelling. Angiogenic VEGF message, also increased after decidual stimulus,
may indicate some vascular reorganisation and indeed there is evidence that TF itself
may act as an autocrine enhancer for VEGF stimulation (Lockwood et al 2002).
This data would support a similar mechanism of perivascular initiation of decidual
changes in the cervix as in the endometrium.
These effects were produced in vitro using a cAMP analogue that is relatively
resistant to phosphodiesterase inactivation, and so to explore a possible physiological
mechanism, a differing regime was assessed whereby 8-bromo-cAMP was replaced
with PGE2 and rolipram (a phosphodiesterase inhibitor). This would produce a pro-
cAMP environment, which, in combination with MPA, should have the same effect.
In fact, this was shown to be the case, but there were some interesting differences
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observed between the pregnant and non-pregnant cell lines. Discrepancies lay in the
morphological changes seen with the PRM regime and the degree of response in
terms of decidualisation marker message.
Although these studies were largely in cultured cervical stromal cells where
environmental influences of origin may be lost, it is possible given the evidence of
stromal cell differentiation that the pregnancy-derived cells have an altered
phenotype that dictates a particular behaviour distinct to that of non-pregnancy
derived cells. Also, one might expect the pregnancy-derived cells to have undergone
this differentiation and if it were terminal then pro-decidual culture conditions should
not alter their behaviour. However, the pregnancy-derived tissue was from the first
trimester and cells were cultured for 10 - 20 days without progesterone stimulus
prior to the introduction of decidual stimuli. It is possible that the interruption of
pro-decidual conditions for cell culture, disrupted any physiological differentiation
which was later re-instigated in the decidualisation model. A similar reversion of
undifferentiated phenotype on withdrawal of stimulus has been seen in endometrial
stromal cells (Gellersen et al 2003).
The role of such a phenotypic alteration can be debated but the cervical stroma
certainly undergoes tissue remodelling specific to pregnancy from an early gestation,
culminating in a more dramatic stromal reorganisation around the time of delivery
(Kleissl et al 1978; Uldbjerg et al 1990). The cervix must initially maintain
continence of the uterus only to assist in content expulsion at the appropriate time. It
is unclear what the role of a differentiated cervical fibroblast might be, the
possibilities are that the major function may be to program ECM for maintenance of
cervical integrity throughout gestation, or that these cells may be programmed for
tissue remodelling and apoptosis toward the end of pregnancy as seen in the rat
(Leppert et al 1994).
Montes et al have demonstrated an altered cervical myofibroblastic phenotype in
pregnancy at term (Montes et al 2002). It is possible that these cells are
representative of the decidual-like stromal cell proposed here as myofibroblastic
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characteristics are shown in the endometrial DSC (Oliver et al 1999; Kimatrai et al
2003). These properties were not evaluated but include ultrastructural features of
high secretory activity, and cytoskeletal markers desmin, and a-smooth muscle actin
(Oliver et al 1999; Montes et al 2002; Kimatrai et al 2003). However, desmin
expression was reduced in both CSC types after treatment with DM, which is not
suggestive of this type of differentiation. Montes' findings were at term in labour so
cannot be compared with the early pregnancy-derived CSC model. It is also likely
that there is a phenotypic alteration throughout gestation with further differentiation
in association with labour when cervical function changes radically. This has been
shown in a rat model where cervical fibroblast desmin positivity is maximal at term
in line with maximal plasma relaxin, both which then return to basal levels in the
immediate postpartum period (Varayoud et al 2001).
Significant suppression of IL-8 mRNA expression and protein release is apparent
after decidual stimulation in cultured cells. This differs from whole tissue where
high expression of IL-8 is seen. This can be explained by the presence of other cell
types, like epithelial and migratory cells, capable of IL-8 expression. However, with
the focus on the fibroblast, progesterone suppression of IL-8 is well documented (Ito
et al 1994), so it is not surprising with localised functional progesterone withdrawal
at the receptor level in the human cervix (Stjernholm-Vladic et al 2004) to see IL-8
up-regulation in association with labour (Osman et al 2003; Sakamoto et al 2004). It
is logical that IL-8 suppression should be an essential function of the phenotypically-
altered CSC of pregnancy, so that removal of this blockade then provides the
mechanism for IL-8 production and subsequent inflammatory response of labour.
Tornblom et al have shown a reduction in cervical stromal PGDH expression with
labour and no change in COX-2 message (Tornblom et al 2004). This would
constitute an overall increase in cervical PGE2 peripartum that has long been
suspected but has evaded confirmation. In these studies an increase in PGDH
message was observed in cervical whole tissue in pregnancy although this is not
comparative as these were first trimester samples it does suggest an up-regulation of
PGE catabolism in the cervix in early pregnancy. Cultured CSC appeared to lose
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PGDH message suggesting that the origin of this message may be from an alternative
cell type. It is reasonable to expect raised PGDH in early pregnancy as a protective
mechanism, with down-regulation at the time of delivery (Cheng et al 1993; Challis
et al 1999; Tornblom et al 2004). Prostaglandin synthesis and catabolism could be
further assessed by estimation and localisation studies of specific enzymes and
metabolites that would provide essential information in evaluating the influence of
differing cell types. It is likely that there is compartmentalisation of prostaglandin
metabolism that would explain the differences seen in whole tissue and cell culture.
To speculate, the cervical fibroblast has the potential to orchestrate tissue
remodelling in all stages of pregnancy, or even in menstruation but the function of
the cells phenotypically altered by "decidualisation" is unclear. Gene expression and
protein secretion resemble endometrial decidualisation, yet the function of this
endometrial transformation is undetermined. Endometrial progesterone withdrawal
results in menstruation and functional progesterone withdrawal is thought to occur
pre-labour (Lockwood et al 1998; Allport et al 2001; Mesiano et al 2002;
Stjernholm-Vladic et al 2004). As decidual changes are progesterone dependent, this
supports the possibility of altered function of these "decidual-like" cervical cells at
term.
These findings on the "decidual-like" changes in cultured cervical stromal cells open
a new area for the study of the cervical changes in pregnancy. There appears to be
phases of cervical alteration, as organisational changes are seen in early pregnancy as
a gradual phenomenon, later replaced by the more dramatic remodelling of peri-
partum cervical ripening. It has been appreciated for some time that the early stages
of labour are associated with changes in the cervix, but probably the most dramatic
stage of cervical remodelling occurs after delivery in restoring the cervix to its pre-
pregnant state. This stage has been neglected and may provide illuminating
information as the restorative processes of tissue remodelling must be highly active.
The "decidualised" stromal fibroblast is a newly identified target for known initiators
of ripening such as PGE2, NO donors and in particular antiprogestins. In addition,
advances in the knowledge of physiological cervical changes in pregnancy may be
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exploited in attempts to prevent pathological cervical events in preterm labour.
Specifically if the progesterone dependent "decidual" cervical stromal change is
important for cervical integrity, then this would provide a mechanism for
progesterone based PTL prevention, particularly where cervical incompetence is
thought to be the primary pathology.
Finally, the role of matrix metalloproteinases in the cervix was discussed in Chapter
1 and in Chapter 6 the mRNA expression of MMP-14, a membrane-type MMP, and
activator of MMP-2 and proMMP-8, was investigated with regard to cervical
ripening. MMP-14 mRNA expression was confirmed by RT-PCR in human whole
tissue cervical biopsies (non-pregnant), cultured cervical fibroblasts and a human
monocyte cell line. Collagen degradation requires the stepwise cleavage of matrix
proteins, and MMP substrates are specific. For instance, MMP-8, sourced from the
neutrophil, denatures collagen type I to gelatins, a substrate for MMP-2, sourced
from the cervical stromal cell. However MMP-2 is released as a latent pro-MMP
and is activated by MMP-14. Cervical stromal cell MMP-2 and neutrophil MMP-9
are increased in the cervix in pregnancy at term, but do not appear to be further
increased with labour (Stygar et al 2002). MMP-2 has substrate specificity for
collagen type IV present in basement membrane. The importance of this finding is
the potential role in augmenting neutrophil recruitment.
It has been shown here that MMP-14 mRNA expression appears to be up-regulated
in cervical explants by PGE2 although the sample size was small due to limited tissue
supply. This up-regulation does not occur in the cervical fibroblasts, but is apparent
in a monocyte cell line with significant five-fold MMP-14 message stimulation in
those treated with, but not MCP-1 or rolipram (phosphodiesterase type IV inhibitor).
MMP-14 production may be largely effected by leukocytes strengthening the
hypothesis of proposed interaction between these and resident stromal cells to effect
the ECM changes seen in cervical ripening. It is also possible that epithelial cells
may be responsible for this PGE2 dependent MMP induction. MMP-14 is
membrane-bound and has wide substrate specificity for interstitial collagen types I, II
and III, elastin, fibronectin, gelatin, laminin and other proteoglycans. In addition
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MMP-14 activates the inactive proforms of MMP-2 proMMP-8 and MMP-13
(Holopainen et al 2003). The overall effect of MMP-14, and its various substrates
once activated, has the potential to coordinate collagen and ECM reorganisation at
several levels and this merits further assessment. MMP-14 is present in the human
cervix but the cervical stromal cell is not responsible for the facilitation of leukocyte
migration by basement membrane degradation as a result of PGE2-induced MMP-14
activation of proMMP-2. There maybe other MMP interactions responsible or
MMP-14 from epithelial or other migratory cells may initiate this cascade.
Valuable information could be gathered from further cervical biopsy studies
throughout gestation with particular emphasis on localisation of MMP-14 by
immunohistochemical means. Owen et al have demonstrated great differences in
membrane-bound MMP-8 activity and inhibitor resistance compared to the soluble
compound (Owen et al 2004) and this should also be explored for MMP-14 and
others.
Any doubt over the inflammatory hypothesis of cervical changes in labour appears to
be close to extinction as strong evidence gathers of the roles of cytokines, leukocyte
recruitment and inflammatory mediators. Collagen re-organisation, degradation and
ECM remodelling definitely occurs as a gradual process from early in pregnancy
only to accelerate in the weeks, days and hours before delivery. Leukocyte ingress
has been questioned but again strong evidence has now accumulated supporting this.
The up-regulation of various MMPs produced by both resident cervical cells and
migrated leukocytes is likely to be a response to several factors including mechanical
stretch, iNOS, prostaglandin, cytokines and functional progesterone withdrawal. The
only factor among these recognised to take effect in early gestation is iNOS, whereas
the demonstrated effects of the others occur peri-partum. The implication here is that
each regulator has its own timepoint of involvement, and if so this may help explain
the varied nature of preterm labour. The gradual ECM remodelling could be
augmented prematurely when this cascade is triggered.
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The findings in this thesis support the hypothesis that the cervical fibroblast has a
central role in cervical changes in pregnancy. I suggest that a "decidual-like" change
to cervical stromal cells is present in pregnancy. The inherent properties of these
cells may alter at this point and therefore affect the subsequent functions during the
progressive phases of pregnancy. The role of MMPs is certain in cervical
remodelling, but the timing sequence of activation is still questionable. MMP-14 in
particular had not yet been identified in the pregnant cervix and I find that not only is
this expressed, but is up-regulated in response to prostaglandin. However I have not
been able to confirm the cellular source of increased MMP-14 production cervical
tissue in these limited studies. It can only be suggested that migratory cells may
have a role here.
Future studies should focus on confirmation of the existence of cervical "decidual-
like" cells in-vivo. Further characterisation of this cell type will need to be repeated
throughout various gestation time-points. Localisation of cell types and
decidualisation markers in relation to blood vessels would be paramount in assessing
this response and understanding its role. Immunolocalisation studies would best
provide the required evidence. I would suggest that ultrastructural phenomena and
cytoskeletal markers should provide helpful clues to localised cell function at
varying stages of pregnancy and post partum. Comparison of myofibroblastic
characteristics of cervical fibroblasts in response to decidual stimuli, cyclical stretch
and progesterone withdrawal would indicate functional propensity in these clinical
scenarios. Equally, immunolocalisation studies of cervical biopsy material would
clarify cell specific MMP-14 and IL-8 production and perhaps confirm the
suggestion of migratory cell activity even in early pregnancy. Clearly all this work
requires cervical tissue with all the associated problems eluded to earlier. Despite
this, various investigators have managed to do this and endeavours should continue.
Should the phenomenon of pregnancy associated cervical fibroblast decidual-like
alteration be confirmed, then the application of this cell culture model will be
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Appendix I: Recipes for solutions
All chemicals listed were from Sigma and all dilutions were in distilled water unless
otherwise stated.
1. Blocking solution
In 1 litre: 20g 2% polyvinylpyrrolidone
5g bovine serum albumin
1 ml presevatives Boehringer Mannheim
1.9g EDTA (5mmol/l)
6.lg Tris (50mmol/l)
2. Complete medium (cRPMI)






3. 2% FCS medium







4. ELISA assay buffer
For 1 litre: 9gNaCl (150mmol/l)
12.lg Tris (100mmol/l)





5. ELISA buffer and tween
As ELISA buffer above with:
0.05% Tween-20





1 Omls 1 OOmM sodium acetate
lml 2g/l tetramethyl benzidine in DMF
lml 6g/l urea-hydrogen peroxidase (in 50mM Na acetate)
pH 6.0
(lOOmM Na acetate: in 1 litre - 13.6g sodium trihydrate, lml
preservatives)
8. ELISA wash buffer (x 20 cone)





At x lconc: 9g/L NaCl (150mmol/l)










11. Neutral buffered formalin




12. PBS & Tween






In DMF/ DMSO 1:1
Dilute 1:1000 to use
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14. 0.1M Sodium citrate buffer
In 1 litre: 29.4g Tri-sodium citrate
O.lg sodium azide
pH 6.0
Dilute 1:10 to use
15. TE buffer
10mmol/l Tris pH 8.0
lmmol/1 EDTA in DEPC water
16. Tris buffer
In 1 litre: 121.1g Trizma base
pH 7.2
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Objective: Control of cervical function is poorly understood. The major structural component of the cervix is collagen and peri-partum
cervical changes are largely due to the action of collagenase, either released by resident cells or derived from an influx of neutrophils. More
importantly, the cell type that initiates the changes in the cervix is unknown although the resident fibroblast is a possible contender. Little is
known about the state of the cervical fibroblast during pregnancy. Decidualisation of the endometrium is essential for implantation and
pregnancy. In man, pre-decidual and decidual transformation of endometrial stroma occurs under the influence of progesterone.
Decidualisation can also be induced in vitro in endometrial fibroblast-like stromal cells where the process is also dependent on elevated
intracellular cAMP levels. Study design: Cultured human cervical fibroblasts were treated with progestin (medroxyprogesterone acetate) and
cAMP elevating agents for 6 and 10 days. Results: After 6 days they expressed and released IGFBP-1 and prolactin (PRL) and underwent
morphological changes by 10 days. In addition, there was an increase in progesterone receptor and prostaglandin E type 2 receptor mRNA (but
not type 4). Conclusion: The propensity of cervical stromal cells to decidualise suggests that these differentiated cells may be a better model
with which to study the initiation of labour.
© 2003 Elsevier Ireland Ltd. All rights reserved.
Keywords: Decidualisation; cAMP; Cervix; IGFBP-1; Progesterone
1. Introduction a rounded morphology and by characteristic gene expression
Abstract
Decidualisation of the superficial endometrium is an
essential process in preparation for implantation and preg¬
nancy. This occurs in the stromal compartment during the
late luteal phase and is coordinated by progesterone-depen¬
dent genes. This process must prepare either for trophoblast
invasion or menstruation and therefore disturbance of this
mechanism may result in menstrual disorders or subfertility.
Decidual cells are terminally differentiated endometrial
cells and form the main elements of decidual stroma
together with bone-marrow-derived uterine NK cells. The
decidual reaction, which occurs in vivo under the influence
of progesterone, occurs more readily in vitro with endome¬
trial stromal cells sensitised to progesterone by elevated
cAMP levels [1,2], The decidual phenotype is recognised by
and protein production [3,4]. Prolactin (PRL) and insulin¬
like growth factor binding protein-1 (IGFBP-1) are both
expressed and secreted by decidual cells and so have been
used as markers of decidualisation.
E-mail addresses: scowan@staffmail.ed.ac.uk (S. Cowan), r.kelly@hr-
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Tel.: +44-1315361000.
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One of the unresolved mysteries of labour is that of
cervical ripening, the process where the fibrous cervix
dramatically softens and loses rigidity prior to childbirth.
The nature of cervical tissue was well described by Danforth
in 1947 [5]. Distinct from the muscular uterine corpus, the
cervix is a fibrous organ with less than 15% of its content
contributed by smooth muscle, mostly found peripherally
and increasingly abundant nearer to the corpus. The remain¬
ing extracellular matrix consists of dense collagen (66%
type I, 33% type III) fibril bundles and elastic fibres with
intervening ground substance. Ground substance is com¬
posed of proteoglycan complexes, consisting of various
glycosaminoglycan (GAG) side chains on core proteins
linked to a hyaluronic acid chain. These complexes bind
tightly, investing the collagen fibrils and providing rigidity.
Cervical ripening has often been compared to an inflamma¬
tory reaction with increased vascularity and enzymatic
0301-2115/$ - see front matter © 2003 Elsevier Ireland Ltd. All rights reserved,
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collagen degradation [6,7] effected through matrix metallo-
proteinases [8,9]. Increasingly, collagen breakdown in the
cervix at term is associated with an ingress of leucocytes
[10-12]. The stromal fibroblast is the most likely source of
collagen production in the cervix, and in addition these cells
may have a key role in cervical remodelling [13] as a source
of chemokines, prostaglandins, and other inflammatory
mediators known to contribute to cervical ripening. If these
stromal cells differentiate to a decidual phenotype, a new
appraisal of their role in pregnancy and in ripening of the
cervix is appropriate.
Human cervical stromal cells (CSC) also express proges¬
terone receptor (PR) as shown in lower uterine segment
stromal cells [14] and as such may play a role in changes in
the cervix seen during pregnancy, such as the increased
vascularisation. Although the human cervix softens at term,
when circulating progesterone levels remain high, proges¬
terone receptor antagonists do initiate changes [12] and
"progesterone withdrawal" may be an effect of alteration
in PR status or function. We show here that both pregnant
and non-pregnant cervical fibroblast-like stromal cells
respond to progestins in the presence of cAMP by under¬
going "decidual" changes as seen in endometrial stromal
cells.
2. Materials and methods
2.1. Tissue collection
Cervical stromal cells were isolated from both non-preg¬
nant (n = 6) and pregnant (n = 6) cervices. Non-pregnant
samples were obtained immediately post-operatively from
pre-menopausal women undergoing total abdominal hyster¬
ectomy for benign pathology in the Department of Obste¬
trics and Gynaecology, Royal Infirmary of Edinburgh.
Written informed consent was obtained, as was approval
by the Lothian Research Ethics Committee and the Lothian
University Hospitals NHS Trust. A thin (~2 mm) section
was cut longitudinally through the anterior lip of the uterine
cervix and placed in RPMI 1640 medium (Sigma, Poole,
Dorset, UK) on ice for transport.
Pregnant women (gestation 7-11 weeks) attending for
first trimester surgical termination of pregnancy were
recruited from the out-patient clinic and written informed
consent obtained, with Ethics Committee and Trust approval
as above. All required a negative smear history and were
chlamydia negative. A cervical biopsy was taken from the
anterior lip of the cervix immediately prior to termination,
using Shumaker biopsy forceps and placed in RPMI 1640 on
ice for transport.
A foreskin fibroblast cell line (HS27) (European Collec¬
tion of cell Culture; http://www.ecacc.org.uk) was used to
compare the decidualisation response with non-reproductive
stromal cells. These cells were cultured and treated in and
identical manner to the cervical stromal cells.
2.2. Tissue culture
The samples were washed twice with phosphate buffered
saline (PBS, Sigma, Poole, UK) and dissected into small
fragments with scalpel blades. Tissue was then placed in
25 cm2 tissue culture flasks in culture medium {RPMI 1640
supplemented with 10% FCS (Mycoplex, PAA Laboratories,
Teddington, UK), 20 pg/ml gentamicin (Sigma)}, 100 IU/
ml penicillin (Sigma), 100 pg/ml streptomycin (Sigma) and
2 mM L-glutamine, at 37 CC 95% air: 5% C02 incubation.
This resulted in outgrowth of cervical stromal cells and with
medium exchange every 3-4 days the cervical stromal cells
grew to confluence and were then transferred into 75 then
162 cm2 flasks and grown to confluence within 21 days.
Where appropriate cells were frozen in liquid nitrogen
using a cryopreservative medium (FCS with 10% dimethyl-
sulfoxide (DMSO). On retrieval, cells were recovered in
complete medium and grown to confluence within 7-11
days. All cells used were from passage 2—7.
Both pregnant and non-pregnant samples were also homo¬
genised in Tri reagent (Sigma, Poole, Dorset) for RNA
extraction from untreated cervical biopsy tissue.
2.3. Treatment regimes
Cells were plated at 5 x 104/ml complete medium in 6 well
plates and grown to confluence over 72 h before treatment
commenced. After aPBS wash, treatments consistedof: (1) 2%
FCS supplemented RPMI as control (with 20 pg/ml gentami¬
cin, 100 IU/ml penicillin, 100 pg/ml streptomycin and 2 mM
L-glutamine) or 2% FCS containing (2) 8-bromo-cAMP
(BrcAMP) 0.1 mg/mi, (3) medroxyprogesterone acetate
(MPA, 6oc-methyl-17a-hydroxyprogesterone acetate) 1 pM,
or (4) Decidualising Mix (DM: BrcAMP, MPA and oestradiol
1 x 10~7 M). Treatments lasted for 6 or 10 days with medium
changes every 3 or4 days. Medium was collected in duplicate at
the end of each treatment period and stored at —20 °C.
A control experiment to assess oestradiol (E) effect was
performed comparing control, DM and BrcAMP plus MPA
over a 6 day treatment period in pregnant CSC (n = 4).
HS27 cells (foreskin fibroblasts derived) were cultured
and treated as above (at passage 27) and control, BrcAMP
and decidualising treatment were compared.
To assess the decidualisation effect of differing regimes a
comparison experiment, with DM versus PRM (prostaglan¬
din 1 pM + rolipram 1 pM + MPA 1 pM), was performed in
both pregnancy and non-pregnancy derived cells. Rolipram
is a type IV phosphodiesterase inhibitor and acts synergis-
tically with prostaglandin to increase cAMP levels. These
treatments were for 10 days and assessed IGFBP-1 mRNA
expression and protein release.
2.4. Real-time RT-PCR
Total RNA was extracted using Tri Reagent and Phase-
lock tubes (Eppendorf, Merck) according to manufacturers'
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Table 1
Primer/probe sequences for real-time PCR measurements
Forward primer Reverse primer Probe
EP2 GACCGCTTACCTGCAGCTGTAC
EP4 ACG CCG CCT ACT CCT ACA TG
Progesterone- CAGTGGGCGTTCCAAATGA
receptor










AGA GGA CGG TGG CGA GAA T
TGGTGGAATCAACTGTATGTCTTGA










ACG CGG GCT TCA GCT CCT TCC T
AGCCAAGCCCTAAGCCAGAGATT-
CACTTT












instructions followed by precipitation with isopropanol. All
RNA samples were quantitated by UV spectrophotometry
and diluted to 100 ng/pl. Four microgram of total RNA was
reverse transcribed (AB Applied Biosystems Taqman
Reverse Transcription Reagents, Warrington, UK according
to manufacturer instructions), the resulting single-stranded
cDNA was then analysed by quantitative real time Taqman
PCR using a Model 7700 Sequence Detector (Perkin Elmer
Applied Biosystems).
Primers and probes were designed using the Primer
Express1- program (AB Applied Biosystems). Sequences
used are shown in Table 1. BLAST nucleotide database
searches were performed for all primer/probe sets confirm¬
ing specificity. All primers and probes were validated for
linearity of response (ABI Prism 7700 sequence detection
system manual). The slope of dilution curves was <0.1 in all
but tissue factor, which was —0.18. The PCR reactions were
run on a Model 7700 Sequence Detector (Perkin Elmer
Applied Biosystems) in duplicate, and 18-S was used as an
internal endogenous control to normalise variations in
cDNA content between samples. To determine genomic
DNA contamination the P-actin signal was measured with¬
out reverse transcription in all samples. The criterion for
exclusion was a measurement greater than 3 standard devia¬
tions below the mean, from population of 66 samples; this
translates to a P-actin FAM signal with a Ct below 27 cycles.
Samples used had a mean P-actin FAM Ct of 35.9 ± 2.99
(S.D.) without reverse transcription, and the minimum in the
sample set used was 29.5.
To examine the gene expression of known decidualisation
markers, quantitative RT-PCR was carried out for Prolactin
(PRL), IGFBP-1 (insulin-like growth factor-binding protein-
1), desmin, laminin, fibronectin and p2-microglobulin, tissue
factor (TF), Interleukin-8 (IL-8) and vascular endothelial
growth factor (vEGF). Changes in receptor expression were
evaluated for progesterone receptor (PR) and prostaglandin
E receptor (EP) types EP2 and EP4.
2.5. Enzyme linked immunosorbent assays
Release of PRL and IGFBP-1 protein from cultured cells
was evaluated in medium collected at the end of any
treatment period. All samples were assayed in duplicate.
PRL estimation was performed using a time-delayed
fluorescence PRL kit (Perkin Elmer Applied Biosystems)
according to manufacturer instructions but, in order to attain
sufficient sensitivity, a 10-fold increase in sample volume
relative to standard volume was used. The analytical sensi¬
tivity is 40 pg/ml and the within assay variation was 7.5%
(relative standard deviation) evaluated on pooled stromal
cell samples. All samples were analysed in the same assay.
The IGFBP-1 assay was performed with matched pairs of
capture and biotinylated labelled detection antibodies (R&D
Systems, UK) according to manufacturer instructions with a
lower limit of sensitivity of 60 pg/ml and a within assay
variation of 1.7% (relative standard deviation). All samples
were measured in the same assay.
IL8 production was assayed by ELISA with matched pairs
of capture and biotinylated labelled detection antibodies for
IL-8 (R&D Systems, UK) as previously reported [15].
2.6. Fluorescence activated cell analysis
Cervical stromal cells were grown to confluence and
treated with trypsin EDTA, washed and resuspended in
PBS/BSA medium. The cell suspension was treated with
monoclonal anti-fibroblast antibody (Oncogene Research
products, Boston, MA) which recognises a fibroblast spe¬
cific surface antigen. Cells were then washed and treated
with fluorescein labelled sheep-anti-mouse serum. Cells
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were analysed in a Beckman Coulter instrument and fluor¬
escence intensity was plotted against number of events.
2.7. Statistics
Data normalised to control was analysed by non-para¬
metric methods. The Kruskal-Wallis analysis of variance
was used and Dunn's multiple comparisons test was used to
assign significance to treatment. For comparisons of mRNA
in pregnant or non-pregnant cervical biopsies, the Mann-
Whitney (/-test was used.
3. Results
Spindle-like fibroblast cells grew out of cervical tissue
from both pregnant and non-pregnant women. The fibroblast
identity of these cells was confirmed by FACS analysis of
fibroblast surface antigen. The percentage of cells that
possessed this marker was between 95 and 98% of the total
(Fig. 1).
Cells treated with DM for ten days had a more rounded
morphology than untreated cells cultured in the same way
(Fig. 2), a change characteristic of "decidual" transition.
After 6 days, cells responded to stimulation with DM by both
expressing prolactin and IGFBP-1 mRNA and releasing
these proteins (Fig. 3). All cervical stromal cell results
discussed are from pregnant women unless otherwise stated.
A similar pattern of decidualisation was seen in cells derived








8 1 | c J ,'j
T 9§f H V..
FITC
Fluorescence intensity
Fig. 1. Fluorescence activated cell analysis of un-differentiated cells to
confirm their fibroblast nature. F-axis is number of events and X-axis
shows fluorescence intensity denoting specific fibroblast marker. Positive
cells are shown in grey. Cells with the fibroblast marker constituted 98% of
the cells.
Fig. 2. Cervical fibroblasts grown in (A) control culture and (B) the same
cells grown for 10 days in the presence of BrcAMP and progestin (MPA).
Scale bar is 5 pM.
DM treatment also resulted in significantly increased TF
mRNA expression (P < 0.05) and decreased IL-8 mRNA
(P < 0.01), relative to control (Fig. 4). IL-8 protein release
was also decreased by decidual stimulus (mean ± S.E.M);
control 10.1 ± 2.8 ng/ml/72 h and DM 3.5 ± 1.4 (P < 0.01,
paired data).
The effects of either progestin alone or cAMP analog
(BrcAMP) alone were minor and not significant. An excep¬
tion to this was the stimulation of vEGF mRNA by BrcAMP
which was evident in the absence of progestin (Fig. 4).
The comparison of DM (BrcAMP, MPA, E) with
BrcAMP + MPA in pregnant cervical stromal cells con¬
firmed a significant increase in IGFBP-1 mRNA (mean fold
increase in expression 253 ± 85 S.E.M.) and PRL mRNA
(16 ±7.8) with DM relative to control (both P < 0.05).
However there was no significant difference between DM
and BrcAMP + MPA treatment groups, excluding oestra-
diol as the significant stimulus.











































Control Brc4MP MP A DM
Fig. 3. The increase in expression of IGFBP-1 with combined progestin and cAMP analog. Changes in mRNA expression/protein release after 6 days
differentiation with BrcAMP and a progestin, medroxyprogesterone acetate (MPA) or a combination of the two with oestradiol, decidualising mix (DM).
Pregnant CSC are shown by hatched bars, NP CSC by solid bars and FF by open bars. Bars represent the mean of each treatment group ± S.E.M. Top three
panels: IGFBP-1 mRNA and PRL mRNA in cells derived from the pregnant cervix (n = 5) and foreskin fibroblast cell line (n = 4). IGFBP-1 mRNA in cells
from non-pregnant cervix (n = 6). In the lower two panels: released IGFBP-1 protein and prolactin are shown as measured by ELISA in culture medium
(both from pregnancy derived samples, n = 5). Although progestin is without effect alone, it is essential for the expression of decidualisation markers.
Significant differences are denoted as follows: difference from control with **P < 0.01 and *P < 0.05.
Accompanying changes in decidualisation, were
increases in agents that might maintain high intracellular
cAMP, such as the EP2 mRNA (Fig. 4) and a significant
increase in COX-1 mRNA (Table 2).
The decidualised cells showed an increase in progesterone
receptor mRNA (Fig. 4). Moreover, the increase in phos¬
phodiesterase mRNA (in this instance Type IVb) seen after
stimulation with BrcAMP is attenuated by progesterone
(Fig. 4).
HS27 fibroblasts did not produce the same response to
decidual stimulus in identical culture and treatment condi¬
tions with no significant change in IGFBP-1 mRNA and a
significant, though much less marked, increase in PRL
mRNA (Fig. 3). Nor did DM produce a significant increase
in progesterone receptor mRNA expression in this foreskin
fibroblast cell line.
Cells derived from pregnant women differed in their
decidualisation pattern from those obtained from non-preg¬
nant women. After 10 days treatment with DM, IGFBP-1
mRNA expression was 10 times higher in the pregnancy-
derived cells than in the non-pregnancy cells, but only 1.3
times as high when decidualisation was induced by
PGE + Rolipram + MPA (Table 3). This confirms that
PGE2 and rolipram can mimic the effects of cAMP, in
combination with MPA, but there was a difference in
magnitude of effect with a greater response to DM in
pregnant CSC, but a greater effect in non-pregnant CSC
with PRM. This was shown for both IGFBP-1 mRNA and
protein release.
Table 3
10 day decidualisation with different regimes, pregnant n = 6, NP n = 5
Table 2 Treatment Control BrcAMP + MPA PGE ± Rolipram
RNA expression in response to decidual stimulus (pregnant, n = 5) + MPA
Message Mean relative to
control ± S.E.M.










1 751 ± 242 354 ±181
1 63 ± 31 264 ± 120
Laminin 1.4 ± 0.11 NS Release of IGFBP-1 pg/ml/72 h (±S.E.M.)
Desmin 0.27 ±0.12 P < 0.05 Pregnant 66 ± 3.5 1423 ± 812 227 ±113
(32-Microglobulin 0.94 ±0.19 NS Non-pregnant 63 136 ± 102 663 ± 136
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Control BrcAMP MPA DM
Fig. 4. All cells were originally derived from the cervix of pregnant women (n = 5). There is an increase in expression of the EP2 prostaglandin receptor
mRNA (but not EP4). Also shown are changes in mRNA for progesterone receptor, vascular endothelial growth factor (vEGF), phosphodiesterase type IVb,
fibronectin, tissue factor and IL-8. Bars represent the mean of each treatment group ± S.E.M. Significant differences are denoted as follows: difference from
control with **P < 0.01 and *P < 0.05, and difference from progesterone alone ®®P < 0.01, < 0.05.
Fibronectin
2-i




Control BrcAMP MPA DM
Prostaglandin dehydrogenase (PGDH) mRNA was
found to be increased (P < 0.05) in untreated pregnant
cervical biopsies relative to non-pregnant cervical bio¬
psies (mean 38.8 ±21.7 S.E.M. cf. 2.3 ±1.2 S.E.M.,
n = 6 both groups). However during culture the PGDH
mRNA expression diminished and minimal message was
found in treated and untreated cultured cervical stromal
cells.
Control BrcAMP MPA DM Control BrcAMP MPA DM
BrcAMPControl
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4. Discussion
Changes in the consistency of the cervix can be detected
in early pregnancy [16] but little is known about the con¬
tribution of the various cell types within the cervix to such a
change. The fibroblast-like stromal cell of the cervix has
been considered an important contributor to physiological
changes, both in early pregnancy and at the time of parturi¬
tion. These cells respond to steroids and initiate collageno-
lytic pathways [13,17-19] and since they have progesterone
receptors, they may play a sentinel role in altering cervical
morphology in response to hormone changes. However, if
these cells respond to prolonged exposure to progesterone
with a change in phenotype, as do cells in the endometrium,
then this modified cell would be the target for any signal for
the induction of labour.
We show here, for the first time, that fibroblasts from both
pregnant and non-pregnant cervix will "decidualise" after
treatment with cAMP and progestin as do the fibroblasts
derived from endometrium. A significant change in mor¬
phology is demonstrated, within a relatively short treatment
period, in association with stimulation of IGFBP-1 and PRL
mRNA and protein release. Fibroblasts derived from fore¬
skin however do not produce the same response, although
mild prolactin (but not IGFBP-1) stimulation is seen as has
been reported in skin fibroblasts [20]. Although progester¬
one appears to be sufficient for the decidual change in vivo,
cells in vitro need to be sensitized by elevated intracellular
cAMP levels [21]. In vivo, raised intracellular cAMP levels
can be brought about by prostaglandin E acting through
either EP2 or EP4 receptors to activate the stimulatory G-
protein (Gs) or by relaxin inhibiting phosphodiesterase, the
enzyme responsible for the catabolism of cAMP [22]. Since
one effect of raising cAMP is to stimulate expression of
phosphodiesterase (Fig. 4) both of the above pathways will
work together in a synergistic fashion to maximise cAMP
levels. Other agents involved in decidualisation may also
affect phosphodiesterase activity since epidermal growth
factor inhibits the activity of an isoform of PDEIV by
ERK-2 dependent phosphorylation [23]. Moreover, the
increase in phosphodiesterase mRNA (in this instance Type
IVb) seen after stimulation with BrcAMP is attenuated by
progesterone.
The increase in progesterone receptor mRNA is in
accordance with observations in endometrial stromal cells
[24],
Tissue factor is known to be stimulated in decidual cells
under progesterone regulation, both in vivo and in vitro [25]
and is thought to have a role in peri-implantation haemos-
tasis and menstruation. Tissue factor may act as an autocrine
enhancer for vEGF stimulation thereby promoting angio-
genesis during this time of tissue remodelling [26], The
decidual transformation in endometrium is also associated
with an increased production of the angiogenic agent vEGF
and its KDR receptor [27] and this process may be respon¬
sible for the increased vascularisation of the cervix that is
seen during pregnancy. The increase in the EP2 receptor
(Fig. 4) may also facilitate vEGF release since PGE stimu¬
lates vEGF through the EP2 receptor in synovial fibroblasts
[28]. Although there are likely to be other cellular sources of
EP receptors in the pregnant cervix, experiments in the
baboon show that the EP2 type is predominant [29] although
its expression decreases during labour [30].
A significant feature of this decidual change to cervical
stromal cells is a decrease in both mRNA and release of IL-8
into culture medium. Since IL-8 is known to be produced by
the cervix [31 ] and attracts neutrophils which are implicated
in cervical softening [32], a reduction in IL-8 release by cells
during pregnancy is appropriate for the maintenance of a
firm, closed cervix up until the time of delivery.
Although decidualisation of the cervical fibroblast has not
hitherto been recognised, ectopic decidua has been reported
in cervix and ovary during pregnancy [33,34], but there has
always been doubt whether this was a manifestation of
otherwise unrecognised endometriosis.
Since labour is preceeded by changes within the cervix
[35], these findings of the decidual-like changes in cervical
stromal cells open a new area for the study of the mechanism
of the initiation of labour. The decidualised stromal fibro¬
blast is a potential target for known initiators of ripening,
such as PGE and antiprogestins.
Whether the decidualised cervical fibroblast serves to
maintain cervical integrity throughout pregnancy, or
whether this altered phenotype is involved in the cervical
ripening process has yet to be established. A more funda¬
mental point of interest is that the potential for decidual
change is likely to be present in all fibroblasts expressing the
progesterone receptor. Thus, the phenomenon of ectopic
implantation and pregnancy may be reliant on this intrinsic
property of fibroblasts anywhere within the reproductive
tract, but particularly the fallopian tube. Further assessment
of this data should include immunohistochemistry or in situ
hybridisation for the presence of decidualisation markers in
cervical stromal cells, and ultimately to show decidualised
CSC in vivo, although these samples would be extremely
difficult to obtain. To elucidate the full nature and purpose of
the capacity of cervical fibroblasts to decidualise will require
further investigation, but these findings should be considered
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